var title_f29_40_30336="Normal follicle";
var content_f29_40_30336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal follicle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of the left ovary. A normal appearing left ovary containing a simple anechoic clear cyst which is consistent with a follicle. A small amount of ovarian tissue is identified surrounding the follicle as indicated by the arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy;Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30336=[""].join("\n");
var outline_f29_40_30336=null;
var title_f29_40_30337="TTTS7";
var content_f29_40_30337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Doppler study of the fetal ductus venous in this recipient twin at&nbsp;approximately 25&nbsp;weeks of gestation. Fetal ascites&nbsp;can be&nbsp;noted in the top image.&nbsp;In the bottom image, the&nbsp;arrow points to the reversed \"a\" wave of the ductus venosus that occurs during diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30337=[""].join("\n");
var outline_f29_40_30337=null;
var title_f29_40_30338="Patient information: Lyme disease (The Basics)";
var content_f29_40_30338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15496\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/29/10704\">",
"         Bull's eye rash caused by tick bite",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/16/15617\">",
"          Tick comparison",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/0/27649\">",
"         Patient information: Lyme disease prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/17/32022\">",
"         Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/41/5778\">",
"         Patient information: Lyme disease treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/10/13474\">",
"         Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lyme disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lyme-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H542901992\">",
"      <span class=\"h1\">",
"       What is Lyme disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lyme disease is an illness that can make you feel like you have the flu. It can also cause a rash, fever, joint problems, or heart problems.",
"     </p>",
"     <p>",
"      People can get Lyme disease after being bitten by a tiny insect called a tick. When a certain type of tick bites you, it can transmit the germ that causes Lyme disease from its body to yours. But a tick can infect you only if it stays attached for at least a day.",
"     </p>",
"     <p>",
"      The ticks that carry Lyme disease feed on deer and mice. Ticks are found in tall grass and on shrubs, and can attach to animals and people walking by. Ticks cannot fly or jump.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542901999\">",
"      <span class=\"h1\">",
"       What are the symptoms of Lyme disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can start days or weeks after a tick bite. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A rash where you were bitten &ndash; The rash often appears within a month of getting bitten. It is red, but its center can be the color of your skin. It may get bigger over a few days. To some, it looks like a &ldquo;bull&rsquo;s eye&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef58798 \" href=\"UTD.htm?10/29/10704\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Body aches and pains",
"       </li>",
"       <li>",
"        Heart problems such as a slowed heart rate",
"       </li>",
"       <li>",
"        Headache and stiff neck",
"       </li>",
"       <li>",
"        Feelings of pain, weakness, or numbness",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a person is not treated, further symptoms can occur months to years after a tick bite. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain and swelling of joints, such as your knees",
"       </li>",
"       <li>",
"        Trouble with your memory and thinking",
"       </li>",
"       <li>",
"        Skin problems, such as skin swelling or thinning",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902006\">",
"      <span class=\"h1\">",
"       Is there a test for Lyme disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Blood tests can show if you are infected with the germ that causes Lyme disease. But these tests won&rsquo;t work if you have them right after being bitten. It takes time for an infection to show up in your body. If you have the typical rash that goes with Lyme disease, the blood test is not necessary.",
"     </p>",
"     <p>",
"      If your doctor or nurse suspects you have Lyme disease, he or she will do an exam and ask you questions. The doctor or nurse will use this information (and your blood test result, if necessary) to decide about treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902013\">",
"      <span class=\"h1\">",
"       What should I do if I get bitten by a tick or if my child gets bitten?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you find a tick on your body or on your child, use tweezers to grab it. Then pull it out slowly and gently. After that, wash the area with soap and water.",
"     </p>",
"     <p>",
"      You do not need to keep the tick. But knowing what it looked like can help your doctor decide about your treatment. See if you can tell:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Its color and size",
"       </li>",
"       <li>",
"        If it was attached to your skin or just resting on your skin",
"       </li>",
"       <li>",
"        If it was big, round, and full of blood (",
"        <a class=\"graphic graphic_picture graphicRef51825 \" href=\"UTD.htm?15/16/15617\">",
"         picture 2",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should watch the area around the bite for a month to see if a rash occurs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902020\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have a tick and you cannot get it off or if you think you have had a tick attached for at least 36 hours (a day and a half). You should also see a doctor or nurse if you develop symptoms of Lyme disease. Some people don&rsquo;t know that they were bitten by a tick. Or they might not remember having a rash or early symptoms of Lyme disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902027\">",
"      <span class=\"h1\">",
"       How is Lyme disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lyme disease is usually treated with antibiotics. Treatment with antibiotics should help your symptoms go away. Sometimes, symptoms improve quickly. Other times, it can take weeks or months for symptoms to go away.",
"     </p>",
"     <p>",
"      Your doctor might prescribe medicine for you to take right after a tick bite. Or your doctor might wait to see if you first develop symptoms. Either way, the medicine will treat your Lyme disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902034\">",
"      <span class=\"h1\">",
"       What can I do to try to avoid getting bitten by a tick?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear shoes, long-sleeved shirts, and long pants when you go outside. Keep ticks away from your skin by tucking your pants into your socks.",
"       </li>",
"       <li>",
"        Wear light colors so you can spot any ticks that get on your clothes",
"       </li>",
"       <li>",
"        Use bug spray to keep ticks away",
"       </li>",
"       <li>",
"        Check your body for ticks after being outdoors. Be sure to check your scalp, waist, armpits, groin, and backs of your knees. Check your children, too.",
"       </li>",
"       <li>",
"        If you live in a place that has deer or mice nearby, take steps to keep those animals away. Deer and mice carry ticks.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902041\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, talk to your doctor. Some medicines for Lyme disease are safe to take if you are pregnant, but others are not.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542902048\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"       Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       Patient information: Lyme disease treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       Patient information: Lyme disease prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/40/30338?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15496 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30338=[""].join("\n");
var outline_f29_40_30338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542901992\">",
"      What is Lyme disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542901999\">",
"      What are the symptoms of Lyme disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902006\">",
"      Is there a test for Lyme disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902013\">",
"      What should I do if I get bitten by a tick or if my child gets bitten?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902020\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902027\">",
"      How is Lyme disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902034\">",
"      What can I do to try to avoid getting bitten by a tick?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902041\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542902048\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/29/10704\">",
"      Bull's eye rash caused by tick bite",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/16/15617\">",
"       Tick comparison",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=related_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30339="Butterfly rash PI";
var content_f29_40_30339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Butterfly rash caused by lupus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Lupus can cause a rash on the face that looks like this. Doctors sometimes call it a \"butterfly rash.\"",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30339=[""].join("\n");
var outline_f29_40_30339=null;
var title_f29_40_30340="Dronabinol: Pediatric drug information";
var content_f29_40_30340=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dronabinol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"    see \"Dronabinol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/27/13748?source=see_link\">",
"    see \"Dronabinol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16116938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Marinol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Marinol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"      see \"Dronabinol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antiemetic: Children and Adults: 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     1-3 hours before chemotherapy, then give 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 2-4 hours after chemotherapy for a total of 4-6 doses/day; dose may be increased in 2.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     increments to a maximum of 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     per dose if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative dosing: Adults: 5 mg 3-4 times/day; dosage may be escalated during a chemotherapy cycle or at subsequent cycles depending upon response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Appetite stimulant: Adults: 2.5 mg twice daily before lunch and dinner; if intolerant, a dosage of 2.5 mg once daily at night may be tried; maximum dosage (escalating): 10 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral: 2.5 mg [contains sesame oil], 5 mg [contains sesame oil], 10 mg [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marinol&reg;: 2.5 mg, 5 mg, 10 mg [contains sesame oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F163526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; take before meals if used to stimulate appetite",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in a cool environment (46&deg;F to 59&deg;F); may be refrigerated; do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nausea and vomiting secondary to cancer chemotherapy in patients who have not responded to conventional antiemetics; treatment of anorexia associated with weight loss in AIDS patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dronabinol may be confused with droperidol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F163530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitations, tachycardia, vasodilation/facial flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, amnesia, anxiety, ataxia, depersonalization, dizziness, euphoria, hallucination, paranoia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Conjunctivitis, depression, diarrhea, fatigue, fecal incontinence, flushing, hypotension, myalgia, nightmares, seizure, speech difficulties, tinnitus, vision difficulties",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dronabinol, sesame oil, or any component, marijuana, or cannabinoids; should not be used in patients with a history of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with heart disease, history of substance abuse, hepatic disease, or seizure disorders (may lower seizure threshold); reduce dosage in patients with severe hepatic impairment; tolerance to CNS side effects usually occurs in 1-3 days of continued use; tachyphylaxis and tolerance does not appear to develop when used as an appetite stimulant as efficacy has been documented in clinical trials for up to 5 months of treatment. Use with caution in patients with mania or depression as dronabinol may exacerbate these conditions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dronabinol has a high potential for abuse; limit antiemetic therapy availability to current cycle of chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cocaine: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Dronabinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: Cannabinoids may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dronabinol is the principal psychoactive substance found in",
"     <i>",
"      Cannabis sativa",
"     </i>",
"     (marijuana); its mechanism of action as an antiemetic is not well defined, it probably inhibits the vomiting center in the medulla oblongata; has complex effects on CNS including central sympathomimetic activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 30 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Psychoactive effects: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Appetite stimulation: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 90% to 95%; first-pass metabolism results in low systemic bioavailability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &sim;10L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass; metabolized in the liver to several metabolites some of which are active",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 10% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biphasic: Alpha: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 25-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dronabinol metabolites: 44-59 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 0.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Biliary excretion is the major route of elimination; 50% excreted in feces within 72 hours; 10% to 15% excreted in urine within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Adults: Mean 0.2 L/kg/hour (highly variable)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/27/13748?source=see_link\">",
"      see \"Dronabinol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lane M, Smith FE, Sullivan RA, et al, &ldquo;Dronabinol and Prochlorperazine Alone and in Combination as Antiemetic Agents for Cancer Chemotherapy,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1990, 13(6):480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30340/abstract-text/2173391 /pubmed\" id=\"2173391 \" target=\"_blank\">",
"        2173391",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13256 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30340=[""].join("\n");
var outline_f29_40_30340=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16116938\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163505\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058225\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058218\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163483\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163466\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163526\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058229\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058221\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058228\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163532\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163530\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058233\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058217\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058216\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299237\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163475\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163478\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386485\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058224\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058215\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058231\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058232\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058223\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=related_link\">",
"      Dronabinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/27/13748?source=related_link\">",
"      Dronabinol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30341="Teriflunomide: Patient drug information";
var content_f29_40_30341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Teriflunomide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     see \"Teriflunomide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15098019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aubagio&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15125017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15125019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15125018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3964368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to teriflunomide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3964371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking leflunomide.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3964383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Do not use this drug if you are pregnant and do not get pregnant.",
"       </b>",
"       Use birth control that you can trust. At the end of care, you will need to get rid of the extra teriflunomide in your body. Taking a drug called cholestyramine 3 times a day for 11 days or activated charcoal powder 2 times a day for 11 days will get rid of most of the drug. Talk with your doctor if you want to get pregnant. You will need to have blood tests showing that your body is free of teriflunomide before you stop taking birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15125023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697151",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak immune system or very bad infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your white blood cell, red blood cell, or platelet counts are low, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697727",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for some time after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15125024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15125025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant during or after care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15125021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15125022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15125026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15125027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86617 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30341=[""].join("\n");
var outline_f29_40_30341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15098019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125017\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125019\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125018\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125023\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125024\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125025\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125021\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125022\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125026\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125027\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=related_link\">",
"      Teriflunomide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30342="TB enteritis - barium enema";
var content_f29_40_30342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Tuberculous enteritis - barium enema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIUAj0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/Hq7D4X/ABr8OfEfX7jSNDstXguYLVrtmvIo1QoropAKyMc5cdvWvz6r6A/Yp/5Knqv/AGBZf/R8FAHuvj39oDwr4I8WX3h7VbDW5r2z8vzHtoYmjO+NXGC0gPRh2HNc/wD8NV+B/wDoFeJP/AeD/wCPV8//ALUf/JdvE3/br/6SxV6T4v8Ag18OvDXiNdEceOtQvf7PfU2+xz2W1IEJDEmQJyNvQZ9qAO3/AOGq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAerxv4u/DDwj4d+FWh+MfCN7rc6apdxRIuovHxG0crfdVFIbKAdSOvXg14dQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1e/1+VdfqpQB4B+2t/ySzSv+w1F/6Inrj/gJoOs+KP2b/E+h+Hbi0tbu/wBYeCSa5ZlVYTDb+ZjapJJXIx7nmuw/bW/5JZpX/Yai/wDRE9fFVAH3/wCBPhlqHgf4hS6lpWqLd+H7vTIrO6iutiTiWEBYmVYo1QqEAXnnkk5r4Aor0X4GeHNJ8T+Lbuy121+1W0di8yp5jphxJGAcqQejH86APOqK+uD8IvAw/wCYH16f6XP/APF09PhB4GPB0Ln/AK+5/wD4ugD5Eor7Di+DPgVsZ0L/AMnJ/wD4up4/gx4BPXQOP+vy4/8AjlAHxrRX2d/wpb4f/wDQA/8AJy4/+OU+X4J+AEQEaByf+n24/wDjlAHxdRX2LdfBnwJGMjQQP+3y4/8Ai6zta+FXgKysxKmh/N0I+2T8/wDj9AHyXRX05o/wr8K31zzoxEX/AF8zf/F129j8DPAbAGbQtwP/AE+XA/8AZ6APiyivuVfgT8Occ+Hf/J65/wDjlPHwH+HH/Quf+T1z/wDHKAPheivur/hQ/wAN/wDoXf8Ayeuf/jlH/Ch/hvj/AJF3/wAnrn/45QB8K0V90n4EfDft4d/8nrn/AOOUn/CiPhxnjw7/AOT1z/8AHKAPheivuWX4FfDlVyPDv/k9c/8AxyqyfBD4dB9reHs+/wBtuf8A45QB8R0V9uJ8EfhyJdj+Hfp/p1z/APHKur8CfhsR/wAi5/5PXP8A8coA+FqK+6j8B/hv/wBC5/5PXP8A8cpD8CPhv/0Ln/k9c/8AxygD4Wor7mPwK+HHbw5/5PXP/wAcqKX4GfDpcY8O49f9Nuf/AI5QB8PUV9x/8KM+HGcf8I7/AOT1z/8AHKmHwJ+G/wD0Ln/k9c//ABygD4Wor7q/4UP8N/8AoXP/ACeuf/jlKPgP8N/+hc/8nrn/AOOUAfClFes/tKeEtE8GeOrHT/Ddl9is5dNjuHj815MuZZVJy7E9FXjOOK8moAK+gP2Kf+Sp6r/2BZf/AEfBXz/X0B+xT/yVPVf+wLL/AOj4KAOU/aj/AOS7eJv+3X/0lir6m+I/w71HxD8RbPxBDpfh3WLCHSXsDZ6vK6ASl2YSDEMg4B9j15FfLP7Uf/JdvE3/AG6/+ksVeVUAfVn7Q/hy98Jfs4+FNE1TUW1K8tNVjWS4OcHMVwwUZ5woIUZ7AdOg+U6K9z+BngXw34n8JXd5runfarpL14Vfz5UwgjjIGFYDqx/OgDwyivrg/CHwNnH9idP+nuf/AOLqRPg/4Fb/AJgX/k3P/wDF0AfIdFfYsfwZ8CYy2hfh9sn/APi6nT4L+ACOdA/8nLj/AOOUAfGdFfaC/BX4fswA0Dn/AK/Lj/45RL8FPACvhdAH/gbcf/HKAPi+ivsKX4N+BEkAOhcd/wDTJ/8A4usTxF8MfA1lII7bROWHH+lznH/j9AHyxRX1V4f+EHhO9+a40Y4PQfaZh/7PXY2nwK+H5UeboG4/9flwP/alAHxJRX3MvwJ+HPfw7/5PXP8A8cp6/Af4cH/mXP8Ayeuf/jlAHwtRX3T/AMKH+G//AELvP/X9c/8Axyj/AIUP8N/+hc/8nrn/AOOUAfC1FfdJ+A/w4/6F3/yeuf8A45Sf8KI+HH/Quf8Ak9c//HKAPheivuKf4F/DpeF8PY9/t1z/APHKiT4IfDl0P/FPfN2/025/+OUAfEVFfb9t8Efhu5w3h3kf9P1z/wDHKtj4EfDY/wDMuf8Ak9c//HKAPhWivuo/Aj4b/wDQuf8Ak9c//HKafgT8Nx/zLn/k9c//ABygD4Xor7lPwK+HPbw5/wCT1z/8cqP/AIUb8OfNx/wjvy4/5/bn/wCOUAfD1Ffci/Az4bk/8i7/AOT1z/8AHKlHwI+G/wD0Ln/k9c//ABygD4Wor7q/4UP8N/8AoXP/ACeuf/jlOHwG+G3/AELn/k9c/wDxygD4Tore8e2FtpXjrxHp1hH5Vnaalc28Me4tsRJWVRkkk4AHJOawaACv1Ur8q6/VSgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACvW/2Zzjx3f4/6Bsn/o2KvJK9b/ZoOPHd/wD9g2T/ANGxUAfTHJAA5qeBcjnHFMRMg+oNWUAUDj3yaAJl4qZOp5xVeNiT+lSqckAdaALEfzyKvrTdTmMStinQFI5wGOWHvXOeMtW+xpIuQDnH1oAjvtXEWd7At6elYNm8+tag2/JgB4rn4JJtSumUyFAx616f4T0cWsCcFsDqe9AGjoukpbRqMdK6OGMBRimQxYGKsquOlACqBSj60qiloAQCjHNL2ppoAU9KZjGKd1FITxzQBDOfl9qoBSWwPrmr82NpzVWRlTtQA2ZC4Vl+8vOPWpYpSgIY02BhLnH3lqWSMMuQKAJg/A96UvxWas5U7TwQacJzke9AFxiM9eaYw3EcVCXzUsZ6UAISVerCNxVdyc9KcjGgC0DThUQalDgUAfIP7Yv/ACU3TP8AsERf+jp68Jr3T9sE5+Jmmf8AYIi/9HTV4XQAV9AfsU/8lT1X/sCy/wDo+Cvn+voD9in/AJKnqv8A2BZf/R8FAHKftR/8l28Tf9uv/pLFXlVeq/tR/wDJdvE3/br/AOksVeVUAFfTH7M5/wCKEvv+wlJ/6Kir5nr6Y/Zn58C3w/6iUn/oqKgD1vkkHjFXIE6E96hRAdp7d6sg7RwMY4xQBMnFSocDg1BG2RyPepUBkJAoAtW3zOxP8IrP1O6aIjBANX7V0CyBTk4P41594w1wo/lIRkg8UAXdS1wQo21tzdM571V8P2Euqv51yMsTkfSue0azk1OdA8hAzkj1r1vQtPFvbqAuOKALOmWKwIBjmtmNQAKZFGMDNTgY6UAAFOHSlA454oxQAUgGKU/rTSaABuR703oaceenWkY8c0AVLrpyarxA7s9O1W5tuRnk1WeQLx6UANZCJt6fxcH2NWYp+AG602LDKHHQ9RSXEe1Cyj3oAsh+aGbNZy3HHPBp6zEnFAFokdqbtySQOcVDuyanU8H6UAMjJDYNWlPSqhbDVLGx70AWRzThUO6lEgoA/PL4o/8AJTfF3/YXvP8A0c9cxXT/ABQ/5KX4t/7C93/6OeuYoAK/VSvyrr9VKAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAr139mQZ8e33/YNk/8ARsVeRV67+zIcePb/AB/0DJP/AEbFQB9PZyRtPPepC3QYqDOOuBS7jnNAExbHU4xSvOI0LZwx6VAG3sq571k+IL5Y+Ebb296ALF9f+TyH5Irn/EkR1mxguIWLPnY6jsR3rJa8mlu1APU8c13PhaxyrGUZSTsRQBn+E/DPkMskiDjBGa9HsoBHGq46VHaWqxIAAK0I14oAeo6VIKQAU4UAAzilzS0n0oAKaehp3cUh60ARuMVGsmSQetTkVSvEZV3xg7hyR60ATORVK7AALdhUUV4rArv+YetRahc+VAxzxjNADLOfE4I6Z5rdRcnI71xNnqQEwCn5WOCa7OyffCp70AVr22A+ZaqRjDDI/Gtd/mUqaypPllIFAEqjJOOlTJxioU4qReuKAHYyc9qcijNR7QuWHfrzUidqAELFVz6UzzDilk5Uj3qMDgUAfJP7XTbviRpp/wCoTH/6OmrxCvbv2t/+Skabj/oEx/8Ao6avEaACvoD9in/kqeq/9gWX/wBHwV8/19AfsU/8lT1X/sCy/wDo+CgDlP2o/wDku3ib/t1/9JYq8qr1X9qP/ku3ib/t1/8ASWKvKqACvpz9mLH/AAgl+T/0EpP/AEVFXzHX03+zIT/wgV+B/wBBOT/0VFQB7Cv3sg8U/dk9OlQhsHt7UBiOtAE4fB6+1NnuBGoUNgnrUcbjcXboorl9d1HbKwR/fAoA1LrVjaygh84OTXN65ozXusRtCS8Mg3g/XnFVtPmlubllJ69RXpHh/T1+yRrKBvXkE9qAKfhXQBZxqWUbyK7eCMADHFRW8IQAAVcQcD0oAcop4pAB+NPBFABziilOKT+VAAaaRThjmk60ARP8uSKakgYVIwyKzb3db5dc7D1x2oAttg9azb0+WCxPWpEullA2sOetZms3nlIAx4zQBo6XNltp+6elaojBUg9DXKaPf75lTt1HvXWo2UyOtAGXdW/lvx0NMixk8YrQuQHjJPUVnKctgdKAJ0BIqYHg5qJM9O9PXkUAKF455pwXCk1GFCAKvQdOc1KOFPNADHcqB700yUkozjnpTT3zQB+f/wATTn4k+LD66td/+jnrmq6X4mf8lH8V/wDYWu//AEc9c1QAV+qlflXX6qUAeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABXrn7Mx2+PL4n/oGyf+jYq8jr1b9nBtvji+P/AFDpP/RsVAH00ZD36fyoeTI6ge1UTKQevWkjZpJAq8sTxQBpWZJWaXGQi8VxfigyB2JKjd0rurqSCz0tlJ6nDY7nFeTapfT6hqhKAmNe1AGt4WtHuZgWVnKnOB2r17SrUxwJxjjpXK+BrLZbhzGAzAZrvIFwAKAJ4xgAVOowKYvOKkxQAvamlsD6U/PpTZE3A+poAFkqQEEdaxru6ayQmXIX17VUtvEdlI4H2mIHpjd1oA6SkNRW86TRq6MCp7g5qTNACnpTHpSeaikOPpQBzfiK3eIG5tuG/jA/nWZHqA1DTXwQHXgiui1FwqMxOB71yywpG8ksPCueVHTNAFKzGHZTgEV3WiXYmtwOjDgj3rhRGzTExAbj0z0/Guk0NjEArAB++PX2oA6h2xgis66GJCw6GrrOWiQ1XlTLHPIoAjiORn3qWPluaAgHFC8NQA9x+VOXil6rRGowAOgoAay8fjUPTNWn+6PrUbLxxQB8g/tbf8lH07/sFR/+jpq8Sr279rcY+JGnf9gmP/0dNXiNABX0B+xT/wAlT1X/ALAsv/o+Cvn+voD9in/kqeq/9gWX/wBHwUAcp+1H/wAl28Tf9uv/AKSxV5VXqv7Uf/JdvE3/AG6/+ksVeVUAFfTH7M7Y8B6gO/8AaUn/AKKir5nr6O/Zwfb4HvhnrqL/APouKgD2MSc88+hpkknFUjL1BP45qaxQ3E4U8IPvH0FAFqQsmnZA+aRjg+leda75onK5G7OeK77xVqENnYjZnKplB+leZ6c897qHmOpYO/cdqAOx8GWBdkl2M2f4u1eoWcBRRWL4ZtBDZRqqhRiulhGMUATIMn3qUDFMXk1IOOtACE96QvjFPqG4jLJ8nBHNAEoen5zXP3uqpY4+0tsx3bpT7HXrOdgq3ERJ7BhQBu+9JTVcEZB4PSlzxQApPPSoJwCrAjINSE8VBK2Ac0AcfrbSaTcCWPJgJ/L2qvq84vLSOSMgg81s600ZhZJQGVhgg96wGiEFuUDFk6igBNLl8p0l67T09RXeWM4lhVlORxXnltFJv/dhQM5YN6d8e9djo8u1FUDGO1AGu56g9OlZjfu3IrRlOZPYiq3lgtzz70AIh4HripYunNN2jFLFxmgBxHzU7sR7UOAevAp4HGaAIZV/lUZ+7Vl+uKikXigD8+viX/yUfxV/2Frv/wBHNXN10vxM4+I/iv8A7C13/wCjnrmqACv1Ur8q6/VSgDwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAr1L9nc48aXxP/QOf/wBGRV5bXpvwAYL4yvCf+fB//RkdAH0MX4O1iOehq/asLaza6YgMTsTj8zWI8u5gqfebpSeJ9UW1tI4I+fLAHHr3oAb4t8RLFoqxhDvmlIBHbArG8FwLc3qKzgk/MQTzWHrF011YW6n+GZj+YFdN8PreFr3z1YE9OnIoA9e0m3SKJQq4PfFbEY4FZ9gMRL6mtBDx/WgCdelOziogTTgTmgCXrSg1HmgH1oALiFJoykihlI5BFebeMPAC3G650pjFOOfLz8rf4V6TmmsAetAHjvg3xZPoV/8A2XrSyRx7to3/AMPvXr0NykqK8bhlPIINYPijwtYa9bstzGFlA+SVR8y1xOm3up+Drn7HrAeWwziO4HIA9/SgD1cyjHWoZZVx8x4rEh1q2ngEkcqsrDPBrNvtdiDMgbcAMnHagCz4kuGhtWbBKnow6Vy2g6l9ruZE6r0YVafXY7mMJEVdW4aJj1qTR9Hj+0NcWeUJ+9GeoNAFu3tmW66/IOa04wVuovL5GeanFofLUlSGzitC1tVUqxAyO9AFtziMDvTRhsetJJ97NIMZoAlKccUKlIrcVKrcc0ANIyKVKUkelCn0oAVhwKRl+Wn545pMUAfHv7XYx8SdN/7BMf8A6Omrw+vcv2vxj4l6b/2CIv8A0dNXhtABX0B+xT/yVPVf+wLL/wCj4K+f6+gP2Kf+Sp6r/wBgWX/0fBQByn7Uf/JdvE3/AG6/+ksVeVV6r+1H/wAl28Tf9uv/AKSxV5VQAV9D/s9MF8D3ue+oP/6Lir54r3/4AOE8G3ue9+//AKLjoA9ULnIw3FaM9wNOto1yPMddzjHXPasezcSXiA/6tTub3ArH8U60XvCFzzxxQBF461wXV3BZIpUrGpZh3zW14Bs45gX3K4U4xXA6rMJ9UjlkPyGFAePbFel/Du2jhtQUIJc5yBQB6PYxLHGoQcCtBBVS34QYxVpT+FAE68UoJqME04E0ASU4HIqIGjPHvQBW1PTrfUIGiuI1dT6ivJfFfge60uVr7SGlkjX5jFn5h9K9jzTJFDDBGaAPPPh741S+26fqLbLpeFLd/avQhMCOCCK4jxf4Hg1LN5pxFrqK/MrrwGPvWd4f8T3FhKuna+jQXS/KHfo/uDQB6Q0ox1qtPIuCN2D2rJk1aAR5Ei+xzWHfeIYlBdjlVOMjvQBH4tvmtQNwIxzk96r6Lcfb7E55U/dNR3V/DqQMMiieA+n3l9xWnoekG1iH2dt8R5x6UASabCVLGQ5XtWtpG77YwHKU5bQiVcDAxnFadvAsIZgBkigCSR/mHPQUKAxzUZwDzTlOBQA9kPGOlOVcCkD1IG45oAaRzmnqOKaSM9KcpoAGGWpki8VKeaQjj3oA/PL4m/8AJSfFn/YWu/8A0c9c1XTfE/8A5KV4s/7C93/6OeuZoAK/VSvyrr9VKAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAr0f4FP5fi28P8A04uP/IkdecV6D8EzjxVdf9eT/wDoyOgD6A0oCa+DEHC5Y/hXM+JJTGZJHcZLV1OiFIra+upW2pFHj6k15rr+ofaHLMeAdqjPb1oATTr1bmbyJG2hiGB9CK7fwDIU1WWIDofzryzzhHcq/AweNten+BbWS81G1uFYKQOT6igD22wz5S1op06VStBiMCrkZ4oAlFOH60wU4UAOzxR64pOlA9aAHE0GkppoAU4qrfWcF5bvDcRrJGwwVYZBqxnmmFuKAPJ/E3h698Os1zpJeSxJy0R52fSuVfW1OeGR2GCG4r3i5CSoyPjB4wehryLx14WW0uGurWImInJUfw/T2oA5i1mcXSkZ25z1r2Twqwmskd8Z9RXkum24mKkhuO5Feo+F326aiIuGFAHYJ8wAB4pzsFGM1Wth5UeXOSagvbgDIz1oAklnGSKI5Vx15rIa4x3pVny3UmgDeV8gYp6ms23mOeKvK3H1oAmZuKajYHWmE5FQmTYeaALwkFNeYA9azpJm3Y6UgkJ70AfKv7XbB/iTphH/AECIv/R01eH17V+1ic/EXTv+wVH/AOjpq8VoAK+gP2Kf+Sp6r/2BZf8A0fBXz/X0B+xT/wAlT1X/ALAsv/o+CgDlP2o/+S7eJv8At1/9JYq8qr1X9qP/AJLt4m/7df8A0liryqgAr3T4GS+X4PvB63z/APouOvC69s+CTf8AFK3Q/wCn1v8A0COgD1a0QjTrqZcgkBAa4TX7k2z4LZYiu31G4Sw8KrK7HzJZNyqD6V5dqdz5tzuYgu2S3pmgDT02dL2FiW+eJSMeo616h8NJTJZqMdD0HavFNIuDDfALgMxHA6V7X8NbF45pps4R+dooA9Rt/ug9sVbUe1VovuirCnNAEgpc00UtADs0o6Cm5oHSgB2eaQ0lIaAA4rH8QaHZ6zaNFdRBj/CwHKn1BrWLcU1mFAHiuu22p+Gp/Jn3z2R+5IOSB71hT6qs0TRR5AJzjPOa9y1ezg1C1eCdQykdDXiniHQG0fUThGMZPyvj+dAC+HLh0v0Jz1x1r2nSAvkRsflOO1eO6RbDzElKnOe4616xp7tJDEseQuOaAN9RnnPFNlkAB5ximKwiQLnnFZt5cA/KD0oAsvOCakSVeMGsU3HP3qkhmy3WgDdDZ+lPBqjbTFgB2qzuoAlkbjrSo+Khc5qLzccd6ALwcUwzAHrWcZmJ6456UbyRyaAPgv4nHPxJ8WH11a7/APRz1zNdJ8Sf+Si+Kf8AsK3X/o5q5ugAr9VK/Kuv1UoA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgArvfg023xRdNnpZt/wChpXBV2vwofZ4huT/06N/6GlAHuGr3clv4Td14FxPsb6AV5rfXBcdOM9a9Mhtf7c8HXVqg/f2komUDupGDXmeo2NxBO6MhBUZoApIp+0KSQQSPwr2r4dnyBGCynIyMEGvFI5CihSv4ius8Ia7JZ6lbmZ2WMHn6UAfUVk+6MVfU1zXhvUor20jkjYEMK6FDxmgCanU0Hgc0ooAdmgGkpKAHZppNGaaTQAjNVW4lKA9welTuapXMm0GgDMudT8oN5ikAe1cnqPiHN2I0kAQkArIMqwNauu3avEyqyhwOma8o1mfF0tuZPmZ8r9fSgD0y2itUmIezG1/mDIeDXSaPLD9yGHYi9yc4rhNAvLhdOiVnDPE4U554NdBLqn2VfLJGcbmwf0oA6e4uhuPOF6Cse9ucy8noOKxY9XS7mHJA6D606a7R7llZ+RQBPLce+cVLFdjK4NY8k6mXABOf0q1bOqqvIJz2oA6Swl3YP6VsRkYB/Guc0+YZGetbkcoKjFAFouNp9aqTOXOO4p8j5HfFUjNhs4+tADnVvXmkDkEEmpN+5cjGaq3BYc4NAHy9+1Wwb4hacR/0Co//AEdNXjFew/tREt4/08n/AKBkf/o2WvHqACvoD9in/kqeq/8AYFl/9HwV8/19AfsU/wDJU9V/7Asv/o+CgDlP2o/+S7eJv+3X/wBJYq8qr1X9qP8A5Lt4m/7df/SWKvKqACvZfg3L5fhe7Oet4/f/AGErxqvV/hTJs8OXAxn/AEtv/QEoA7/x5ePAljaMcIkCsB7tzXn91KZJR24wK9K8Zaa+r6RpmqWyliYRDIB2ZeP5V5hc28sYO9eAcUAWNDjLahGpZQc9WOK+hPAcmyFEOMgV85w3DI6lBh16elek/DfxIIL0pcyMNxAAPrQB9EQNkCrCmsvTbhZoVZSCCM1orQBMKUGmg+9OHSgBSeKM0maSgBxNNJoJppNADWbr2qhd3DRqeCSOatyHis69n2KSSMCgDLvtYWKI+YCM9MiuWi1cahdtbyskkbjiOUcg+xqTxTcLPA/lOAO+K86huHm1YeTJiSLkn29aAPU7FbRRtksmVk7Z4rq9OnQwbxGEUDjPeuL0+8mlMOWBWSPJJ9RwatXOurCDn7inAwetAHTTXXXJyaxbi5yWJPes+01FZmZ9xDYJ/CohdRyK53c56UAWjcASBiaswXQJwKwhKrkgAgDua0YJQD8uM47UAdPYvkDJrRU45rE0+YYFaqyA/SgCZ5MLx1qnIzO2V60+d8KTgmqqzYbGOtACsGDZycUqybScmnuxI4GfpVKZmV+aAPh34j/8lD8Uf9hW6/8ARzVzldD8Qznx/wCJj/1E7r/0a1c9QAV+qlflXX6qUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFdd8M2267cH/AKdW/wDQkrka6n4eNt1qc/8ATu3/AKEtAHsvhrXpdHvluIsMCNro3Rl713t3pOg+I9NF/bxbJDgOE4KH3FePRu28EetekfDDzLi/kt1JMe3cVzjP+NAHKXPhpYruRFeBwcncTt4qG58PIjosJy5GVYdGPtXsHiHwXYXl2lwd6OTnYp4x9Kq6V4cFrrkstwYzbgYRMZHtQBynhe/u9AQCWR2hHJBr1Pw74tsNTjULJskP8LVxvjDw5IYbi+0wgzqu7yj0f1FYXhlotOtxdXsZid2JCnqntQB7ujhgCCCDT8151pHjjTRciD7Uo/3jgV3FjqFvewiS3mSRT3Vs0AXs0ZxUQOeKUNigBxamlgKazVXllx06UAPkfArF1S7CRMcjinahqCwpliPTFcJ4p1xIQVD4JOOKAMTXtUM2o7YWKvnBHrXP31s0k6MzAOBuLd6sCWJppbj78mODVTRre71DW0eQYgHBJ6EUAdrpKPp+ivczH/W7dmTyfes2+1BpfkjYlz1NTeOtWht4Le1gOAi5wPpgf1rl9MujcEO+TnrQB2Gjkkrzgryasq3m3LEnvUWhxNLNtQEgDmrrWsqTsNgwTQA65+WMMoAx2qS1bcwOMDrmhreTbgkbTT4YY9wBkwPQCgDYsDlcgcHofWtqBvlGetYdkyrjBOPetyBgV9/WgC4oLJxVWWE5Iq5CcqPemOfnx1oAqQKwbBq19nEi8ilaPC5HHekjlIOCeRQB8oftWR+V8RNPHrpcZ/8AI01eMV7X+1mSfiLpuf8AoFR/+jpq8UoAK+gP2Kf+Sp6r/wBgWX/0fBXz/X0B+xT/AMlT1X/sCy/+j4KAOU/aj/5Lt4m/7df/AEliryqvVf2o/wDku3ib/t1/9JYq8qoAK9M+GsmzQJ/+vpj/AOOJXmdehfD59uhzj/p4b/0FaAPYfCHiZLANZX0YmsJmBdSM7T6itvxR4U0i4tTc6fhBKm9HHKNXl9q5EnWvZ/hxAdR0ZhcL5kQYx7Sen4UAeXR+HELFXaFVDbS27k/SmDQWW5P2bcjIcHHUD1r1W58D2cWoSzQOzSEEgPyobtVjwzoSWdpMt6UeaQnBxyBQBheHfE8uixpHfs7xgbRXqGja7ZalGDbygnuD1FeQeMPD9zpoSWyT7TbSOVkTunoRWjo1/Z6JCiXD7ZAoLMO5oA9mVsjinZrh9A8babdfJ9rjGDj5mwa7CKdJow0bBlPcGgCxmjPFRZzSluKAHFuaYzYFNZsZJqrNPtBOe1AD55Qqk54rmPEGoCCBmzkY7VZ1PUkQ7CRk815z4j1tZJjCJMcc4oAy572S7uZVhkwmelZtvaN/aIZGALNtwOpNOklWCydrYfvXPJrR8AWcv25rrUB+7DblB5OaAOlu5G0uytraQ4l2ktg9BnpWDPeNcTDYf3YPSqPjLW1k1WQQtwp2D+v60zSpPM27s/4UAdbYsVtncHjbinWWGbcwz7U/Srd5rSRlBK9s06C3lBwVAx3oAWdtkq9CD1q3aHjLcdvrULW7ZAkIAFT20UY58wk9gBQBu2WQF4wRWtE3IrHsXAwBx9a2IiMDGKALEiFkwKpSQtjg8itEcqfpUI+ZqAIYFOMGpntQ3OOaJFKYK0+KXcOtAHwR8Rxt+IfihfTVLof+Rmrna6T4lf8AJRvFX/YVu/8A0c1c3QAV+qlflXX6qUAeAftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQAV0vgI41eb/r3b/0Ja5qt/wAFsF1WXJxmEj/x5aAPRQwyOldR4NvXtNctJFdh+8AOD1B7Vx0T9ATXS+FJ0h1qykkQyIsgJUdTzQB7XPcXmoaxYh4HgiXcWbPp2rUFuVlZ5GwD6mq+t3cMOlO8Gd56beqnGeadMkmoadGwIJKdPqKAKPiAXC2M7QBXwvCg9a8R1d9QklkjdXGf4T1FemeJb1dAtreNmnfcgSQoSQnvXEXv21HluowlzCi7vl6/lQB59eR3UMhc78etX/DPizVPD9+k9ncvtzlo2OVYVtaRqkWtX0djd2saLLIFBThl9ak8bfD+50Yvc6fuuLLqSB80f1oA9y8EeObHxDaptkC3IHzxMeR9PWuzVgw4718YaVfXGnXMdxbyNHIh6qa9t8FfE2OWKKDVj5chwBJ/Cf8ACgD12WTA+lZd1dosbEsBjkmrAu4rq1EsbB1I6qa5TxDdLbW5cMGiOQfY+9AGJ4g1hFLyK27H3cnHNeWa9rH2u7O5+2cA1va1MtxIV3/L6DmuXutLXc03JPbAzQBZ02+lUiFApY9O9djp8vkBzuyQMyMOgHfFcjpdiVAckh/YVq6/fppeh/Zhjz5x+IX1oAwPEeqNfX0jZO0nCj0HatbQSqxID16muMhfzbjnkZrp9NdsDBxjigD1/wAMSJ9m4wN3U96W/gkS5+QthuRWf4MPmwxb2GQcGuxu7Tcq9KAOdlBXG454p0JGcnr6AVJqRWMoOKohwJPrQBuW2AeMY71r2JLjisPT5QVKn0resHXPIwaALyZQkHNSYDSAkU4ruHBpVjKsD+lADyOMH0qrsIYjvV1uMcU4Kp+tAHyJ+1eCPiJp2f8AoFR/+jpq8Wr239rYY+I+nD/qFR/+jpq8SoAK+gP2Kf8Akqeq/wDYFl/9HwV8/wBfQH7FP/JU9V/7Asv/AKPgoA5T9qP/AJLt4m/7df8A0liryqvVf2o/+S7eJv8At1/9JYq8qoAK77wC2NIlH/Twf/QVrga7XwS+NMlGcHzif/HVoA7KJvnODzXo/wALtTmtbyeOJXl3R7hGD1IPWvMIGy3XpXpHwmuYY9bdJoy/mRkAj+H60AejaX9qu9T1CadGiHCoueCcdcVopAI0IZxuPqaqapfrDqFituThmG4g8EEH86XWNPe8KMGwN6sSDjGKAOb8d/bU0/MKeYCT909PevHtT+3Tht+75T19K9K8S6sqX8umpJMobJjlf7hPpXF6nc3ul2rTzW6TI7YDDkUAcLMbm3Y7i65PWuy8AfELUfD92sNzNJPYscMjHJX3FXfC9naeM5XtrqMQyLETvi9exrmfFXhS+8O3REyb7cn93Mo4YUAfU3h3xDZa3aJPZzLIpHY8j61slhivkLwv4hvdBvFltJCAeqdjXvXg/wCINlqvlwTt5NyR9xu/0oA7q4lCKSTxWLqt/HDAXLADpV6/ljaHcSQp53CuE8U3ohzFIQc8qc8Y9qAMTxDrf2dXKEFjkEk9q8zu9Q+03TMHy27jnit7VALp33PuPQelYEml+Sw2BizH0oA2tIvJbl1jBQKPvMfSukk1EWGmSSqW2AYU/wB5vWud0uw2lFU/eIyAP0qv431ZCYrGEjEIO4g/xUAYk1y11eAliSWyTXbaJIoZOmOmK8+05t0hfGSOlddpcjh0IPcGgD2LTystiIxwMYwKzVhlS5KlmwDznpV7wygliU7uoBGK0ru1xIWOOKAMF8q5B5PvzU9uQMDPWobt1W5ZRjNQwSYbHPWgDetztX2HStq1BdOKxLOQNGpwMj0rfsGUrxwTQBPExHB61JEo3E96DHk8GnxKVODg0AJKu5CO9V1U9qu5+bGKdsXbwOaAPz++JP8AyUXxT/2Fbr/0c1c5XSfEv/ko3ir/ALC13/6OauboAK/VSvyrr9VKAPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAK2/CR26lIf+mR/mKxK2PC//IQf/rkf5igDuYXOa67wVaNea5ax5IAYOSPbmuJgbnivSPhQiNrrySZ2xws2KAO78e3jWvhuWW2ICSyEyN3PatH4aeIoNU0fyHk3XMAwRjt2NYfxJnltNFjtraNXjlUAgjOK5H4WXLf29cWSOFMkDDcg/ioA6/xjaQ6tcPaJqEUW6TLq749q0dF8FJY26ZlZwylSDyCDXml14X8RXuuvZiAzImSHbgEfX1r3XwjYXGm6Fa298wMkaYJJzj2oA8l8T+F59L1pLqzt0WLIbzUGGruPDtxFPp7RXMbunKbiMnp+tdQZrS8uZLbcrYGSMZBqJLS2DpFHDjY24EcUAeZN8Kku9ZeWG5X7I2W2gfMD2FaUXwrdtyXMqeWoyhUYwfevU7SHa/mbBH2x61IJH891kRRH/CwPWgDy2PwxrWjuh0nVvlB4SV8D8q6SLT21fSpIdXWNbkgh/Ib5W9/Y1q61caYrFriUB04wDz+Vcze+KYLeF49OiAYn7zUAYifDuCOViL8juNx6CrbaTo2lwMsl7avJ3d2zj6Csa/1iaYSSSSYHcDgVwmr6hudj3PvQBu+K9dsbVhHo7rK45aTbhc+w715/qV1NezGWdy7t1YnrTbmbzCTmoQeQMZoAuWMG3BbuetdJpuCVByBnNYMCFVG9sd8Vs2c6+YgTHOKAPQ9CvxCqbBj1H9a9D0y9juoEDNk4rx6zlJX73TB5rq/D+oeW53OSo6igC/4ol2SEodoXua5mPUZQ+BlhXReI40mtRKv3DzxzXLoFjPHJ9aAOq0W4aQgEf/XrrrL5sHOK4XS2LMuOK7TS5S6AHgigDcjJ+XnFWQKrQngEc1aH3c0AOYcUq+lA6ZpO4oA+SP2t8/8ACyNOz/0CY/8A0dNXiVe3ftbjHxI07H/QKj/9HTV4jQAV9AfsU/8AJU9V/wCwLL/6Pgr5/r6A/Yp/5Knqv/YFl/8AR8FAHKftR/8AJdvE3/br/wCksVeVV6r+1H/yXbxN/wBuv/pLFXlVABXXeEG26fL/ANdT/wCgiuRrqfCpAsZP+uh/kKAOttnJIHrXpvwtth9qubuRiqRxlOO+a8rtG5Fe0fCiGJtGmMmcyTqo/DmgBvxD1abS9T04IwjhiAMYB4yK9B03WLTVfDq3cMmVZPmPTBHWvJ/ipdTy6gLcogii53legqbwd9p1jwNqFrZyGOWKXKhe4oAv3+gR+IdXjCajGyx8KgkG6unXwdElnJbO/mI3PzDocfyrzTwr4V8Rahqq3UsBjEUozITtIx3FfQAIgtQbhlGByTQB4XZ6RdaFrjhoPIhJP+q6HFeh3Vpa69oRtLqMo8qA79vQ+tdCFtNSgaQgSKhxjbk5qS2giaYyRwfMo27c8GgDyzSvhK/76RrmN2DfuiFyuPU1qJ8LysYmnuPKuFb7yenbFerWsRijOMDPIX0pI5S0TG5VUYdQDkUAeaWWl+I9In22+owXVuBho7hyRj6Vr694bttd01DIzwy9flbhT3x6ir+q32kW8jSmTe7ZO1Tnmud1TxWTGIrKNY4gO/WgDPtvAFtbjdJqIVR94ualvYNBsIQjXlqqr1b77NXPavqkn2dmeQnPQZrg9TvslgD+NAGt4h8RgXMiaUxjg+6HIwW+npXGTbppsk8nrmlmfc3Wlhy8gCjmgDRsYhGRnriuo0hlV0dhnHaubtgsbqXYHHUVuabPmXCnGO9AHpuhaoImQA4X1/pXaieK4tmfOeK8hs5iNrbgBjFdloWoKYAkjEhuBmgDM1y4aK4Yg7QTwO5qhbahKzAMCeetXvEluBcBjxnpWXAypIAB3oA7TRpS4HHNdPZjHOfwritIZgQw/wD112Vg+9Q3T1oA1Yid2M8VYUYx61BEemKn7igAI59qdnjig8AUg6n0oA/P/wCJf/JR/FX/AGFrv/0c1c3XSfEv/ko/ir/sLXf/AKOauboAK/VSvyrr9VKAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqACtXw6cXzn/AKZn+YrKrT0A4vW/3D/MUAdfavyK9i+F2nCXQb64jHmTysIVUdQM5NeM25A2817x8IIZU0u3nRl8pvMG0HktnvQB1niRX8lQQoZF2YZdwbI5FZXhvw9pUV0yxWEltcKN4n3Hk+gp/jPxFc22r21tbWLSyqRhxyGJ7Guga8uPLVVgCzkA8fw0AJZ2TaZdhpbsygnO9xz9K6ZGjuIipIIYdjWZpkE8sGboAtnjI6VoWlqtsGI6t15oAS0sYbQkwxjJPXHNZGoXGox6zAkUC/ZWGWkPauhPFVb0DYZNwyB3oAda3Kzwoz/e7VX1qdE05pGk8s4+U579qp6XPbs/lvMrT9c9PyqTxTYLf6Wyb9gX5gRQB5VfXLyzuXcuSeTmqM0rZI44olGyZ13ZKk1C+D/nrQBS1K4MduwB5bvXIXpZs810uufKAOMCuYuDknJoApOg7kYqeEIi7wM4HWq02e5p8Lf6Ow5OKAJEmwevXvVy0nCSKSTxWSQcjA4qeN2wMjpQB2trd/MhJ5zW1pt4Iycc5HSuDiuiFUcnHStrTr4LJk53ZGPSgD03TLhrzTtjgcjFY01qxlx0wea2NHVms4HhC/OpJI7U+7tR5jMufegA0dBGgOc+orprLIKkVzVqhjkBI6HpXUaepkAOOfSgDctDuC5q+egHaqVku1eRir2cCgByHsaRzg00EDJFIzcUAfJn7W5z8R9N/wCwTH/6OmrxKvbP2tDn4jab/wBgmP8A9HTV4nQAV9AfsU/8lT1X/sCy/wDo+Cvn+voD9in/AJKnqv8A2BZf/R8FAHKftR/8l28Tf9uv/pLFXlVeq/tR/wDJdvE3/br/AOksVebT2E0cXnIVmg7yRHcB9e4/ECk5JaM0hSnUTcVe25Tro/DbYs35/wCWh/kK5yug8PH/AEVx/wBND/IUzM6izbJ69a+hvBWm/Z9K0b7Ou8YaeRx7ivnWzI8xR1r6g8FxzWdhtdlYYUgA8BdooAy/Elml/OYbmISwzHc8e35uPftVrQNAsTYONOjl0xzlDhsk471n2fiK7vfFjwwacyxHIct0AH8QrpZLq6mYLbRhT0Y4zn2oAs6KosJTFJMGbpyME+5rbuLeK8h2ycrVWGzaSBfNA3kfMe9XreJYYljUcD1oAZDAttB5cEagY7CsGxvdQjv7r7XCsUSMNh7sK6Xp3rK1b91GxWQLuPLMM8UAaSzIRu53cA1znje5EFoRHN5cp7DuK1dLmtZVzC4YjhvrXN/ELThJB9s8zayDbjsaAOBklLscn8zVSWUnvgUZG0nJ5NMYBmPv2oAxtcuDtEYPTrXLXILScnit3WG/fN2rBm7880AVyg3DcR1qckRRHAwScZqnLneKnlbMMZwTnvQBKk2QFzxWppVyI5flJyawFyH6ZxVuCQh1JBBoA7W1ugcg9CB0rcstQaOJQoBIIwa4G3uyHBro9CvFM8ad24bPSgD0K+zd2O4/eXmsJLY+bu7V0sMLYdcARdMj6VSe1Kt8oJB6ZoA0dNAVFUc5FdDYkq3B4rmtO/dv0zXUWcZZQQM0AbVtyKs5yagtRhQKsE9qAHqdw96Zuw1IDgcU0tzQB8C/Ez/ko/iv/sLXf/o565quk+Jf/JRvFX/YVu//AEc1c3QAV+qlflXX6qUAeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABWjon/H23+4f5is6r+jf8fT/7h/mKAOntySwAr2T4NSXEOpxQyrL9ncMd3VRivFrd9rA4r1n4U30l7df2e7OkRibc6cFc8ZoA9wuoIDMkqrkj5vMx29KvWPlsTLtXe3euVn1rT7G3WwNzgQoA0hPTHv61Z8I+IrHVJZba2n8x4hnOMbhQB2SN6dKfVeJ881KDkUAZ+rXjW6qqMAx5zivOJtcu5NSlSW9LK7HaF4AX0rv9cLk4j2gEENkdBXkMtjcy6w1uFOHOQVP8NAHV2lzdw826iUSEY3dfzrS8YazNZ6JFAG/fyjD4/hGK5p/EsWlAW1nH5qx8bj0z3xWBrGryag5Zyceh7UARK5YsWPXnJprP2qp5jc+vWrNnBLdTKkSlnPYfzoAy9aJYjjFc3cJ19e1d5qVpbQA/aJFYp97HOfpXF6xqttHcYs4gAP4j3oAzZYyBnFRLlYW4OCe1SS6/PN8shUqP9kVC90sw/dnYe47GgBiyMDwTT1umQjPI9DVRp15DKc+xpplT3oA2EvFkA24BHar9oWZgQcmuYW5VWHFdRoUiXBUjoOooA9a8JaiLfTEjkGcVuwHz3+6Tnk1yehRHaoI+Qjj2rutJURkEgehoAnj08Fc8dOwq9ZhYcKKdLKUQH8KijkBI+tAGtAeetXlIIrMtpAwGRzWgp+X3oAex4qIt6UuKYRz70AfJ/wC1gc/EXTv+wVH/AOjpq8Wr2n9q8Y+Imnf9gqP/ANHTV4tQAV9AfsU/8lT1X/sCy/8Ao+Cvn+voD9in/kqeq/8AYFl/9HwUAcp+1H/yXbxN/wBuv/pLFXl8E0tvIHhkaNx3U4r1D9qP/ku3ib/t1/8ASWKvKqGr6McZOL5ouzNA3NtdDF5D5Uv/AD2gAGf95Oh/DFaWmxC3t2Kus0O7cZI+QvH8Q6r+IxXO1s6MB5BYZVw5wynBHA6Gs+Rx+FnV9YjV/jxu+60fz6P56vudFaOSN0YMh6gL1P0r6J+Dt2bvRJfPZ9g2hHY53Z//AFYxXzto1tNNeI6qAiMC8q/LnHOCMYbPsAfevQvC2tDRdRi+1PL/AGW8yyzpGTlGH8YA6j+8O/UcjB55YyMKqpS0PapcNV8RgJY2h71norWbXVrzXldPo7o97EcNvcPJGgTPGMfez3rXs1jjjAUAZ54rhtQ8V6XJCJheqkSn5GUgh/p6iuj8N6vb6vpq3Nq2VB2kdCK7D5o6JTxQaijbin5yOlAHO+ItUlt4Z/IlWNkXGSO9cPaarcXSmO4vJHYfe5xz6/Sup8WpLNZXKLs2HG33Oa870a1ZppJb3ckFuSXPbI7UAdtpFzfLcwQqi7Byz4wQKzfiFrTzXS2cbnyUXJPqaz5vGLKGihh+XGN5POK5m+vXuZi7Ek9s0ASBjs5OCKQuSTxzVQSNjgexFaGn2UtyXYcRryznoKAOX1UFpXzkVizR/Nxye9drqa2FrueY7h6Ac5/pXF3OtCK4drVFjGSBkZoAqTxkHpTZWIjQHPSnvrT3DZnCsPTbVeafeu6M5T+6ecUAKsrKODUsV6Ub5wGFUWmQ/wAJH400zJ15oA2kuQ5yhHNbOkb/ALTGR65rkLe7RZBkcV23h9VldHHIPSgD1ux1MPaJHgbiAAav2cXnsOOOmTXP6LCSEDdR/Kuz0zCx4wOelAAunqoBPPPPFaVowC7V7VXnm2nae/P0ohk5yKANm3PvVrIxVG2cEjFWycj2oAV29qiZqUjg0wjrigD4K+JP/JRPFP8A2Fbr/wBHNXOV0/xBgluPiV4nit43llbVroKiKWJ/fN0ArO1PQNQ0q0SfUoVtTIfkhkcCVh67M7gPcgVLnFOzepShKScktEZNfqpX5V1+qlUSeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABV/R/+Plv9w/zFUKvaRxct/uH+YoA34jgjmu88B6skOr6fAI9gY+UzD+LPrXARHmu9+FUVtc+KrKO6GRnIHv2oA67xV4TvJBqc9hcb0BLiLPzHjoKq/CG6n03UJRdxSImNpLDkGtnx7fvoetIbFWkkcB5o2ORgenoa09IS01/T/tUYkt5uBvUZ/A0AepW1zDLGpibIPNXImGME1x+l2rW5gjkm3bV4YcZ+tdTGQVAyCMdfWgB88Edwm2VeDWHd6KIpVEIXyyCMkcjPvW8rYx6D1psr7sA9M0AeC6vp09heyRSoRhj296oGMhvmzzXud/DZIcThJTnJEoFZWp6Tpl4Y3XThK3A/d8DFAHl1lpl1dK0kMZ8sfxHufQV0trpd5ZaZMyKsWBl5HIGfYV2Wp31noumxxtFGJScIijhT715H488XG9tjaySlSG4WM8Ee9AGD4gv/PjdIizMeC3r9K4q6Vgvzde9bEFy0kSxvjGScntUV7Y74w65YH0oA59GFPjco4K81oDTgPvukf61Pb6WrNlbmM+2DQBWuNsqJKFCkjBx61Tcdq6htFlNnIYUVgMZwe9Yk1q0bsrqysOoNAGft5rf8Nu0N5Hjo3FZiwZcDpW/pcQV0I7EUAeweGtgAMhIOOPSu0tmXaNuPc1wnh2TfFGfaursecAZxQBvuAyhWpI4gBhRUe3LAAngVcji5z2oAlto8bRWhF26CqiALwKsIeBnFAFnAxUMmKerZzSMoIzQB8l/tYf8lF07H/QKj/8AR01eK17T+1eCPiLp+f8AoFR/+jpq8WoAK+gP2Kf+Sp6r/wBgWX/0fBXz/X0B+xT/AMlT1X/sCy/+j4KAOU/aj/5Lt4m/7df/AEliryqvVf2o/wDku3ib/t1/9JYq8qoAK2dG/wCPZv8AfP8AIVjVsaOcW7f7/wDQUAa9qEVwdvGckDjNeleAbHS9dur23uLZoz5JZGWRgUx6YNeZwnpXs/wStbW5TUHIJuAoA5xgHrUuMXujWFerD4ZNfM53xN4RvtJ0e2ktWae3ViNqEsV75Oa9I+EOpeRpaW94rR5bIJHWuWudfbStemtkjabTlcx7icsp/qK7S00mC6+zXVpI9sz/ADFduVJqjLc9IjlVsbDkdqshwV45Nc3pCbJm3yfMDjHY1vAg9aAIrzT4LxcSL27Vy3iPQ5ZdNvYo1XOAy4GC2PWuyD46/hUMwE+5GJGRjI6igD5+lt5YpWR1YEcYIqIJyQck17dPHp3ngPFDKemWHIrNOi2D6kssOmjdnd5hOFH4UAecWeiXsyo3lsqueB3x61q67DcaZo6PKVt4BxsyNxNdd4n8Q22nExWyJ56Lkt0AHpXiXjjxIdWvAwlcyAcgH5QfagDM8RXLXTYiDBRzzXLXg2nNdD5v2nG8qDgLn1qjeacRKMLkH1oAxgwI4qa0mMUgO0Mueh71dGnpj5pkU+mCat2ukg9J43B7UAZt1GFkO0fKeR9KrMMmul1DRp0gjdI9yYOCpzxWK0GOMH8aAKiLlhxXbeCZG8/yj9RXLW1vmXJ6Cuu8OAQ3iMv0oA9h8P8AliFecMexrqLZhuG3GO1cRZ3cFtbCW5lSKMsqgs2MknAHuSa6rThuZc5xQBpyoJGORzT0iGAFHFZWp6zpekbX1O/t7beflWSQbn9lXqx9gK5i/wDiTbrcfZNE025vLoj5RKGjJHqIlDSn8UA9x2mU4x3Zcacp/Cj0y3XBqDVvEGkaGq/2tqNtas33I3cb3/3UHzN+ANeY/YviD4l/4+bkaPZt1Ab7Px6hULSn8ZI/pXOXln4T0BpFFxceI9Skby3ED/Z7UydNrOmXlbts3St2IFRKo0r2+/8Aq5pGim7N3flr/wAA7nWfizbLJJbaDplxd3CjcTcBo8D+95ShpcD/AGkUe4rzLVvHvivxDcrbwXE0cMx2oLbMKSn0jWIvNL9VcD1x26/R/Auu+JIEXVEg0TRAdyWUNusSn3EAJUH/AGpS7f7C16foPhfSvD0bnTLfE8gAkuJGMk0uP7znkj0HQdgKjlqVN3Zfd/wfvfyNOalS2V39/wDwPuXzPjnW/Fl9ot9fafpsBsryOV4rmZ0QSFwxDDC5HXPLF2/2q4e4mluJnmuJHllc5Z3bczH3Jre+JAx8Q/FAP/QVuv8A0c1c5WlOlCn8KMatedX4nounQK/VSvyrr9VK0MjwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACruk/8fDf7h/mKpVd0r/j4b/d/qKANqIiu8+Fdl9r8SQSHfi3Il+XviuBjPNemfBS+Ft4pVJMmOWNlPHtkUAdv4ym26z5PleZNKQFbHr2rb0V4ILKOzs3RhEcylD1b0/CuF8fa+IdcvUiAWRoyI2PVeO3vUvw5lWG1RrsEktuGT196AL/AIz+JU+l6i1lpkUZMQAd3GefQCrfgX4n3eo6mltqFsBG5AEq9jWZ4m8Etr9/Nc2oS3kZgwZzw9bXgzwTDo0iT6hOZpl5CqMKDQB6/vyo96r3UyxpmRsKKrrc7kyOmOlct4xvLuOyZ7VcsOwNAHRXEkTgMBuIHGeRWPqU5jtTsnMJzkgcCuS8HeKXntL1tVJhEDbVZ+4rF8TeLLO5SRbW4BKcjPGTQBreINfgijQ3sqNg5J/vH2ryLVJI77VZZYAWizwDU/ii9XU1gaJyWQYb0qnYxLGA8hK8c0AWTar5DNMSo64XtUEuo7YxHEhWNeOTnNQ3l1lt247ewrKkmLk4oA1o5ftBEe0bj0IPepLeOeKbiNifSqmgyY1GNiu4Jzj1roLnVzsItI0jbu7DJoAZ9oktomjkJ8yQgkE9BVRHWecrNukj+vIqmqyzTM8jFmbqSeppsIMd0oZ9gJwT6UAXru1EEqMh3xsMq2Ooq1p+d4xVq3hM6vaTMuc5jf3/AMDVnQ7FmuSsiYKnBzQB6F4ajb7LGW9q7nS7fjcMYFc/4etGFvHlSB06V21jGEhPrQA63QFixGCasu23AJqu06xttz83pWdd3chY4IGRQBqNcIuTmnxXa4HWuc89mzlySOatRTfKOaAOkjuVY1aRty1zkEwOB/kVr20+SMdKAPlf9rX/AJKPp3/YKj/9HTV4nXtf7WRz8RtOP/UKj/8AR01eKUAFfQH7FP8AyVPVf+wLL/6Pgr5/r6A/Yp/5Knqv/YFl/wDR8FAHKftR/wDJdvE3/br/AOksVeVV6r+1H/yXbxN/26/+ksVeVUAFa2k/8e7f75/kKya1dK/492/3v6CgDViPTFez/BWyKw3d4GkDSKYh6Dvk14tCcEV7n8GNSRPDepRTAsYzuTj1FADGMN5rD28kaxRRsWlkYYGAetdxb6hEsa3KEfZYk+UDsB3rxbXtZe6V7WA7Xaf94R1b2+leieFpYRpYikQtK0WzH9KAOc1L4tX4v3+xQRJbhiFBGWI9a9C+GfjmbxGTBe2/kzgZBHRhXnVz8Nbi6uRPayxW4Jw0b8kD1Fej+CtAtfDoVvMaa5Ixvb0oA9CLZ5Gap3NwiOodsMemKikuDsJzmvO/Heq6hYHzrZWKqM/L2oA7m6eM5KoCW65Gaw9YvXgZWiuyoAxsY4FY9l4qtx4ctrnUpBDNIuWQ9fwriNc8UwT3CTQzAoTg88gUAaXizX7ICdJ2Bdk2gDrXl9vE0srOF3ZJx7Uutt9s1R54WZkc9DU8Gy2iJJOewoAfPDFAscku5mXooPWq8+pNI3KgL6E9Kq3VzyctuJrPMpY57e9AGyubpD5afOvJxzkVPZJcDKJGxJ6Gm+G7lII55JIyykBT7Vb1DVJ5UZLYJDGeMKOSPrQA6a8IjEIc4jGCwPeoLVI7rPnkqx4Eg6A+9UEhcxN6/WptLVjMyCXa20lR6n0oAkMLQTvGwwQcGtfSZGS4iCI8srHCRpyzH2/xPA70PB9stfN4+0Qj5hj7y/8A1q1fDOkh7jz1aeKaQBC0crKdvp1xUz5rPl3Lhy8y59vI6N7S4js2vLoRz3ka70hy3lxgYJVcAkkgEFgMnoABxVm0tPGviKBJEuBp9jKNysrfZwynoQELSn/vuP6dKsJYKur2OnDUdR82ckylWixCpUlSdyE5JXAH1Pbnfl1zSfBFnNZy6ndancg+b9mJiLwg9dxAVY1PXL474zXBh6VWDk60rryZ6eLrUKkYLDwaa7r8d3f7iDQvhbpluxm1O6ubyd+XEZNujf7xU+Y3/A3arGqeKvDPgy3mstHtbYzREB7ezVY40b/prJjap9jlj2BrnJL3xX45UiHGmaO3PBZEdfdvlkl/Dy0I7t32dA8J6ZoZikRBcXcP3J5VH7v18tB8sY/3QCe5Ndcf7it5/wBfqcMn/wA/HfyX+e33fgZD23inxwf+JnJ/Zujuf9UUZEdf+uZw8n1kKr/sGu88KeGtG8PMslpAZr3btN3PhpcegOAEX/ZUAe1MWckg7ie1XFm4BzVxgk77szlUclZaLt/X6nRxXCseKsZytYVtMNwPYdxWpBNleaszPgz4l/8AJRvFX/YWu/8A0c1c3XSfEr/kovir/sK3X/o5q5ugAr9VK/Kuv1UoA8A/bW/5JZpX/Yai/wDRE9fFVfav7a3/ACSzSv8AsNRf+iJ6+KqACrml/wDHw2P7v9RVOrml/wDHw3+7/UUAawNdB4Q1eXSNYhuIs/3SB78VztTwPtYH0oA9H1a3NxeHU75wIhuWTI+8wHC/jVTwhqtw94ZZTmCHJCdh6Cuh0a4h13w3a206IsJBM0gOGDr0P41wtvfLp2r3DJslhkJ2gDhs0Ae16HrbzhXmORjp2AqW68V2Ns58yZCncLyc14tPrupWcdxHtZYJBhCv8NZFtdzSSBiSVPqaAPfX8dWUcZMRY8YGaw9a8bTTBUt4lI9W5rgLPTri4YYJPPaujh0lrVEe4fCvwKAMXxRrFze26QtiJfRBjn1rk47eV+u4gdTXp994cN5CslvGZGA78Zrk7iFrWV4W+XnDAdjQBSiiSNBtwx6mmTuGXpSXMqIh524rEnvnOQv50ATXDgHbnJPAFR/ZJyobGA3TPeqccuJA7Dcfet+LV45lREgJdRwB0JoAuR+TocC5CS3brkf7GfWs0SNJISOppkz+eWkm/wBcTwoq3p8DA7ivFAFqE+TECx5NQOElkyKkvEPc9OlR26kkEDigDd0CPN0oZsjjr2r0bTbCFb4SbQWfD4rg9DiPnJ8vA6mvTNGQssBYHIWgDsdMXaigDtWq0mxNq9ayLaXy1XJHSr1s4diGGaALLwbwJOeayL2PbcMWIGOBXQxOvl9gBWD4i+6JF+7jmgDPLIGxkD3q1ajzFOCM1zpugZBtOa09PucEZIOaANeL5TySM9K0rOXoKySQx3DOfSrlm3zZANAHzd+1dz8Q9N/7BUf/AKOmrxevZv2qjn4gaaf+oVH/AOjpq8ZoAK+gP2Kf+Sp6r/2BZf8A0fBXz/X0B+xT/wAlT1X/ALAsv/o+CgDlv2oF3/HjxIoIGTajJOB/x6w15vqOkX+nKr3duyxN92ZSHjb/AHXXKn8DXo37Uf8AyXbxN/26/wDpLFXm+nane6azGxuZIQ/Dqp+Vx6Mp4I+tTLm+yXHk+1/X9epSrU0v/UN/vf0FTnUtOveNT05YpD/y3sSIj9TGfkP4bau2WlxyxkaTew3oY5ETfuZu3Gxjhj/us1T7S3xKxXsm/gd/z+7/ACuRKcGu48B65cWcdzZw5xKu76Y61w8qSQzNDPG8Uy/ejkUqw+oPNaGjXpsr+CZVLMrD5QMlsnpjvV3W5nZp2Op1WD+yYbieRg08pVoFI5x3atzwfrNxb2puJm3ySEKhPOPU1c8Ti01PSpL2XyokiiC2zKcq6sO4rhtI1J4LZ7PYHkz8uf4celMR7pY6yot2kuHGOpZu1V28YafDJtklDH+HZzXiGo6/qTWaWt3vUqxJ7A+lQadLNNJsLHJ6ZNAHuk3ju2ACxZLH3rmdV8YXV1O3lwIU/wBoZzXK6dpFxM6nJJ/lXQW+mCCYQzP+864xQBxvii+uNRuyzuQR0UcAD0rKtrZmdWkJCnua9A1nw1IqvcQw5QDJJ7Vy8mAuxjlV6UARYSIfKAwHfNVbpsj9aZfXKouQQD6Vjz3jvwOAaAJpG8x9iHc2amtdNnmuo4WITcec9hVSwultpxIyBwPWtk6r5weS3gIbpk8hRQBau7uGyhaxtFQno8nXP0qhBudsDvUBRSV2ZLnlvr6Vq2UJRORyaAHs6xLsPNV4Y1aQMpIPakuVIfJPNT2iMWHHFAHW+EYleUK+CGyvPfNdZbSR6TGiWsSS30hKQxseMjqzeijufoOpFcz4bjYSAhSDkAfWu7ttEsL29+03dpHNKBs3SDIABzjHSpnzNPl3Kg4qSc1dGVc2bLps6C7eO6lO97nzDGzyccllIIHAHBGBwMYFanw/8PeHJEWZJU1K/gYNIsu3bBIf4ljGRk/3yWY8/N1Fb9toeiQE+VpGmoxGMpbIOPyroLFIUjHlxooznCjAzXHhcJKi25S5r67dfvPQxuPjiIqMIcttN+nbYllttpYjr15rDkUKTuOMnkV1LSLsBbAzXIa8fJuCScLnINdx5oB0B4YZFXY0zGGBH4VzcdzlztPfrW1p9wCoUnINAGjC23AycitezlyQPasNcA5GWzWnYtjGBQB8Q/En/konin/sK3X/AKOaucro/iR/yUTxT/2Fbr/0c1c5QAV+qlflXX6qUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFXNM4nb/AHf6iqdXNM4nb/d/qKANMHJ9BUkbEdO/FRZ9acDQB2Pg6eW4t7zTIQfPmXfEc4wR1H4is3UrdoLyKG0U7wcFTyAx6gGo/Ct+2n6zazq2AGwfoeDXU6/oWo2WsG+sQzwl/NjYDK80AMltZtJ0O5l1OMOG+VRnOW/wrA8NWk+q36QQRgnOcdMV1HiiTVZdBtvtkUW5j8yonHsTVzwpqGnaVDG0NtsushJy3v8AxLQBb1nwxqFobUafJIy/8tNvY/4V2em6IJIIlvH3Kgzz606y8TaHcbY3vI2lUYyDxSz65aywOli6SyMDt2HIoAzvEmtx20EtjpcsQkUYLZ6eteX6zJNsLyN87dT3NZ2um7tdTuZJ3USBs/KcirY1DTp9OW4n8xbn7jIOQfcUAYjJJLndVWXyQu3ad3rVyzs7i7nYxhtmeKff6Y0DAyOq+oJ5oAyfLyRtPHvVuzkNuwZByD1phidgTDGzIP4sVXLN900Aazr5lxvUfe5IHatGO58ghQATj8qxLSTawZjnAqwJ1zzQBoPM8rZPerdjESCWHHaqVvIrMAQOtbNsUxjfwe1AG9oRc4RVGPWvTbSL7Nb2wJGWQNk153oEYEw/ma7+7lYW9s2MBExk/WgDQmvRtABxVq2vTGc5zxxXFtqO2T5ux6Vagvi0n3s8ZAoA72O/3QMxbBrLuL4XIaM8KeM+9YJ1TZZzZxnGMCqum3ryQNLknBwfzoAoX7S210yhiOTU+martZVl6+tW9YtTP+9UdRmufdWibHJY0AegWV4syLhgG9M1s2swXk9fevMrG4kSTcGOR6muv0q984gNycZNAHhv7Ub7/H2mn/qFR/8Ao6avHa9d/aaOfHWmn/qFx/8Ao2WvIqACvoD9in/kqeq/9gWX/wBHwV8/19AfsU/8lT1X/sCy/wDo+CgDlP2o/wDku3ib/t1/9JYq8qr1X9qP/ku3ib/t1/8ASWKvKqACtPTQDbsGAI3d/oKzK09MP7hv97+goA2YNTuo4VgkdLi2T7sFyvmoP93PK/8AASK3fB1rBqfiLT1tbe4tpYZknZUPnRbVYE8sQydMcl+cetcqDzzWhpmr6hpqSJYXcturnLeXgE/U4z+Huawq0m4tU9GzqoV1GcXV1S+/5dj1bxj4beSLztPRntd+6e0T36sg9e5Xv1HPXzmwtrq81MxWHzBhkMRg4Fb/AIO1S91fUXtL/UbwvJGREwuXTDDp90gUtlpuu6PrMjRIzSzv8xmBYNk8mowlKrSjyVHfsaY6tQrz9pRi433Kvir/AIl+l2trcwqbtuQeuF/xqfwLok+s3AfAWFeGf0qTxYLmbW4FvYFkiABIVccdwK67w7rul6ekcVsq21mVD736g9w1dRwlWHw/qcHiMIkkn2P+Fj0wPWu5g0q2iU3d6y5QfeY9qZH4j0KeJ5Y7uLcOSWbg1k+K9RN/otxDphUnbyxOB+dAGX4r16W9QRWEqC3UkNt6tXnGrvKr4B59B2qjHeS6fcKzncC3zJngitDWbjTjb4s2laWVd2CM7Se2aAMeWJmUvJ074qrL5LNhVIrT0/S7mePcVO33qtc2S28reZIuB2ByaAKCxc8nitGynMfyBRsYYI9aqSRyqu/y2VT3xUIZiwJPIoA2LSPbMSMlfWtAXpVCigZ9ax7eUIjAnJNTRzLux3oAubmkPPWtWyjKqpYc5qhZurPk4GO9bNoFYqC+T7UAdb4aWS4mhQgKNwHHevQI2FvM68fIcYzXE+FF2SRnHQ5966PVbho5pnIxuOcUAapvA0oAbt2rQtr8xjGcnPNcPFqOJOvXjNXLe9IQtnJ96AO5uNQCQK27p29awdUmN9aPzhwMjHpWNqmqlbOIA/NnOR2qeyuG2w5yVkB60Ac89zNCzDcflPQ1taXqqk4b72fWqOqWTLIWHA9azAWjbC5BHegD0e1uVkwyNkdxmti0nUEAd/WvNtLvJIWBDHBPOTXY6Tc+cFPfOKAPkH4jHPxC8UH11S6/9GtXO10HxC/5H7xL/wBhO5/9GtXP0AFfqpX5V1+qlAHgH7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFW9N/17f7v9RVSrenf69v93+ooA0u9OGPxphpRQBYiYhhjrXpXg7xhLDokmnXDRnywWiZxn8K8xQ4rR047rmEA4ywH60Ae3XGqCeS3tdV0wKGQbZUOVc4rzHxzqFvLdsLMeWwJRgp7DtXoOtavEulwac6jfJFshmHO2vGL2Mi5feTuzz7UAOhvjFZNAqDcTnf3HtXReHfEV9Y2hgg2hTnkryK5gRtFKm9d0ec8dxWg96hbMa4HZcUATeJGnudkzgBR97Hr6mqWmXENuczRecpOdp4FdHZy2csAV2DFuCjd6t2WlafLdi38vD9fYigDMOuyrCy2Fqkan+IDJFYbWl3czFnJkcnrnOa9d0vw9YtF5AjVd2Tk1Hd6fpvh9HmVTcTYysfofWgDyyU3FvH5BBU4wVxVIxNu+6c/Su3SMym6vb1REknOwLk/hXOXBT7SfKBWPrjrxQBmKp6dKkVCW45rQ8kkrsAZW5Gf5VestPSZgu1g3tzQBRtkKEetbVmm5gc8jnFQf2fMpyInwDxlauW0EwUYXb6mgDqfDqSeerAkrkDFdRqurLHtVT8kY2YPf1NYGgzpa2bTzEhxwnuag1KQvb7kO7JznNAEt1eo5JCg570sN6Yydo/DNctLcyRyEZ4HY1Ytb1nO4/TigDXvtQkYbRuCk11fguRb6CWNjg8da4Fmd2yAce9dH4Zu2s2UJxnk+1AHfXlusUYjB+Ud6yptNEzHaoJAwcVLHeT3rENg55FdJpsIEOXUZIwcCgDkoNHdc7jxn61s6fZeUwxxWjcNHGSMDNU/tB3dcDtigDwL9pYk+OdO3dRpkY/8iy15JXqf7Rbl/GtgT/0Dk/9Gy15ZQAV9AfsU/8AJU9V/wCwLL/6Pgr5/r6A/Yp/5Knqv/YFl/8AR8FAHKftR/8AJdvE3/br/wCksVeVV6r+1H/yXbxN/wBuv/pLFXlVABWlpn+pb/e/oKza0tN/1Lf739BQBcFOXGeKjpy0AXLWZ4XV42IYHgivYtE8YXGqx6eoWB7xW2MjDG4Adc14vG2DXV+Az/xUFuS20L8w+vagD0q91W1uBdzXumm3uIASVJGAPX2rx7xDdxzXri2OISc4B4zXofj/AFRNTt7iGNPKuITukI/5aDp+leViINIVDc9s9zQBZm1BpVhREC7AAcfxe5rrLbxLfy2K2xCeX0IC43VyNmwt7gtcRk4GAMdDV6C8TzwD9zvx0oAqa0kn21nlwA5yMdBVvTL62t1AlthMwHDMcVvKljeIsZ2ykcgHqtXdI0fTrwsyxnCnBB9aAMC/1e8ubbyYI1t4zxleOPrWRBp1y7bwpbv617JH4asbu22FVQJgHmsjVza6PataafAbieT5C56L7UAeaXMk8vyHJA7CqvlkHofyrsri2ittNVbrBkbJCgYx9TXPpgyHcTsJwMUAUFU9j0qWKMs2BV9bdi7IyBgO/fHrWjBpoeBnjVyVHYZoAp2gKkCtzT0wQwJ9KorYzI3Mb/iK0rSOVXQ42qO1AHb+Fd0GJJiWQDcfpVnUtXDTOJCMPzz2qlHcxW2npEWxNIPm9hWNq7NuBUcY65oAuSXStIMKKmS/ZU2gEg8cGuSF7JG3Jzz3q9BdFk7884FAGhLqMjXCFs7V7V6J4dhS+0yByenPvXlah2cbgSCRxiu28PanJbQ+XHgYG0e9AHTX0QaQKSOOgrLm0oygtGMZyc1dtHlunVmAJHWumjiUW4BAHegDkLfSSpG/Fb2m25hZdvGKfPKiZ2gZqFbht3Xn2oA+RfiAc+PPEh9dSuf/AEa1YFbvjsk+N/EJPU6jcf8Ao1qwqACv1Ur8q6/VSgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACrenf69v93+oqpVvTf9e3+7/UUAaNGcmkoFAD1NWbd9rKc9DVUVIhIxQB6ZpEUGs6eLZ5gL+FS0ffeOtcZqFjd2kmLiPdjjcetJpOpy2c8UsbFZYzlHHauwmvLXxBYzG7kRbsxnEYGMkd1/woA4EXUkZKAKFHqKYbp9xLBT+FWL6ykgKlgDkZ46iqYjDHBPNAD7dnafcMk+1bVodSlmjKRtkcA47VL4b04gi4a3mkA9EJBFdXBr9rHNHHDp1wMcMGGMigCfwzpniPU9RV5yY7aP7zNwMe1dlf+DtwWQzuZF5BPrXOn4heXOlrp9ieoGXOD+Veh27arqdhAZIwjufnwOFFAHkOvQTJJNbIGcJKQXzkA+lYNnp81zcmK1iMzAZbAr2P/hDnaZGurnCmYs6MAOO2KfrmmWekaPdTWcawNsKq4GCTQB5G+m3lvKIbmHyEBzkjOK1NDt2+1Ih+WMtl5GOPxrZ0LS2a3+1XrSOs3yxo3ILVr3jR6XZDeI5Lj723AKg8YyKAMi/tbKC4k3ahKrZyABuGKzJpLWE4t5JZvdhgVFf3Et1cNPKdzscniqZBOO1AF37ZLJwSMDoOwp81xK1qRxgVSjQg89KtqMjB4B4oAxZ7ts/OuRRa6kkcw3x/L6ii9hKuwx3rNK/MeOaAOzWZJok242nkEVtaVGhZcnlhXDaNcsjGJiSvUZrtdEZTOjNnjpQB32i2qgKxPP07VvT3CwRhVwM9M9qwNNvUQY3bvpUepagGvNoJOO1AF26lKAsTnngVntcb3HXmobi6V4GOSe+arWsytzzxQB4z+0E27xjYn/qHp/6MkrzGvS/j42/xdYn/AKh6f+jJK80oAK+gP2Kf+Sp6r/2BZf8A0fBXz/X0B+xT/wAlT1X/ALAsv/o+CgDlP2o/+S7eJv8At1/9JYq8qr1X9qP/AJLt4m/7df8A0liryqgArS07/UN/vf0FZtbGlRRSWpxcpHLuOVlUqp+jjI/MAe9BMpKKuyTOKBxUlxbzW6hp4mRG4EnDI30YZB/A1GKAjKMleLuPU1qaRKyXcZRtrdjmsoVNE5RgR1oKPR9UsI9Y0h77TZP9I4WaMDlTXDXUM0DsJ4tp65xWv4f8QT6bMXh2guNrq3Rx/jWrr8FnqdglzaS77jzPmXGGUHsf8aAOL+2y7cfKMcdKjNyxUggZPcVJdWzwysrAYB6iokiDnjJPtQBYsGmRi0O4v2xW9pR1cXDSW8ZEnX7tXdBtk02AT3FncSIcEjyznPtXQ6Z4mtI7hnOnziFBnpyDQBqeDNA1u8V59UlaGOT7oJ+atPVvChtUmuEmIbYS2T2x/OqWh+PbzUdUjt9PslX0LHNdvqmn6jqcMi4KIY+DjkmgDxHV45JypZWWMKPmbuPWq+n6Vd3kbPa2rSRg4BxivYrTwdBHcsb6YTxCNQEI5J7jFZHjq2TT7GC1sR5Jkk+4hwcUAecJZ3AYi5Xy2XgLjkiul8N2gmDLM3kRhMJyQSa19P0UwwpDIS92fnzIOFU9OaXWr9bDEVntaTGwyYBwMDp6UAZEsOnx/KdRnPqNuaovcxxNi33sB0Z/8Kqy5LEnnNRlSx+tAF0XUrncTlvWm6lcS7FY+lQwqR9anmTzIWHccigDEku/mO9ATVvTNTi8wI6BSeh7VQuoyOxqntIHGaAO4VlklUjjHFdHo8Ss21T82c5rhtGujIiq3LLxXc+HnSNizEhj1zQB3ek2yRqMn6jHerl3dZ/dKQOPzrNsb9BGBnPGc1lnUA87tknnGaAL91OY+DyTyarQzbpeh47GqV9crtU8/l1p1pMMhhn8aAPmDxvz401//sIXH/oxqxK2vGxz4y14/wDUQuP/AEY1YtABX6qV+VdfqpQB4B+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABVrTv9e3+7/UVVq1p3+ub/d/qKANI0goooAcKcOlMFPWgCZGxWjZXCrhZMlRypHVTWYtSq2KAPRfDVrpWq2zrrEhULjZIv3uvINeg+H/AAj4RiXdHDFdyE8M7ZP5V4LbXDocoxU+oNaemahPbXUc0c7pIpBByaAPpy1srCC2CW9pDsHCoowKpXFti4DW9hAvIB8xBz9DXmlp4n1Myp9nuvLhbBbcAQD3xXeaPrV3HbNNcFJmBGccce1AGhB4es7rU/Ou7GL5RkNsHb3ravw0dkTZkB0+6uOD7Vhy65PL5bGNYIGzuwcmoNA8Sw3y3FuJEMkZO0s3b3oAo+L7nVLvQjJHbGCTPz45IA7isrSb+61SC2s9SCzwnrkYYds130E6yWp81Vc45Udqo3UsCXsarYbyQMSYAAoA4ifw/Layu1pcPNHLIV8tGwFrL8W3GxoLFY4lMKDcyNuyT2J9q9U1KW20y0cv5RJ+bDDqK8p8U/YbiRbvTwybuHU9PYigDmWzgUAdPWnuDtJxxTFUen40ASKvNSL1x6UwZDVKuOo60AR3Vt9ojLL94dvWsGeAqxyMGuqh4Gew5NRX1klwC64D9x60AcvbI32hCvrXf6OhCFiOAK5mGx2c4Oc13Gk2+LVeDnGOaANbSVaSRRg88/hTbqMtdtj5lz+VX9Ft3VmZT/D0NOtLR5pS+MAH0oAptbt5WAfcYpthaN5g+XC55zXQy2exMRryehxUllYOrhnB+mKAPnP9oGLyfGNgvrp6H/yLLXmNes/tKx+X45sF4/5Bsf8A6NlryagAr6A/Yp/5Knqv/YFl/wDR8FfP9fQH7FP/ACVPVf8AsCy/+j4KAOU/aj/5Lt4m/wC3X/0liryqvVf2o/8Aku3ib/t1/wDSWKvKqACtHTv9S3+9/QVnVo6d/qD/ALx/kKAL0E0tszG3leItw2w4DfUdD+NS+fDL/wAfNsoJ6yWxEbfivKn8APrVaigzlSjJ3tr32ZaFukn/AB63EcjH/lnJ+6k/InafwY/SmSI8Evlzo8Un9yRSp/I1F1GCMirENxNFEIlfMP8AzykUPH/3y3A/DFBNqkdnf10/Ff5Do2xiteyuhkEkrLkDeD1HvWUGt3+9HJbt6wnen/fDHI/BvwqaKKRj/o5S5A5PkElh7lDhv0IoD20V8enr/nt+J6ho+jeHtVt4JNTlMVw2d2zhW969A0Pwv4Wto4/sllbyOOS7HcT7mvna3vG2lY5CMcEA9PqK6Hw3rkmmXPmfaGWJhtcEkjB70Gx9HvbWojUJaI4x0A6Cs6K1Pnsi2VssTAnBQBhXn+j+I9YluAn2tRH0QOo5Fd5aa7Nb28XmRCbevrjmgC7oegWNq73bWccVxuPzBAD/APXq1rFxdWbRzWcfnjoY+maxNT12WKG4luWESoAyAGrena8mpadFNC0e/IDgn+VAHLeNrnVYNRtLmBXgjXnKjPJ7U9VOvxT/ANoCMSRphJgOh967p5IXWPeivz97rzWfZeVcXskK2RhBzmRsDNAHE2uiz2tzFEZmuIEAfe8mFx/9auW8Q3n23UZpFRY13YCr0FeseJL+ws4FguFjdPusBwa8m1qGCK9c2ZY27/Mu7qPUfnQBltyef0pVHPFDgjGRwelKg575oAeg4qSM9DTE9D0qVABj3560AU9Qs9yeYgyD1HpWI8W3tXYxHAG7kHjms++05Sd8fIPUDtQBlaIjC79jXoGnApCpI5Y4rltOs/LuYgAetdzbwfukCg880AalipNvIzZAA6+9U4YGaQ5APYGtWCGSPTHwcgnv1qXT7Fmwz5Ct2xQBk3VuzJ3OOwq1p1mx6jAPStaazZiFjXHrV2xsWTqDk+ooA+OfHC7PGmvr6ahcD/yI1Ylb3j8Y8d+Ix6alc/8Ao1qwaACv1Ur8q6/VSgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACrWnf69v93+oqrVvTv9e3+7/UUAaNJRRQAq08UwU8dKAHKeKkU8e9RrTx+tAEyHFTI/vVdWwMYp60AacF3JGMB2APatix1u8gbKzu2RggntXMqTn1q9ESAKAPRNG8UmdplvSCsgxsPQnpx6VpWOjNp8GoXCRu1tNDnbn5kOe2OtebQMQcAV21vdXY0Dck5VpGEagnk0Adp4b1G4bRYZeJrhPlIbrjtmnahM2r6ZNdhpLV7f7wJ4+oqz4Ns1tLNLOZfMnaPzHkznr2rm/HWs3NndfZYEWOyj4cf89T7+1AGTZ+I7m+uFt5JfNjGRub+dS6ZZSGW5tboAJJHuQn+91GKk8JWdndCSSzjXzWGHic9j6V0l5dQK0GmLbAeWQVl9D3FAHn80LRM0cowwOCKiKY6V3+oWVndakGvh5SsTGWTpx0auf8R6E+lTjDb4HOUf296AOeAJPpU65wM0xgQ2RwadESRz+tAFiNieCBVmNeeec1VTGQea0LWPOM8k80ASGxZ3Tavyn0rt9IsV+zIrLljyTVDSLMShB1xyK6yzg2OBxgcUAWdPsl8kgDANTwWI3DjBHpV+3UC34FXLKIMMgGgDLul2kBQOfaqbSMpxnj0FbepwhUBHTvWDIMNxQB83/tKnPjqxP/AFDY/wD0bLXk1erftH5/4Tixz/0Dkx/39lrymgAr6A/Yp/5Knqv/AGBZf/R8FfP9fQH7FP8AyVPVf+wLL/6PgoA5T9qP/ku3ib/t1/8ASWKvKq9V/aj/AOS7eJv+3X/0liryqgArS07/AFDf7x/kKza0dO/1Df739BQBaNHaiigBy04UwU8UAPBp+1W25GcHI9qYKeKALPnyPgTFbgDgeeCzAezjDj88e1a3hqH7Tq0AiEyhDvdXxIuB/tcEfQg/WsQEnjHSrdlfXdmGW1uXiDHJwF5/Sg4sThnKlKNDRv7vu/4B1ur6fPpxN1pzMLZeWiXrF6lf9n27fTozS/Ed5bY2ymRRyMnI5Fc8mp37kBr25IPpIR/KnW4CDC55JJySeTz3oFgaWIo0+SvJSts/8z0qy1SLW9OFhc5klc4HOGX6Hv8ASrM1pc6JpFtGN/mpcExyqe3uK4HTpnjuI2j4ZTwQa7a5S8vZ9PsVuMeYAzDP3Rmg7juW1aW1tkniiE0TICxU9zWJ4qme0s4tWhuZYRJyFJwc+ldTp0du2llRENkHGc53Y715f4k1ye8vpIdRiBtmO1IR/AB3HvQBNFqd1rlvMjlWdiu0/wBKctnJPop3jFzA5wMfMU75rb8OabatZxPbor2wO8kn5lIrRiv0v9SeWK2WJ4kKkHo/XFAHnboDweoqMrjtXdw6JY3088DO0Nw43xjtkjOK5XU9PlsLx4JwA6+nQ+9AGcmcjip1JDdqiOQeDUqHjNAFiI7vTirdvGGbaRnPrVOIfNgd+la1jEC6+xoAfY6e5vl4IAPFd5Z2UZVRs+7x0qnpFiGZX6kDmuksYsDJxzzQBMlkDbqAOnarNpaBDuA46YNXGUbEGOKvQQgxd9tAGFPlWIAAAquJTuwTkVo6pEEcjselZDZ5xQB8b+Pv+R68R/8AYSuf/RrVg1u+PP8AkefEWev9o3H/AKNasKgAr9VK/Kuv1UoA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAq3p3+vb/d/qKqVb03/Xt/u/1FAGjSUoooAKcOabSigCRetOHWmgU4daAJV6U5fempUqjmgCWIVaiB6ioIua2NItPNkMjrmJPvUAX9C0u5u5QY4iyLySeld5ounxnUYLWeISMmCIs8BjVPwlH9q1VIwhjtQPlGOHI/pXe6D4ea38QXeoTyo6sAqKvWgDbj0y207M6qwlC/Mc5yK8L8aXiajrc1xEx+z7sLnrXvF1HcyefFEVEhXCE/1rh77wJNd3e6OJEg6MAOS3r9KAOb8MJHNeW89mGjRWX5SPTrk16Tr2kCbTo73Tgr3MILbf79YE9suhpb2Qty1vg7mAwQcV0HhW5uxG/mIWiP3M9cUAc9oU8OrzXVteRmGSP51zwM9xSazNFKkllcrvYD92+O1a3i6y8uISWVuQ8j7pTH1FYtvGnFvdsxIG9WIyUz1FAHEyQ84HWoxGR04rotT0uW2fzNoaBj8sicg+3tWWFAJBGfegCGBfmGRxmti1jJOAO/FVIVUHPGDXQaSscjKvGfSgDe8PRbQrkdK6mGPcxJOc1iWmECIMgd+a37YgqMUAaVugaPaBjvVu0HljBz71QR9uPm6VYMxVeKAJbxldSvHTvXJ3s0cUxABzWnc3oFwEPXofas3WbUSAlPvHmgD5r/aJlEvjWyKnONPQf+RJa8tr0v4/Js8ZWgPX7Cmf+/kleaUAFfQH7FP/ACVPVf8AsCy/+j4K+f6+gP2Kf+Sp6r/2BZf/AEfBQByn7Uf/ACXbxN/26/8ApLFXlVeq/tR/8l28Tf8Abr/6SxV5VQAVpad/qG/3v6Cs2tLTv9Q3+9/QUAWqSlooAKeBmmdqcvWgCRactNA4pyUASjpTlFInNSoKAJYxgVbhUk4HeoIhntXRaLbJCqz3Ee5T9we4oA0/D2i3MwEjQ/ITjJ4xXoPgzToL69djGXk5HmZ+6o6AVT8FWkl5b3LSkxygEIrDhBj+ddl4N0JtI05kaRXuJGLZXoBQBJrX2PQdHupFDrDgjjk7jXg6yINWE94C8bMSVB5Ir3zVLKfUbHyiqNFnMqH+ID0rkIfAErXJmukXyd25Qq9vQ0AReBLcLd7nciCRcEEYH4Vu+LNPk0qZr+xjEttJxIo528Vn3Fy8VxJAYGR48CF1XHFdjpMk02mCG8iVtwIbPIxQBy+j+RqGmR36kx3UZKkH26EVh+IpYr+Av5e25jbDEd61/EFjJHqSRWsUkdrtAV0PH1qsYIry3cO4S4HyFm4Dkdz/AI0AcO0JOcDgUioR2rXvrCazkMc0ZRu3oR6j1qsqjA49smgBtqoJ5HOK27GIll4BxVC3Cqwzg811OjxxyEMuD9OKAOi0SPy4/Qkda3LWIDbnmsmyceYOwA7mtuDBAx+dAGh5e9BjqKuwsFjwc4FZ0cmD97rT5Zyq/hmgBmpFHjY8YFctNdRozAZGK2EuhPMydj+tYerWZEhZBwKAPkDxywfxr4gYdDqFwf8AyI1YlbPjMY8Ya6PS/n/9GNWNQAV+qlflXX6qUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFW9O/wBe3+7/AFFVKt6b/r2/3f6igDRFFFAFACj6U4daZ3pwoAeOvanCmKaeOlAEqVPH+tVl61YjPHWgC5ZxNK4Reprq5oTY6R5DHAPz59Sa5S3cxuGXqK7C9gabRrO8Mm8yZBT0xQB1ngW6sUsog02ZlO3OOhJruNOtjFrplllKxqvyx5wC3rXh2lz+VrMAV9kKkORnjit3VfF13LrRa1l/do+0A9Ap4oA9wjvUN5t3BnI3ADvWtps6SxHBG7vXjmmalItvBcQM5uQdgJP+eK6fwh4gmk1WeC8MagdCDwaAO9vo4jEWMSuQMgEZrGhuYrhmMBxj+HHK1JfaxGs4iTBz1NVGuIZHDKAr45YUAQ6tfNbwySbA+0d+9cJcavuvXnjj2xydV967m5gNwhXgg1inw4hLhgSX5xjoaAMaxv5AzqiERuOUcfKfrUt3oouLdrixQh1G54M5IHqvqK2LbSmtkaKVfMB4Bx2rS07THScOm5AG+U+lAHnQiZHAKnIrR01jHcK3OB1rr9f0iNbvLIFSQZDYwP8A61YF3Yvp86+dny3GVfsaANyyuMHkbj24rasbpmkHAx6VyVozpsKHcPY9q6LTmDAMpAPcUAbAuP3hXpj1pt3frFHnnI4qtIyx5PG7vzVCSdJ3VD2PWgCSJzPPknOTn3FbgQMiqeWI/KotNtYsbwQT0NaSQjfkDIFAHyr+01bi38e2Cj+LTY2/8iy/4V5FXs/7VgA+IWm4/wCgVH/6OmrxigAr6A/Yp/5Knqv/AGBZf/R8FfP9fQH7FP8AyVPVf+wLL/6PgoA5T9qP/ku3ib/t1/8ASWKvKq9V/aj/AOS7eJv+3X/0liryqgArS07/AFB/3v6Cs2tLTv8AUN/vf0FAFo9KKOtFACinCmCnA0APFPWmCnigCZeamUZHFV0NWYzx1oA1NJs3vJlReBnGa39UYLJbxyNsEfyfgK5/SLhoLqMqcZPWuk16zFtqG13EqkAlu2TQB6Z4ans7iFI7WTdJIhbHrjiuh8NJ9jhuGlmLSs3AY/dXsK8Y8GaqbC6uLmSXARCqLUtj4mvLi7cPKTFLgk98igD3e1vUMcmw52na3tW7bukkClcFTXj0Op3FtvNi3DpvfeeCcfzrsvBOu/a9OJuWRXGcrmgDf1VoLdTM8KkDqQuSKpRSq0fmROGHrjrUcurxyyuvG1TjnuKg82NifKAUHsOhoAy9e1b7HDl4QytkH2rj49RKhomjJUnKgfpXb6hp/wBsQqRn8M8VlHw2rRqIyRIvRqAM20umuLcQXEXmxZ+43BH0NV9V0R7dBPbZltmONw6qfRvQ10sWnfu1jkiJZe/vWvpGmMMrJ0ddrAjhvTNAHmMSEMRtNbmiyGNmHPPSta80UG5eHAjlB4zx/wDrrJ8lradoJsxyqeAaAOns7rCg7QT64rZsbgtG24A/SuUtJHjfBGUrorPlPlYFSKANGK5z8xPSq1/qAGUUnLVBNMsSHBGKrRMlzPuPy+9AFjTQXlDDkjoRWs8AmyvB96fY20UcY2EEHmrtvEAckdfSgD4U+ICeV488SRj+HUrlfylasCuj+JAx8RPFI/6it1/6OaucoAK/VSvyrr9VKAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAq3pv8Ar2/3f6iqlW9O/wBe3+7/AFFAGjRRRmgBRQtJTl64oAcKctNFO+lAEi8nAz61NERUC1NGeaALkQ49666xnF7osEJKqbZiADxuzXIoeMjrV+OYrbKi8YbOaAO60/webjTPNndEnLEg9eBWTe6C+lFblj5xbnYBwR9a3vA+oSXdjc28so+SParE9ia7K3vNOGngXSRNBBhAAcnP1oA4rwnfTwzyG9tn8kxlRxkjPHArWudHvYdNt9S02K4ZDIyv5gwQOx/GvRNKtdJ1G2zbwrvIAz/d9Kdq91/ZcD2s8Qa38s7BjIbA/wAaAPNZtcuoZFW6VlbjIIrZ0jUVuJc+btCnDKeM5rndfuVupXMh2sRuXHY9xWVot+sV5l5MsOcHpQB7VbSBolK8knqKuRxBnJI68fWuM0bxPBgJIVPqfSuysLiOTyw0nDd6AJGVNgO3GOKnsyrfKQc06URiQoGZsDODTIthYbDg9QvegA1O3L2D8ZMfzID+tYlnJa3lq0F1HmGTjBH3D7V0wkDwnzOMAjmsGe3hJYxrhQc8fzoA43XNJuNInDQtIbc/df8AoaSx1eWMfvOld1b+VqFnNYXJDr90Hup7V55qNnLY3ksDjlWx9aAN9daQyqk5+V+/oatySRr86cn2rlFTzUwfvDkVuaYrzRpvPA65oA6DQnZnG4fM9dTb9AccVgaPGFkB29K6W3HAFAHyr+1h/wAlF07/ALBUf/o6avFq9p/av/5KLp//AGC4/wD0dNXi1ABX0B+xT/yVPVf+wLL/AOj4K+f6+gP2Kf8Akqeq/wDYFl/9HwUAcp+1H/yXbxN/26/+ksVeVV6r+1H/AMl28Tf9uv8A6SxV5VQAVpab/qG/3v6Cs2tLTf8AUN/vf0FAFqiiigA7U4dKbT16UAKOlPWmilFAEq+uOKsR89OtV1/Kp4TzQBetzsdGHY5rsbxG1d0mhKGWZANucYxXFp6Y4NaSXcizRSRsUKgYx7UAdzeeCwttE0cqLIVUMBnkntWDLp0ujXBhiRp5D0OPumu30W9W+0e2uLlk+WUswLdcdK6QX2lNLbyXkcbSS/MpXtQBx+kXRl0WW2vbeYSu+VMYy3Hart9p2qaHqSG3hlNtJGrKT1zjkV6Xa6Xp9zHHJZxKMHduHf2rG8R6sY7cw3EQ+0I+0Er90Ec4oA4eLXpPPKTZyB6V0+hXizESeaCH+6PSvPtXlUlpFfEqnBPYj1q14a1aO2Xd5gYg457UAewxNuIwO2TU8cKhM7c45xXM6P4ht7sLFuAc8A+vrXW2LxzMwaTBUcYNAEUgVTkA81bgVZYiADkfrUTGMgk7mAOOnSnwsFBaM7sdQO1AGf4iTykjuXXdztf19jVG4s7TWbIQzAi4UZjkHX6e9dDfmKS2Pm4IOODWHJCsZWSP5MdCO1AHDXcV5pN20Um8EHjuGHqK0rHWZFID9a6nWLRNc0feuDcxLvVh/F6157taN9pFAHU2uqRXMhilIDjp7ipZJdnyxDJJrmUU70lT74PNdLYxM5DPz6CgDo9FbMeCOF5roIOvTmsfR0CpwOuPwrcj+5+FAHwZ8SOfiJ4p/wCwrdf+jmrnK6P4kf8AJQ/FH/YVuv8A0c1c5QAV+qlflXX6qUAeAftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQAVb004nb/AHT/ADFVKt6d/r2/3f6igDRooooAKdzTcGlFAD1NOFNHWlHWgBwPNSoTmoqeh9aALsTd6txN1z+FUIm5FXImzwaANO0upLdj5LMhbg4PWtCK+mZdpkOM5I96x4RnGauxLtoA9S+FmpO2qSq7fKsJOPWuo8R6k13ZCCMbpWY8egri/h7asNOvLkYDsViBJ6Dqf6VuzvIkbyugxyiEnGcdTQBy2tQRmZVIy3C/LXOzLFFL+7TB6ZNdDcKDdG5OS5BVRnjHrWbcxoG2lSZCPSgCgiTLcRFCVjbnr6V2mkaxLHtVpDvT1NYSRj7DCyrls456VNp8BN9Fuwdx5Y9vagD1G01FmSO6LAovDD1rWt3EsiTgAq3fuKw9H052sWUbShHORWxp1s1paBZCoPbByMUAajSHzEQKSGH3u1Y16zQGUBShz9QwqwuqqS0ZbG3uOuKo6ndoybSSwI4JoAhsJ0VizY8zPLdKTx5aB4bTUI1wZF2SY7kVk28v+kmEgvnrXWXFsbrwlcxOufKxIn4UAeeQ9DtrptDiMlt1+b0rmol+fsMmus8PA7sDj+VAG5p2AynGOxzXQWpUDJY1mRQjAI65zWjBGQPwoA+VP2rmDfEawwMD+y4//Rs1eL17L+1T/wAlDsP+wZH/AOjZa8aoAK+gP2Kf+Sp6r/2BZf8A0fBXz/X0B+xT/wAlT1X/ALAsv/o+CgDlP2o/+S7eJv8At1/9JYq8qr1X9qP/AJLt4m/7df8A0liryqgArS07/UMP9r+grNrS07/UN/vH+QoAtUUUUAKKUU3mnLQA4HinCminDmgBymp4m5quKlQ0AXojVuE5AyOaoRNzVyNtwz3FAGra3s0SCNJGWPrtzxWhb38xdGLk46VjRLk8dauQDBABoA9t+HmqOPDc8jNlhLtAPbiovE1ydQuk2DMcYBZz61R0K3a08O2W3A3KZmHck/8A1sU3UpJIbYrIoV3+ZsH16CgDkdSghaeQ7TgfMceuayBsVyiLgE1vNCIxIi5LSHcx6/hWfIkfmfKpGG5oAi0s3MF4SWZdnQe1d7oeuOJUPmZBODk1ytzHiYeWuMqMk9RWh4dtN1y6EAYAwf73vQB6Zb33kyfvGBE33fY1qWQEchBAGe471if2XJLaRj5DggITWvn7LCu4gFR096ALUpMqyx+WflHGe9YF9MyRBRlOCCp5xWkuqrMoJfH+761jatcCbcoOGHegDS0W4jjli2KACeR0zntXM+L7EWGtyqgxC/zr9DVrSpPPkACk7WyG9DWv47tzJpthdso3gGNjQBxkIPy7fWuwsov3Eb9QBziuSs1+cdOO1dtoYLW4HagDX07AGOncVsoyrESSTWbDDhhjpV0qVgNAHwd8Rjn4heKD66pdf+jWrna6H4i/8lB8T/8AYUuv/RrVz1ABX6qV+VdfqpQB4B+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABVvTf9e3+7/UVUq3pv8Ar2/3f6igDRoopR1oAB+tLijFIaAHilpB0pyjigBRT14PpTVpw60ATR9RVyBumapJxVqI9KANO1+aQZ9c1ZVvn6nFUoOx5q7CuSPegD1f4eWsd14XnB3ArcZ9mOOKs+It094YEf8AcxIE/wAateDY1stC0+Aq26QGfI9Tn+gFc/fyOb11DFirGgDOv45ImRlJ47Z/Wqb3JKq0wJZeOnP41cE4nuPIkRiyj86ZNYgQmSUFQvIHr7UAZkt+0MZ3cL2GKn0/UJJSWcKoU/Lzk4qi/luWaUExocYHerMb2SyebEm2PPC54NAHpun6ndT6fBDaSLySH7HFbUEy2sAhlmEsjAjr+ledaZBNMxnQssR52qeR7Ct9p/IdS43yCgC9qytEqSRggp1I9KrrfxXsI3H5hwe1PW6MkLhlPXgetc5OHimkAyozkUAdfo7wPK7HDMB612+kROdGuhcOJBJGxHGMDHSvLNHkVnQpJsYdvWvWfD5E1gYSQQ0ZGfTNAHlEcZ83b33cV22gWjJEHbAJ7Vhw2WzUXVhgoxHSuv09cIoHb2oA1bWPjpxxWgEwmMdaq2pIGPXg5q/jK0AfIn7WKeX8RtPHrpUZ/wDI01eK17d+1wMfEjTf+wTH/wCjpq8RoAK+gP2Kf+Sp6r/2BZf/AEfBXz/X0B+xT/yVPVf+wLL/AOj4KAOU/aj/AOS7eJv+3X/0liryqvVf2o/+S7eJv+3X/wBJYq8qoAK0tO/1Df739BWbWlp3/Hu3+9/QUAWqKKUc0AHUUo60e/SgdaAHClFJ9KcOlADhyKepxTBT1oAniOOauwH86ooefSrcByRQBqWuNrN3Aqxbtluapw9MVp6Vbm4vIIR/G4X8zQB7XpNrCdL0q6JYBbcHB4wAP6kVzeoCS7nknkbOXLAV0946rp11CgZTDGIge2BXESSyZkdckUAUbnzredtjEn1FV57gckLlmGcY4q5GwvVdljbfnH0NQahapbReY/3z27UAUJ9TaMhcFn7A8Vr6JqDiaGVyFY9cc4rET7MrrJdqXDgnHYVdsZLeCQBEyWHAJzj3oA9S+1XeoTKqTKlsFBDA9K0JriOWLyFYSMpByTXD6Ra3EQRmkY5J2kHj8a00uxE7BFySOtAEt/cNYXZlAYRnGfQ0sl1DNiZWwfXNMvpTcWgUqckd+1c8rsm0OTjuMe9AHeaTsNuPs5CyMcBuwroPFsJPhALId0iOvzdMn1ri/Djjz0ZZflJGVr0LWovtnhicdSmGGO+KAPM9PiaSYBRk9K7/AEq18qJAeeK5rRbUK+7oc+nSuytM44oA0baPhelW5Y9y7elR2xzgHtzVnGSKAPz9+JI2/EXxSvpqt0P/ACM1c5XS/Ez/AJKR4r/7C13/AOjnrmqACv1Ur8q6/VSgDwD9tb/klmlf9hqL/wBET18VV9q/trf8ks0r/sNRf+iJ6+KqACrem/69v93+oqpVvTf9e3+7/UUAaNKOtBFAHFABS96PWgYoAdThTRxTqAHU4CkA96cKAHqOKsw9qrr0qeLgigDQt8cVpwjGKyIWIOK0rd84/WgD3HTrtbWPToUUM32QBQOxK1y0ziN5TOpAPBI61raZcb9D0y9JAZECfUjjFULyEpcTlgGRzkfSgCO0jhlaNhkKw4bHT05pt8DdA28Zyw/JqiMpiCrGCMDOO1WrRQ0haU7GK5VcdaAOWW18y6NszbUwTyauabpVujs58xsHjHTNbUenw3dxllVZQeSDya1lEEDERfwjp0zQBX0NykLo6BSD1PpUkuHm3HovemE7HZlO2I84NRuZHYlNphx160AXTeJFkthUXuxwKz7y4MkytEAyucEjpVadHvIBCpT15Oc1pWdiYGUFCN3txQAtlYvLKpRhu9OleqeE7d7a3AkYndjaD2FcVZ2fk3EbqVEnqe9ei6WwJhRsbsZWgDmNTgH9tziIH75z7VtWSYjA4z60zVIFS9lYDlmyaksyF6DPrQBpwKeKvRjgCqkcijH0zzUwnUcCgD5P/a94+JOmf9giL/0dNXh1e3ftbtu+JGmn/qEx/wDo6avEaACvoD9in/kqeq/9gWX/ANHwV8/19AfsU/8AJU9V/wCwLL/6PgoA5T9qP/ku3ib/ALdf/SWKvKq9V/aj/wCS7eJv+3X/ANJYq8qoAK0tN/1Df7x/kKza0tN/1Df739BQBa7Uo6GkpcUAApwpO1KAKAFFOHUU0cU8daAFAp4FIBThQBIPWrUOKqrViE+lAGnbdRXS+EUD+IdOVsYMy/zrlYH5rd0O5NtqVrOP+Wcit+tAHsGoXpmstShiXLeYCze3PFco8kaKiyghi3y7a6W9AjuJogQDcIeP5VzzxbVVJUBYH9aALFvFGgdgdrDnpgEVm6pGb2J5VzsXqPSp/PcsVVSQTjBq1GgFq/IMgJ3LjpQBykNmt3FIZWx5ZwBnmtSx0+O3t90ayNKeRnpWxp+mWzSeeFVUH3lFaAaERlV5VsjHpQA60mzZJkBTj0wc1FFtWUu45NRq/lDErgKTxmoJGmVC8uAAeDQBfa/jQASFFLcDce/pWdveS4ZAPk6g9jUbWr311G/yELxjrWrbQx2yObhhDFEpZ3kOFUdck9qALOh6dI1ypjbIz2r1Wwi26Q8Ep3Hyzu/KuK8OwCK8TymTaTyK7+z2ywzj+LbhhQBxenQnzjt4UHr6101uvyjAxXI33ibQtOuWtmv4pbhfvW9qDPKPqiAt+lYl98V7W0WVdP09pGiGWa5mC7B/eKRiRwP95V+o61Si3qkRKcY6NnrUCkHpViaeC1hae6mjghQZZ5GCqv1J4FfOV/8AEzxPqhRbWR7WGU4jaGJbdZOM/IW82SX/ALZqD9Kydaj1OFkn1aKObUGTzFOpuztGp/jZXZ3jXPGS0R7KjHitFRfV2MZYlfZVzzbxboWp+I/iJ4mm0KymvrafVbp47iFcxMplYgiT7uCOc5rkdSsptOvprS58vz4TtcRyK4B7jKkjjp9a7bxj421Mvc6XBdXQZWMVzNIvlMSOCipxsUcjn5z3PavP6mooLSOpdKVSWs0ku39f5BX6qV+VdfqpWZseAftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQAVb0z/Xt/u/1FVKuaX/x8N/un+YoA0cUtB60ozQAmPSlFBFKo5oAUUuOKQ9aUUAPX3p4NR09RQBKDxxVi3jaQjapqWxsml5fIHpW5aRRRqDgZHQUAVrPS5JCueM+tdTpGgwjHmkufQ1BpjLwPfrXTaWiFhlTjvnvQB3Hh3Sre78LtaKoQwyZHtnmmahoksONwDwrxwO1X/BTpDebFUeXMu0g+vaunvbc4KBMqR0oA8jkixqPlnAj6Duc1oPZmJfLA3N2JHStS80/7PMz+SDg5rMulkvrcvBIUKNkgdWx2oAwJoTa3T7Zyq4y2e3NUzqaXcu3zWRlOMjvV7XbyJ7fyrqIrMDtMg4yPeuUsIiLwKW+Xd19vWgDtHuYBaolywK45UDr7U9gpaJkkMUZGQhPWqmm2Z1O+ERz5KchweDXSDTYBGCArlB0PagDJ054VuMiPAXua3PtzE4RFwxwKw7axkvdQlAcqufujiur0/SEigBYiRlOQT2oAtadDNKYgVVvmAOe1dvp0S+cFRdoiAH/1qxtHtwg81h0FdBZEeUHbhm5/CgDL17K3voCMiqSzlO3HatrXY0IidsZPFYE65X5DwaALcNw24A5zWjDIWOB1rGgBCgMPate1jIVcfnQB8t/tYAj4iadk5P8AZUf/AKOmrxava/2ss/8ACxdNz/0CY/8A0dNXilABX0B+xT/yVPVf+wLL/wCj4K+f6+gP2Kf+Sp6r/wBgWX/0fBQByn7Uf/JdvE3/AG6/+ksVeVV6r+1H/wAl28Tf9uv/AKSxV5VQAVp6aP8AR2/3j/IVmVqaZ/x7t/v/ANBQBZpevakpwzQAn8qUUEYNOXpQADtS4waQU4CgBw4qRajFSIpYgAZNAEgIyOOKuW0DynCqansrEAB5fyrahWONPlxmgCGx0Z5WwWwK6/R9Ct027h5hHqaqaeVKAe3auo0lI8DepxnpQB3dxpEWpW1hdREK3lAZ98YrE1DSpIC5uFz3BHFdd4RZX0+S2KgiM70+hqTWbNpreSMpnFAHmOnW5uZXRyA2TjaO1Wry0MkTJjHGGYd60riEafvcxbQMjcOKoXkc6ul3DISgX7g6fWgDnvONhG7mfKKTtBHWmWl4tzcLIkhB/uHoag8Sz294SI4zFLtzgdCaoaCu1izsBtXvxk+lAHVy3Fq9wglBkfooA/WkkUK0vmyFx/cz0pdC077YHu5wUK4ADd6vax9k0yBJGKmWdhFHgFmJJxwPQZ5PYUAQ2d/BYrv8pmkc7YokG55D6KP8gdTgc1Zv7C6vdNuZ9RVWlWJ2gtEPyRttOCxx8z574wOwyMnN0zQVmla/e6mgkC7TKszIFXrjrjFM1PXrexhDafrV5fkcCQiEWxPp5pQbvohZvauvDSpRd5ptnn42NeatTaS/Mt6dqfizWmVtH08RREBhKIDgD18ybZ+kbVJqWiOVH/Ca+KkWWUZ/s+FnvZ5R6iIBU/HySPcCo9EsvG+rWHkxyPY2UjffAa1XB7Lkeew6npEOeDjiu68PfC/RbMk6ozanK53SRMvl27N6mMff/wC2hc+9ZNqL/wAjdKU1s/n/AJLf5nkkcNvflrPQNLuL2NGKn7SyzgfWKMrbRn/eOf8AZ7V0ul+Abmd4X1i6WFYzlIIArsn+6xURx/8AbONT/tGvT9dOnaLFLJKYLOygTcTwiRr/ACA9q8s1XV9U8X38mm6LFJDZLgS7yUYqehmI5RSOkY+dh12L1FJy1Wnn/X6DcIwVnr5f8D/MsXGtWOjytp/giyWTUrhjE9+F8+V2HVUZiTKw7ljsT+I/wnpvA/gVLSZdT11vtWpl/NCM/mJE+PvljzJJ/tngdFCjrZ8JeGrPQ4v3SmS8kULJcuoDMB0VQOEQdlGAPc5J7O2RgeBUOXRGkYdZf8BHwh8SePiL4p/7Ct1/6OaubrpPiV/yUbxV/wBhW6/9HNXN1BoFfqpX5V1+qlAHgH7a3/JLNK/7DUX/AKInr4qr7V/bW/5JZpX/AGGov/RE9fFVABVzTP8AXt/u/wBRVOrulf8AHw3+5/UUAaWKUdKO9KPpQACjpQKUdaADHNOApO/SpYlLtjFAAkbOcAVqWlltAeTtS28awpuf73apg7SN7UATpu3fKdoxV22j5yQSaggi+UHvVyDrtI96ANfTVIauntvlUYOK5jTjhl6CuqtxutkPfGKANzSrmSGeNlySCDzXqkNzFdWkUwPDj8jXkdgxzsP6mvQPB9wskMlrJ1X51z+tAEt4tvOyq+07icj1Fcx4iszYRzyRLhG5G0V1GoQoJWwVTnpSTxi701kkCnaM/hQB4xqSzXkbYw7MRyRVK00m4adZJAd33dvTiuw8QRJZyrhCyq3YfrWHqF2kqNHby4mHYd6AOg0WAQKsUKYjbjFdLZ2wiIVULlupPYVheGLSQ2EW4v5mPmJ7V2SQP5WVUFvQd6AKsVrDDKxRBubrgVO0DLDkfNj+H1pI1aGQpITknK5pWu18zylYFyPXpQBds5/3fkhGVyPyrcgX5E3k5AxmsewCRzAuRux69a14iJCgIIwRigCv4lkEVjCzdA2M1y0N4juBu6jvW944lSPRF5AzJwTXnK3iovzOelAHouniNsZCtW3AFA4FedaDqTzTbVJCD3ruLSVmQZ6UAfL37XGP+Fj6bj/oExf+jpq8Rr2z9rT/AJKLpnOf+JTH/wCjpq8ToAK+gP2Kf+Sp6r/2BZf/AEfBXz/X0B+xT/yVPVf+wLL/AOj4KAOU/aj/AOS7eJv+3X/0liryqvVf2o/+S7eJv+3X/wBJYq8qoAK09MGYG/3j/IVmVq6X/wAe7f75/kKALRGBS/QUA/SloAO1FHanCgBAKePamj6VZt4i7DAoASCB5GAArXtrVYAGIyxpI9kChQBvp8eZGGaALEQc5+bAPYVoW0WOg/E1Wjj29OtXYDkDjkcUAb2lKflz/KuitmYMNrH8K53S3IYdODXShPnUrk55oA6vwnqBtb+Mvnyz8rH2Nd/ePGFY5HTP1ryvT2LbSe3vXpGkTR32kKWAZ0XYwNAGfcWtrdySIQrccA9jiuJ8SLLp6rGCU5xkDoK7aRBHNuRlyO1M8QWsd5brI6jP9aAPF9Qt7ieRGiUEjnJGDUmlaOUk/wBIBdD8zc9DW5fOltfkMpUY+92FZU8zXlxD9jlYpuG5V6igDpftKWtskbI0kjfLDCn3pG9B7epPAHNE+lT/ANnzzs6y6owVgwTcqbWDCNFJXjI7kbjySOMXrTw9bXdwlxKLgSbBHvS4kjO3rj5WGOa038JWZA2HURkHn+0bjj/yJXVh6tKmm5K7OHF0K9ZpQkkkcXpXhHUPEEUNxq16FtzyqHbM4Of7hAiRgePuOwx97NdrpvhnT9HuEuLa1866I2m5mcyy4/3myQPYYHtU+i6ba6Ss4t/PDSMGl824klyQMZG9jjj09BV+G5FxJtjYEA8471hKTei2OqEEtXuadtcCRVIOwRnLFuBgVzFt48is5b2+1FpXtbnD6ZbRR5kkC5zk8Y3Ah8sQFGc4wai8Y6tZ29omkPdQw/a/muWeQLtgB5XOern5fpvxyKz5bR9ctzDb6ReXsOQctCIo+CCDmXarrkA4G4H0NdFGjCUHKbt2OTE4mpCrGFKLff8Ar8TFvW1bxxqMepanIbPTAQ0Hl52gdjDkfO3/AE2YY/55jndXaaFBZWFqlrYRpBbochB3J6kk8kk8knk1V8RTapGII9cFlHdKvH2ZywKdt2VGG9ccelZC6gsZB3HINc0pX06HZCKWvVnplisZAO1Sa1oQoArhvDt88yhiT7DNdfbuW25OKks+Dvib/wAlI8V/9ha7/wDRz1zVdL8TP+SkeK/+wtd/+jnrmqACv1Ur8q6/VSgDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKu6V/x8N/uH+YqlV3Sv8Aj4b/AHD/ADFAGpQBS96KAAUo60U4DOT2oAFBJxWlaxLGm56hsYN5yatyHc20fdFACjMrAt07Vbgj6AVDCmCDV1M44oAkXoKsxkhvrUMa5Ge561YRQdo79aAL9o3zj+VdnoLC4jZDyev4VxduvI2113hV9t5GM4D8HNAG9HFtbjqTit7QJ2t76GXoQwz9KoTQ+XIVI5Bq1brh1OMgdSTQB3upWgkIlUDpkVTihTy23AAkYx61p2T+dplu2c5UCs6+EiEkAFaAOO8XWAkjM0EZ+UYbjt615wbQW2oNck/IDuwe9ezzhJYyjfckHIrzjxXp+1HWPhDntQBqaJqfnkCEcEDjNdnDcYUY4OOT6V4zocy217EWZ1CcZ7CvQdP1KWbHlNFJAQRkGgDYvrqEyr5ynceAQe9Vo4kFzGUiBcDlientWYJt94ItrEnJye1a9hE013mSPGw5B9aALVjLFJebVVhOmRuI4xXU2ymRlySSpBrO0/ybgb4kKHOMkYzW3ahVG0/f7CgDi/ipIEsbOHOMszGvLSSZAu7jPSvRPii8kl3GqjcsSYJ9zXnliN0pyOfpQB2PhiPYASfSu9smHy7ec1w+hFUGMckV1+mNgKM8ZoA+bf2s/wDkommf9gmP/wBHTV4nXtX7WJz8RNM/7BMX/o6avFaACvoD9in/AJKnqv8A2BZf/R8FfP8AX0B+xT/yVPVf+wLL/wCj4KAOU/aj/wCS7eJv+3X/ANJYq8qr1X9qP/ku3ib/ALdf/SWKvKqACtXS/wDj3b/f/oKyq1dKH+jN/v8A9BQBcopRS0AJS0U4A4HHWgB0KF2ArUjCwoMD5u1Ms4dsfmN2p4/ePk/hQA+NNx3N1q7CuOewqGBcdquLnHHSgCSP7w561ZgbHBxxUKrxwKsRqpYn0oA1dPk2uCDmu305RPaI/ccfjXC2gwwxyK73wmPNhlhz23AUAW4EKEbe3P1rs/BcxW6aE/clXp7iuYVMSAYx71r6O/k30T9MOOc0AdTfWflyFgAcnBFRSwxiD5hkZyR71tXSk5wawrovG/7wDaTQB554t03ZMzKhEMvQnsa5TR9ulT75SDuOADxXrOrQR3Fq6Sc7OnFeW+J7IpNk5CqcjFAHdaDfGYrgZQe9dILnCnHT3715R4Xv0tnkZpSm7oXPBNdpFezy27iXaV6hlNAF6aaCWZ02t5pwTz2pLZUjMzRRhU6kg8n3rNsJTK8hRSSvAJ4zxW1pirHFJczxkDoV65+lAFjRIbOW9a9treNLgja0pjG8jnjPXFdXaR7zv55GOaoWcUZUNEu0HnbWvDt2fKeR1oA8l+JUvm+IZVz9xQo/KuStQ0k4Gc5rb8bvJLqt1MV4d8g+1ZelKCVyKAO98OgJGmT2x1rsbJskY6etcZpLKYVVeCDXWaa/K5NAHw38TP8Ako/iv/sLXf8A6OeuarpPiXz8RvFR/wCotd/+jmrm6ACv1Ur8q6/VSgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACruk/8fDf7h/mKpVe0n/j5b/cP8xQBqdulKBRmlFAAKfGu5gKbjrirenRedOqj1oA1Ej8i0BIwWqOGPJzj8KvX0RDxoOijH406CDpjvQBHFETjFWFGAD61MIWBGKeIh2OaAEjQ4q1Gme1Ecee1WY4uMYoAktkAPQ10WjNsuEOOQQaxbdDkVuaYmZE9jQB6NcQrNaxTgZJFRQKMdgfar+kRifSih5K/pUMcJjkI2+tAHV+H23aYyH+BjUkyfL7VD4aODMvYjOK0bmMKDgcH0oAw5IZC4VEUr6+lc/4s0l3s5fIMYmxuCE9a6mVGIO1gD61na/ao9o8khO/b/D1oA8ThsTbXzMwyXzuUngetdZ4bjni0xBFGuQW2+hGaxG09L+8ljtWm89Duw64yK6HTtLvhDFAFcRjq2cH8qAJ5oru4eGS2dE2n94Bya6DR5JB99suD19arJbGBQkcYBxycfzq1YxMpDAA464PSgDprdSSjMmMcZHStKEgSDuTWbZvGZEXc+XGcY4Fa0hSC3eTHKL1oA8/8XsJdWnUYIzg/lXPxaRBPMWj+V8fnWpqavNdPIx5Yk81BZq6SZGRz16UAXtP0+W3YZXr6V0dlGUUZH6UulSxtEocq3ua1FWMnKgGgD5R/aqOfiDpv/YKj/8AR01eM17T+1gMfEXTsDH/ABKo/wD0dNXi1ABX0B+xT/yVPVf+wLL/AOj4K+f6+gP2Kf8Akqeq/wDYFl/9HwUAcp+1H/yXbxN/26/+ksVeVV6r+1H/AMl28Tf9uv8A6SxV5VQAVraT/wAezf7/APQVk1raT/x7N/vn+QoAuUo6UZpfrQADpVi0jMkoAqCtjQbfzZg2OF5oAnulCIsYHPcUkMfHrU8qb7lifWrUMGSBzQBFHGQMnkDvU6jB2/yqVYiM5OB3p8cYBBFACovrVmNB6UJHkZx1q0kfNAE9omCODxXZeEJRHeR8cHg1ylshz14NdPoC4uEYUAdpfWwjmyF6063TlSOvXitC5gE9jHIBk4xn3qtbIQcY70AdorCWyhc5+ZRVK5jyMN+GauaMN+morc4JFJdJjjGPSgDH+zySuytGuwjr61wnjrSZPK3QFGQZEgB5Ar0XYwddrADPI9a5TxtaQx2MjZkyc7vLGaAPLLe0MNvLDgOQcjc3fNd7AbiK3QiNdoA3A9q5Sz0g3hWezMpjB2sGHINdbY6bdyyg3KMI17bs5+tADI4Lxbxp45VFuQNoHIrq9JkYqoHOeoNZJiYLsVAqD24rU01TE6swyp7jmgDorVcO3y7SauKwWGY9gpyaq6eY3dkUsxQ4JIpdflFvpkgjGGkOBj9aAPNr9VnnbeAVqGz0RCd1uep+6amniYFjmrmllo3XcSooAvadaSRDYVI9a6G1BQLxUlnJE8Y3bc+tW0VM/KooA+DfiP8A8lD8Uf8AYVuv/RzVzldH8Sf+Si+Kf+wrdf8Ao5q5ygAr9VK/Kuv1UoA8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKuaW6pcMXZVG3GScdxVOigDf8+H/nrH/wB9CgTxf89Y/wDvoVgUUAdCJ4f+e0f/AH0K1NCu7WO7DS3MCKO7SAVxVFAHplzqFg9wW+22xHr5q/41NBqOngDdfWoP/XZf8a8tooA9bXU9O6/2jZjH/TZf8ak/tTTAMf2hZkf9dl/xryCigD2NNW0zH/IRsx/23X/GrMWsaWuM6lY5H/TdP8a8TooA93h1nSN2TqtgO/8Ax8J/jWpYeINEWQFtX00emblB/WvnSigD7O8NeMvDUcW2fxHo0eRj576Ifzap5fF3hbzTjxJomM9r+L/4qviqigD7m0fxv4UguBv8TaGqkYJOoRf/ABVa8njzwg7GNvFWgbSMZ/tGH/4qvgKigD7sl8ZeElbA8VaERjHGown/ANmqLVfGvhZ7b/R/FGgF/T+0If8A4qvhiigD66vvE2gXD+XD4p0W2kPV0uYsf99ZqzpfizRbWM2z+LdFlx0kkvIv57q+PKKAPs1PFXhYXwmm8Q6OkjDDNHqULKT9N3FaaeLvCKdPEmgnceWGoRAj/wAer4fooA+9LXx14Qiwp8UaD0zn+0If/iqfqnjzwk+nzLH4p0Esy4CjUYSf/Qq+CKKAPr+fxZ4bZiD4g0cr7X0f/wAVUK+LPDoYbdf0gAf9Psf/AMVXyNRQB9mWnjHw3EOPEWjc+t/F/wDFVp2fjzwwvDeJdGH1vov/AIqviCigD1n9pTV7DWvHNjcaVfWt9AmmxxtJbTLKoYSynGVJGcEce4ryaiigAr6A/Yp/5Knqv/YFl/8AR8FfP9fQH7FP/JU9V/7Asv8A6PgoA5T9qP8A5Lt4m/7df/SWKvKq9V/aj/5Lt4m/7df/AEliryqgArU0yWNLdg7op3dC2OwrLooA3vPh/wCesf8A30KcJ4e8sf8A30K5+igDohcQ/wDPaP8A76FdD4fv7KGFzLd26E/3pVH9a88ooA9IW/sN5P2y1znj96v+NXYtS04Dm/tc/wDXZf8AGvKqKAPXF1LTe+o2fP8A03X/ABp/9q6bnnULM/8Abdf8a8gooA9lTVtMGP8AiY2X/f8AX/GrUes6V31Kx5/6bp/jXiFFAHvVvrWjrgnVbAe32hP8a3NI8SaHFIpbWdMU55zdIP61800UAfbdh4z8LHTvLk8S6IGHZr+If+zVXXxd4X34/wCEk0THT/j/AIv/AIqviyigD7x0bx14SjidJPFGhJzkbtQiH/s1WJvHPhC4QhvFWgBlOR/xMoef/Hq+BqKAPuyPxr4SWUE+KtCIzn/kIQ//ABVZ+t+MvDLuPs/ibQHQ9R9viP8A7NXxHRQB9aT+INCupSbfxfpFsqnJVbqNAfpzzWxZ+NNDaFQ/ibQmK8MJL2Jdw+u6vjOigD7Q07xR4ShaVD4j0mIMc4bUYXX8w1akPi/wijhB4l0BVXkEahDg/wDj1fDdFAH3zbePfB4GP+Eo0EYOP+QhCP8A2as7xL448KzQRJF4n0KTBJO3UIj/AOzV8L0UAfXcnivw2+S2v6QSOmL6P/4qlh8WeHd5z4g0gA+t9Hx/49XyHRQB9o2/jXw3GgX/AISPRsD/AKf4v/iq1LXx74XCYPibRRj1v4v/AIqvhqigDe8fXEV3468R3FtKk0E2pXMkckbBldTKxBBHBBHOawaKKACv1Ur8q6/VSgDwD9tb/klmlf8AYai/9ET18VV9y/td6JquvfDbTbXQ9MvtSuU1aKRorO3eZ1QQzAsVUE4yQM+4r5F/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5Siur/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mgDlKK6v/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5Siur/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mgDlKK6v/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5Siur/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mgDlKK6v/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5Siur/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mgDlKK6v/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5Siur/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mgDlKK6v/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//iaAOUorq/8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+JoA5SvoD9in/AJKnqv8A2BZf/R8FeVf8K48cf9Cb4k/8Fc//AMTXt/7InhPxHoPxJ1K61zQNX022fSZY1lvLOSFC5mhIUFlAzgE49jQB51+1H/yXbxN/26/+ksVeVV7r+0f4K8Vav8Z/EN9pXhrW76yl+z+XcW1hLLG+LaIHDKpBwQR9RXmv/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylFdX/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNAHKUV1f/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylFdX/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNAHKUV1f/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylFdX/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNAHKUV1f/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylFdX/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNAHKUV1f/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylFdX/wrjxx/wBCb4k/8Fc//wATR/wrjxx/0JviT/wVz/8AxNAHKUV1f/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE0AcpRXV/8K48cf8AQm+JP/BXP/8AE0f8K48cf9Cb4k/8Fc//AMTQBylfqpX5rf8ACuPHH/Qm+JP/AAVz/wDxNfpTQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema demonstrates ileocecal valve region. The cecum is fibrotic and contracted (red arrow), the ileocecal valve is irregular, narrowed, gaping, and incompetent (green arrow), and the terminal ileum appears to empty directly into the ascending colon (Stierlin's sign; region of green arrow). Note the diffuse ulcerations in the ascending colon (orange arrows) and the lymphoid follicles in the terminal ileum (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis, 4th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30342=[""].join("\n");
var outline_f29_40_30342=null;
var title_f29_40_30343="Tiaprofenic acid: Drug information";
var content_f29_40_30343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tiaprofenic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/23/6517?source=see_link\">",
"    see \"Tiaprofenic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tiaprofenic&reg;;",
"     </li>",
"     <li>",
"      Dom-Tiaprofenic;",
"     </li>",
"     <li>",
"      Nu-Tiaprofenic;",
"     </li>",
"     <li>",
"      PMS-Tiaprofenic;",
"     </li>",
"     <li>",
"      Teva-Tiaprofenic Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"     Oral: Usual initial and maintenance dose: 600 mg/day in 2-3 divided doses; rarely, patients may be maintained on 300 mg/day in divided doses; maximum daily dose: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Usual initial and maintenance dose: 600 mg/day in 2-3 divided doses; maximum daily dose: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. May consider lower initial dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F227617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug primarily undergoes renal elimination; the manufacturer's labeling suggests that dosage reductions are necessary, but does not provide specific dosage recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13362524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment provided in manufacturer's labeling; however, caution is advised.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis (degenerative joint disease)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Dyspepsia (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (1% to 2%), flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 4%), headache (3%), drowsiness (&le;3%), depression (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (2% to 7%), pruritus (2% to 7%), rash (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 8%), heartburn (3% to 6%), epigastric pain (3% to 5%), vomiting (1% to 4%), constipation (3%), abdominal pain (2% to 3%), diarrhea (2% to 3%), flatulence (2%), stomatitis (1% to 2%), xerostomia  (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin/hematocrit decreased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased  (3%, up to 12% in elderly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, anaphylaxis, angina, angioedema, anorexia, anxiety, asthma, AST increased, bronchospasm, bruising, conjunctivitis, cramps, cystalgia, cystitis, diaphoresis, disorientation, duodenal ulcer, dyspnea, dysuria, enterocolitis, erythema multiforme, eye ulcer, fluid retention, gastric ulcer, gastrointestinal hemorrhage, GGT increased, hematuria, hepatotoxicity, hepatitis (fatal), hypertension, incontinence, insomnia, interstitial nephritis, intestinal perforation, jaundice, leukocytosis, leukopenia, melena, menstrual irregularities, oliguria, onycholysis, palpebral edema, palpitation, paresthesia, photosensitivity, pollakiuria,  polyuria, renal failure, serum creatinine increased, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, toxic epidermal necrolysis, tremor, urticaria, vaginal bleeding, vertigo, vision blurred, weakness, weight gain.",
"     <b>",
"      Note:",
"     </b>",
"     Aseptic meningitis, neutropenia, and leukopenia have been associated rarely with NSAIDs.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tiaprofenic acid, any component of the formulation, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs); patients who experience acute asthma attacks, urticaria, rhinitis or other allergic manifestations with aspirin or NSAID therapy; peptic ulcer or active GI inflammatory disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Fatal asthmatic and anaphylactoid reactions have occurred in patients with &ldquo;aspirin triad.&rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular events, including MI, stroke, and new onset or worsening of pre-existing hypertension. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention and in heart failure. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cystitis: Severe cases of cystitis (bladder pain, dysuria, urinary frequency, hematuria) have been reported. Avoid use in patients with prior history of urinary symptoms and discontinue at first sign of genitourinary problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events: Gastrointestinal bleeding may occur without prior symptoms of gastrointestinal irritation. Discontinue use with suspected/confirmed peptic ulcer or with GI bleeding or perforation. Use with caution in patients with a history of GI disease (bleeding, ulcers, or previous GI symptoms with NSAID use. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause blurred or diminished vision; discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with asthma; severe bronchospasm may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease: Patients with autoimmune disorders may be at greater risk of developing aseptic meningitis, as rare adverse reaction associated with some NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal liver function test (LFT). Rarely, severe hepatic reactions (eg, jaundice, fatal hepatitis) have occurred with use; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. Monitor LFT periodically with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Effective dose: Use lowest effective dose for shortest period possible; bleeding risk has been correlated to dose and duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F227607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tiaprofenic acid peak serum levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F227597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Tiaprofenic acid crosses the human placenta. Fetal exposure to NSAIDs late in pregnancy is associated with premature closure of ductus arteriosus. An increased number of stillbirths as well as delayed and prolonged labor were observed in animal studies. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Use of tiaprofenic acid is not recommended during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F227621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F227598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F227585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC; occult blood loss; periodic liver function tests; renal function (urine output, BUN, creatinine); electrolytes; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation; with long-term therapy, periodic ophthalmic exams",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F227599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Artiflam (BE, LU);",
"     </li>",
"     <li>",
"      Derilate (ES);",
"     </li>",
"     <li>",
"      Fengam (TH);",
"     </li>",
"     <li>",
"      Pain Will Pass (TW);",
"     </li>",
"     <li>",
"      Sufen (TW);",
"     </li>",
"     <li>",
"      Surgam (AU, BE, CH, CZ, DE, FR, GB, GR, HN, HR, HU, IE, KP, LU, MX, NL, NZ, PK, PL, PT, SG, TR, TW, ZA);",
"     </li>",
"     <li>",
"      Surgam SR (KP);",
"     </li>",
"     <li>",
"      Surgamic (ES);",
"     </li>",
"     <li>",
"      Surgamyl (DK, FI, IT);",
"     </li>",
"     <li>",
"      Torpas (VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal (10%) to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% as unchanged drug; &lt;10% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andreassen KH, Eldrup J, Hansen RI, et al, &ldquo;Tiaprofenic Acid-Induced Cystitis: Three Cases and a Literature Review,&rdquo;",
"      <i>",
"       Scand J Urol Nephrol",
"      </i>",
"      , 1999, 33(6):408-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/10636583/pubmed\" id=\"10636583\" target=\"_blank\">",
"        10636583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/40/30343/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10110 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30343=[""].join("\n");
var outline_f29_40_30343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227645\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227615\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227616\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227617\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13362524\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241428\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234352\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227591\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227590\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227643\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227594\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227577\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300138\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227581\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227607\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227597\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227621\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227598\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227585\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227599\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227576\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227593\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10110|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/23/6517?source=related_link\">",
"      Tiaprofenic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30344="Drug-induced lung disease in rheumatoid arthritis";
var content_f29_40_30344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced lung disease in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Fiona R Lake, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30344/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/40/30344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-related pulmonary disease is an important consideration in the differential diagnosis of patients with rheumatoid arthritis (RA) who present with respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinicians should exclude undiagnosed pulmonary disease prior to initiating drug treatment in patients with RA on the basis of a thorough history and physical examination, chest radiograph, and assessment of baseline lung function. Patients with RA need to be instructed to report new pulmonary symptoms immediately.",
"   </p>",
"   <p>",
"    A review of drug-induced lung disease in patients with rheumatoid arthritis will be presented here. Other aspects of pulmonary disease associated with rheumatoid arthritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a common cause of abnormal lung function due to drugs used to treat rheumatoid arthritis (RA). As an example, in an observational study of 16,788 patients with RA, patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    had a higher risk of hospitalization due to pneumonia than patients not taking glucocorticoids (hazard ratio 1.7, 95% CI 1.5-2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/2\">",
"     2",
"    </a>",
"    ]. The effect was dose dependent. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and tumor necrosis factor (TNF) antagonists were not associated with increased risk of pneumonia in this study, they have been associated with pneumonia in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/3-11\">",
"     3-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all lung diseases due to antirheumatic therapy are infectious, however. Many drugs can induce alveolar inflammation, interstitial inflammation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial fibrosis, resulting in lung dysfunction (",
"    <a class=\"external\" href=\"file://pneumotox.com/\">",
"     Pneumotox.com",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/12\">",
"     12",
"    </a>",
"    ]. Bronchoalveolar lavage and lung biopsy are often abnormal in this setting, but the findings are typically nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The net effect of the disease modifying antirheumatic drugs (DMARDs) on the incidence of drug-induced lung disease in patients with RA remains to be seen. Medication side effects may become more common as the clinical use of disease DMARDs and biological agents such as TNF blockers increases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, DMARDs may have a beneficial impact on the natural history of a variety of forms of rheumatoid-associated lung disease, and use of these drugs may influence the frequency or presentation of these problems. In one study of 59 patients with RA who were taking DMARDs but had no pulmonary symptoms, abnormal histology was found in 18 percent of patients on DMARDs, compared to 42 percent of those not taking one of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between a drug reaction and underlying rheumatoid-associated lung disease may be difficult, since there is significant overlap in the clinical syndromes. In addition, many of the pulmonary reactions to drugs used for the treatment of rheumatoid arthritis are rare and are published as case reports (",
"    <a class=\"graphic graphic_table graphicRef65141 \" href=\"UTD.htm?7/44/7885\">",
"     table 1",
"    </a>",
"    ). An online repository of drug-induced lung disease is available to help identify potential culprit medications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Response to therapy may be one distinguishing feature. In general, drug-related lung disease responds better to glucocorticoid therapy, and it often regresses upon withdrawal of the offending medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     METHOTREXATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is the most commonly used disease modifying antirheumatic drug (DMARD) in patients with RA. Unlike the other major side effects of methotrexate, pulmonary complications are not associated with folate deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/17\">",
"     17",
"    </a>",
"    ]. Pulmonary disease may occur with the relatively low doses (&lt;20 mg per week) that are used in patients with RA. MTX has also been associated with progression of preclinical pulmonary disease in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious complications must be excluded in this population prior to the initiation of therapy for a possible drug reaction. Infections reported in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy include Pneumocystis jirovecii pneumonia, cryptococcal pneumonia, invasive pulmonary aspergillosis, disseminated histoplasmosis, pulmonary nocardia infection, and viral pneumonia caused by parainfluenza and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/3-8\">",
"     3-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute interstitial pneumonitis is the most common noninfectious pulmonary complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy. Less commonly, interstitial fibrosis, accelerated nodulosis, asthma, and air trapping may occur. In many cases, it is not clear whether these less common abnormalities are drug-related, or are due to underlying rheumatoid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of acute pneumonitis may be a hypersensitivity-type mechanism, based upon pathologic changes and the beneficial response to glucocorticoids. However, reports that rechallenge with the offending drug frequently does not result in recurrence of the pneumonitis suggest an idiosyncratic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few clear predisposing factors for the development of an adverse drug reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/13\">",
"     13",
"    </a>",
"    ]. One exception is preexisting lung disease, which appears to predispose patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pneumonitis, and may increase morbidity if any reaction should occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, preexisting rheumatoid pleuropulmonary involvement increases the risk of methotrexate pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with RA, the overall likelihood of developing acute pneumonitis during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy is 0.3 to 11.6 percent. Pneumonitis can begin early after the drug is started, when switching from oral to parenteral administration, and in one report one month after the drug was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/13,17,23\">",
"     13,17,23",
"    </a>",
"    ]. Most cases occur within two years of the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter, case-control study of 29 patients and 82 controls documented the following significant risk factors for MTX-induced lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age (odds ratio (OR) 5.1)",
"     </li>",
"     <li>",
"      Rheumatoid pleuropulmonary involvement (OR 7.1)",
"     </li>",
"     <li>",
"      Previous use of disease-modifying antirheumatic drugs, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"       auranofin",
"      </a>",
"      (oral gold),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      (OR 5.6)",
"     </li>",
"     <li>",
"      Hypoalbuminemia (OR 19.5)",
"     </li>",
"     <li>",
"      Diabetes mellitus (OR 35.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of dyspnea, fever, and cough is usually subacute over weeks, but can sometimes be more rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/24\">",
"     24",
"    </a>",
"    ]. Crackles and cyanosis may be observed on physical examination. Typical clinical findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia and a restrictive pattern on pulmonary function testing are observed, although the patient may be too unwell to perform the latter.",
"     </li>",
"     <li>",
"      Chest radiograph demonstrates diffuse bilateral interstitial opacities (60 percent) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58722 \" href=\"UTD.htm?14/59/15280\">",
"       image 1",
"      </a>",
"      ) or a mixed interstitial and alveolar pattern (40 percent). Unilateral or reticulonodular changes, effusions, and bilateral hilar lymphadenopathy are uncommon.",
"     </li>",
"     <li>",
"      High resolution CT demonstrates a ground glass appearance and occasionally fibrotic changes.",
"     </li>",
"     <li>",
"      Gallium and technetium-labeled diethylenetriamine pentaacetate (DTPA) scans may be abnormal, but these findings are nonspecific, and do not help confirm the diagnosis.",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage (BAL) demonstrates a lymphocytosis with a low",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio that is difficult to differentiate from underlying interstitial lung disease (ILD). BAL eosinophilia may also be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"       \"Causes of pulmonary eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to perform invasive investigations depends upon the evidence supporting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis, and the clinical condition of the patient. Patients have been managed in some cases without a pathologic diagnosis. Bronchoalveolar lavage and transbronchial biopsy may be most important for ruling out important alternative diagnoses, such as infection with P. jirovecii. Transbronchial biopsy is occasionally diagnostic; however, open lung biopsy frequently is required to establish a pathologic diagnosis. Histologic examination shows an interstitial pneumonitis with granuloma formation, occasional infiltration of eosinophils, and bronchiolitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    should be temporarily stopped and a chest radiograph performed in any patient who complains of a nonproductive cough and dyspnea without other symptoms of a viral illness. Methotrexate should be permanently discontinued in a patient with respiratory symptoms and a new interstitial pattern on chest radiograph.",
"   </p>",
"   <p>",
"    Patients generally respond to withdrawal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and the prognosis is usually good, although the reaction may be fatal in some cases. Uncontrolled studies suggest glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    can hasten recovery and may be important in severely ill patients. Rechallenge with methotrexate has been reported without recurrence of lung disease, and can be tried cautiously when the drug is felt to be essential for the management of joint disease. In this setting, there are no reports that glucocorticoids protect against recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controversy exists regarding the long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    upon lung function. No change, a mild increase in residual volume and DLCO, and a mild reduction in spirometry have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/25\">",
"     25",
"    </a>",
"    ]. None of these changes was found to be clinically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LEFLUNOMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    blocks a key enzyme of pyrimidine synthesis in activated lymphocytes. Interstitial lung disease and cases of new or accelerated pulmonary nodule formation, which stabilized after cessation of the drug, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. In a review that used linked prescribing and administrative databases for more than 235,000 patients with rheumatoid arthritis, the relative risk of interstitial lung disease among those treated with leflunomide was 1.9 compared to those treated with other disease modifying antirheumatic drugs (DMARDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there was no significant increase in risk among patients who had no prior diagnosis of interstitial lung disease and no prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    use. Thus, an apparent increased risk of interstitial lung disease in patients treated with leflunomide may be due to preferential prescribing of this agent for those with preexisting lung disease or prior methotrexate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were reported in an observational study of 5054 patients who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    ; 1.2 percent developed new or worsening interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/31\">",
"     31",
"    </a>",
"    ]. Risk factors included pre-existing lung disease (most important factor with OR 8.17; 95% CI 4.63 to 14.4), smoking, low body weight, and use of a loading dose.",
"   </p>",
"   <p>",
"    In two reports, a 1 percent rate of interstitial lung disease was found with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    treatment. In one of these, the lung disease was fatal for 11 of 29 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/27\">",
"     27",
"    </a>",
"    ]. In the other, there were no fatalities; the authors attributed this to prompt recognition and treatment with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually avoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    in patients with known interstitial lung disease because of the possibility that leflunomide accelerates the interstitial lung disease in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BIOLOGICAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor (TNF) blockers (soluble p75 TNF receptor fusion protein [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ], dimeric anti-TNFa antibody [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ], anti-TNF monoclonal antibody [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ]), IL-1 blockers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ), anti-B-cell monoclonal antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ), a selective co-stimulation modulator which prevents T cell CD28 binding (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ), and similar agents have been shown to improve symptoms, joint disease, and possibly lung disease in patients with rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/32\">",
"     32",
"    </a>",
"    ]. However, substantial pulmonary toxicity has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The British Society for Rheumatology Biologics Register (BSRBR) prospectively collects data on all patients in the UK receiving biologic agents (&gt;8000 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/34\">",
"     34",
"    </a>",
"    ]. An early report in the organization's newsletter suggested that the odds ratio for mortality was 4.4 times higher (95% CI 1.8-10.7) for those patients with RA and preexisting pulmonary disease who were treated with biologics compared to those without pulmonary disease. The significance of and causal relationship of these preliminary findings is unclear, but deserves close watching.",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was evaluated in an observational study of 7091 patients with RA; the most common reactions were injection site discomfort (5.3 percent) and rash (3.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/35\">",
"     35",
"    </a>",
"    ]. Pneumonia and interstitial disease were the most important serious adverse reactions, occurring in 0.8 and 0.6 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of serious infections have been described with use of biologic agents to treat rheumatoid arthritis; chronic obstructive pulmonary disease (COPD) and the combination of biologic agents with glucocorticoids or other immunomodulatory agents may further increase the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/10\">",
"     10",
"    </a>",
"    ]. Pathogens include Histoplasma and other fungal species, Listeria, cytomegalovirus, and tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, a four-fold increase in hospitalization due to infection was attributed to use of TNF inhibitors, compared with a two-fold increase that was associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common infection was bacterial pneumonia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has also been associated with an increase in serious infections, including pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/10\">",
"     10",
"    </a>",
"    ]. It is not clear if the incidence of most of these infections is greater than that associated with other DMARDs. Presenting symptoms may be subtle, and a high degree of clinical suspicion should be applied in the assessment of patients treated with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tuberculosis screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted TNF inhibitors are associated with an increased risk of tuberculosis (TB). Appropriate screening before the start of treatment and vigilance for the occurrence of active TB during therapy are essential, although screening does not eliminate the risk of development of active TB. These issues are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inflammatory pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of pulmonary toxicity is also of concern, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung disease characterized by granuloma formation (both noncaseating and necrotizing) without evidence of mycobacterial infection has been reported in at least eight patients with RA who were taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ; some of the patients were also taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/36-40\">",
"       36-40",
"      </a>",
"      ]. Lung disease improved over two to four weeks after withdrawal of etanercept and treatment with glucocorticoids.",
"     </li>",
"     <li>",
"      In small case series, 10 patients with RA developed progressive usual interstitial pneumonitis (UIP) temporally related to initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , and one developed organizing pneumonia; eight patients died from progressive UIP [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Among the fatal cases, all had preexisting interstitial lung disease with a UIP pattern and three were concomitantly taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and glucocorticoids. In these patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      had been avoided because of the preexisting lung disease.",
"     </li>",
"     <li>",
"      Three cases of acute interstitial pneumonitis have been reported in patients taking a stable dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , shortly after addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/43\">",
"       43",
"      </a>",
"      ]. All patients improved with discontinuation of methotrexate and infliximab and treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      One patient with RA on a stable dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      developed rapidly worsening interstitial lung disease after initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/44\">",
"       44",
"      </a>",
"      ]. Respiratory improvement followed discontinuation of methotrexate and adalimumab, and treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although more data are required, these case series suggests that the potential for serious, adverse effects should be carefully considered before administering TNF-alpha blockers to patients with RA and preexisting ILD, especially when combination therapy is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GOLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis due to gold is well recognized but uncommon. Its occurrence may be associated with HLA-B40, A3, B35, and Dw1 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/45\">",
"     45",
"    </a>",
"    ]. The pneumonitis typically begins after the cumulative ingestion of about 500 mg of gold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=see_link\">",
"     \"Gold-induced pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients commonly present with cough and dyspnea. Crackles are usually evident on physical examination. The chest radiograph is usually, but not always, abnormal. There have been rare reports of acute respiratory failure requiring mechanical ventilation, obliterative bronchiolitis (OB), and fibrosis associated with gold therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features of gold-induced pneumonitis that may allow differentiation from underlying RA-induced ILD include the presence of fever (50 percent), absence of clubbing (1 percent), BAL lymphocytosis (70 percent) rather than neutrophilia, and extrapulmonary signs of gold toxicity, such as a skin rash (36 percent), eosinophilia (36 percent), liver dysfunction (19 percent), and proteinuria (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"     \"Major side effects of gold\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pneumonitis frequently resolves upon withdrawal of gold. Systemic glucocorticoids may be needed in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PENICILLAMINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications related to d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    are rare, occurring in 1 to 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]. Original reports of obliterative bronchiolitis (OB) in patients with RA suggested that d-penicillamine was the causative agent, but OB in the setting of rheumatoid disease has also been associated with gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and no drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    has been extensively used in Wilson's disease with very few pulmonary reactions, suggesting that some interaction between d-penicillamine and the underlying rheumatoid disease may predispose to the development of OB. This predisposition in patients with RA also extends to the other side effects associated with d-penicillamine.",
"   </p>",
"   <p>",
"    OB has been described between 3 and 14 months after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    therapy, and at daily doses of 375 to 1250 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/1,48\">",
"     1,48",
"    </a>",
"    ]. Patients generally present with the subacute onset of cough and dyspnea on exertion, frequently in the presence of a chest radiograph that is normal or reveals only hyperinflation. CT scans may reveal gas trapping (particularly on expiratory images)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mosaic pattern of ground glass opacification. A progressive obstructive ventilatory defect without bronchodilator response is generally present. Definitive diagnosis requires a lung biopsy, which reveals typical findings of OB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of OB associated with d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is poor, with an estimated mortality of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/1\">",
"     1",
"    </a>",
"    ]. There is little evidence that glucocorticoids are of benefit, although a trial of therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is warranted because of the dismal prognosis. Trials of other immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    100 to 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a daily maximum of 200 mg) can also be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other rare complications of d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    include a pulmonary-renal syndrome, drug-induced lupus erythematosus, pulmonary hemorrhage, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs have both analgesic and antiinflammatory properties, but do not alter disease outcomes in RA. Several NSAIDs have been associated with pulmonary infiltrates with eosinophilia, but not all of these were in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30344/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. It is not known whether this is a class effect or a unique feature of certain NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most of the drugs used to treat rheumatoid arthritis (RA) have been reported to cause pneumonitis, including NSAIDS,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , gold,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , and biologic agents. Many of the pulmonary reactions to drugs used for the treatment of rheumatoid arthritis are rare and are published as case reports. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary disease may occur with the relatively low doses of MTX (&lt;20 mg per week) that are used in patients with RA. Acute interstitial pneumonitis is the most common noninfectious complication of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in this setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pneumonitis, chest radiograph demonstrates diffuse bilateral interstitial opacities or a mixed interstitial and alveolar pattern (40 percent). Unilateral or reticulonodular changes, effusions, and bilateral hilar lymphadenopathy are uncommon. Bronchoalveolar lavage is helpful to exclude infection, but otherwise the findings are nonspecific. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interstitial lung disease and new and accelerated nodule formation have been described with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      . As the risk of pneumonitis from leflunomide is greater in patients with underlying lung disease, we usually avoid leflunomide in these patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Leflunomide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A few case reports have described progressive pneumonitis in patients treated with the tumor necrosis factor (TNF) blockers. A growing number of other biologic agents are being used to treat RA; further study is needed to determine whether they also cause or contribute to interstitial pneumonitis in RA. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Biological agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Targeted TNF inhibitors are associated with an increased risk of tuberculosis (TB). Appropriate screening before the start of treatment and vigilance for the occurrence of active TB during therapy are essential. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tuberculosis screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interstitial lung disease due to gold therapy is uncommon and usually occurs after ingestion of a cumulative gold dose of about 500 mg. Patients present with cough and dyspnea and about half have fever. Withdrawal of gold is usually sufficient treatment, but occasionally glucocorticoids are necessary. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Gold'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obliterative bronchiolitis (OB) has been described between 3 and 14 months after the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      therapy, and at daily doses of 375 to 1250 mg. Patients present with cough and dyspnea; chest radiograph shows hyperinflation. There is little evidence that glucocorticoids are of benefit, although a trial of therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) is warranted because of the dismal prognosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Penicillamine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/1\">",
"      Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med 1998; 19:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/2\">",
"      Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/3\">",
"      Belin V, Tebib J, Vignon E. Cytomegalovirus infection in a patient with rheumatoid arthritis. Joint Bone Spine 2003; 70:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/4\">",
"      LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/5\">",
"      O'Reilly S, Hartley P, Jeffers M, et al. Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole. Tuber Lung Dis 1994; 75:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/6\">",
"      Stenger AA, Houtman PM, Bruyn GA, et al. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/7\">",
"      Cornelissen JJ, Bakker LJ, Van der Veen MJ, et al. Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis. Ann Rheum Dis 1991; 50:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/8\">",
"      Altz-Smith M, Kendall LG Jr, Stamm AM. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 1987; 83:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/9\">",
"      van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/10\">",
"      Khan, S, Justice, E, Jobanputra, P. Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARD) for rheumatoid arthritis. Adverse Drug React Bull 2007; 242:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/11\">",
"      Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125.",
"     </a>",
"    </li>",
"    <li>",
"     Camus P. The Drug-Induced Respiratory Disease Website. www.pneumotox.com (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/13\">",
"      Cannon GW. Antirheumatic drug reactions in the lung. Baillieres Clin Rheumatol 1993; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/14\">",
"      Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003; 62 Suppl 2:ii2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/15\">",
"      Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997; 23:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/16\">",
"      Scherak O, Popp W, Kolarz G, et al. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol 1993; 20:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/17\">",
"      Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/18\">",
"      Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/19\">",
"      Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/20\">",
"      Belzunegui J, Intxausti JJ, De Dios JR, et al. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001; 19:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/21\">",
"      Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/22\">",
"      Alarcon, GS, Kremer, JM, Macaluso, M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study. Ann Intern Med 1997; 127:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/23\">",
"      Collins K, Aspey H, Todd A, et al. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatology (Oxford) 2008; 47:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/24\">",
"      Kremer JM, Alarc&oacute;n GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/25\">",
"      Dayton CS, Schwartz DA, Sprince NL, et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995; 151:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/26\">",
"      Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006; 25:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/27\">",
"      Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004; 43:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/28\">",
"      Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/29\">",
"      Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/30\">",
"      Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/31\">",
"      Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/32\">",
"      Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/33\">",
"      Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/34\">",
"      Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005; 64 Suppl 4:iv42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/35\">",
"      Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/36\">",
"      Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002; 122:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/37\">",
"      Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 2008; 35:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/38\">",
"      Vavricka SR, Wettstein T, Speich R, et al. Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax 2003; 58:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/39\">",
"      Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol 2005; 18:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/40\">",
"      Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008; 26:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/41\">",
"      Ost&ouml;r AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/42\">",
"      Tengstrand B, Ernestam S, Engvall IL, et al. [TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports]. Lakartidningen 2005; 102:3788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/43\">",
"      Kramer N, Chuzhin Y, Kaufman LD, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/44\">",
"      Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006; 45:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/45\">",
"      Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/46\">",
"      Blancas R, Moreno JL, Mart&iacute;n F, et al. Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation. Intensive Care Med 1998; 24:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/47\">",
"      Stein HB, Patterson AC, Offer RC, et al. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 1980; 92:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/48\">",
"      van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum 1985; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/49\">",
"      Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992; 152:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/50\">",
"      Pfitzenmeyer P, Meier M, Zuck P, et al. Piroxicam induced pulmonary infiltrates and eosinophilia. J Rheumatol 1994; 21:1573.",
"     </a>",
"    </li>",
"    <li>",
"     Foucher P, Camus P. Pneumotox online: the drug-induced lung diseases. www.pneumotox.com (Accessed on April 22, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30344/abstract/52\">",
"      Karakatsani A, Chroneou A, Koulouris NG, et al. Meloxicam-induced pulmonary infiltrates with eosinophilia: a case report. Rheumatology (Oxford) 2003; 42:1112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4378 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-C2C579228A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30344=[""].join("\n");
var outline_f29_40_30344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      METHOTREXATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LEFLUNOMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BIOLOGICAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tuberculosis screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inflammatory pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GOLD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PENICILLAMINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4378|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/59/15280\" title=\"diagnostic image 1\">",
"      Methotrexate-induced pneumonitis in RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4378|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/44/7885\" title=\"table 1\">",
"      Respiratory disease from RA drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34918?source=related_link\">",
"      Gold-induced pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30345="Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors";
var content_f29_40_30345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30345/contributors\">",
"     Kees Brinkman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30345/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30345/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/40/30345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of potent antiretroviral therapy (ART), the life expectancy of HIV-infected patients has improved enormously. However, the chronic administration of antiretroviral medications has led to the recognition of long-term complications of these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Mitochondrial toxicity is recognized as a major adverse effect of nucleoside analogue treatment and can lead to myopathy, peripheral neuropathy, and hepatic steatosis with lactic acidosis, which can be life-threatening.",
"   </p>",
"   <p>",
"    The induction of mitochondrial dysfunction by nucleoside reverse transcriptase inhibitors (NRTIs) will be discussed here. The use of NRTIs for the treatment of HIV infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF MITOCHONDRIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main function of mitochondria is oxidative phosphorylation in which fatty acids and pyruvate are used as substrates to produce energy in the form of adenosine triphosphate (ATP). Normally there is tight coupling between oxidation and phosphorylation (OXPHOS) that is governed by normal mitochondrial enzymes, such as the cytochrome oxidases and other enzymes of the respiratory chain system. OXPHOS is also responsible for neutralization of free radicals and beta-oxidation of free fatty acids.",
"   </p>",
"   <p>",
"    Mitochondria also play an important role in the generation of reactive oxygen species (ROS), which are produced physiologically during oxidative phosphorylation. Oxidative stress can occur if there is an imbalance between the production of ROS and cellular antioxidant defenses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/3\">",
"     3",
"    </a>",
"    ]. Mitochondrial DNA polymerase is a target of oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleoside analogues are effective in inhibiting HIV replication due to their high affinity for the viral enzyme reverse transcriptase (a viral DNA polymerase) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, NRTIs can also bind to other human DNA-polymerases, like DNA polymerase beta (necessary for repair of nuclear DNA) and mitochondrial DNA polymerase gamma, which is exclusively responsible for the replication of mitochondrial DNA (mtDNA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitochondrial DNA polymerase gamma",
"    </span>",
"    &nbsp;&mdash;&nbsp;By inhibiting mtDNA enzyme polymerase-gamma, NRTIs can lead to depletion of mtDNA, resulting in organelle dysfunction and impairment of oxidative phosphorylation (",
"    <a class=\"graphic graphic_figure graphicRef62034 \" href=\"UTD.htm?4/41/4752\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/2\">",
"     2",
"    </a>",
"    ]. mtDNA encodes 13 mitochondrial polypeptides involved in the respiratory chain that are essential for oxidative phosphorylation (OXPHOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/8\">",
"     8",
"    </a>",
"    ]. A disruption of OXPHOS leads to energy loss (decreased ATP) and an increase in electron leakage from the electron-transport chain, which increases the production of reactive oxygen species (ROS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/9\">",
"     9",
"    </a>",
"    ]. ROS, in turn, damage proteins, lipids, and mtDNA, leading to a cascade of further oxidative damage and lipid peroxidation. mtDNA is vulnerable to mutations since it has no introns or histones.",
"   </p>",
"   <p>",
"    Although the so-called &ldquo;pol-gamma hypothesis&rdquo; still remains the most important explanation for the induction of mitochondrial dysfunction by NRTIs, nucleoside analogues can also influence intracellular nucleoside transporters, disturb the delicate balance of the intracellular nucleoside pools or alter kinetics of phosphorylation of natural nucleosides [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The impact of all these effects on mitochondrial function is still unclear.",
"   </p>",
"   <p>",
"    Expression of mitochondrial toxicity may not occur until a specific biologic threshold of mitochondrial dysfunction has been reached. Onset of mitochondrial toxicity may vary depending on the individual cell type since copy numbers of mtDNA vary, as well as cellular dependence on energy production [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/12\">",
"     12",
"    </a>",
"    ]. Mitochondria are found in all cells of the body except for erythrocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Production of lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early effects of mitochondrial toxicity include decreased energy production and increased production of lactate. During glycolysis, glucose is metabolized to pyruvate and energy is produced in the form of ATP. Under normal conditions, pyruvate is taken up by mitochondria and metabolized to acetyl-CoA, which feeds into the Krebs cycle. This pathway is responsible for most of the cell's energy production. In the presence of mitochondrial dysfunction, the metabolism of pyruvate is shifted to lactate, with a decrease in energy production.",
"   </p>",
"   <p>",
"    A decrease in OXPHOS will impair ATP production, beta oxidation of fatty acids, and neutralization of free radicals leading to oxidative stress. Furthermore, since acetyl-co-A can no longer enter the Krebs cycle, it will alternatively be metabolized into ketone bodies, while lactate and triglycerides will accumulate (",
"    <a class=\"graphic graphic_figure graphicRef76153 \" href=\"UTD.htm?14/62/15343\">",
"     figure 2",
"    </a>",
"    ). Since every cell type has a different dependence on OXPHOS, cellular dysfunction will only emerge after the decrease in OXPHOS has dropped below a certain cell-dependent threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMPLICATED DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial toxicity secondary to drug exposure had been described prior to the development of antiretroviral medications. These drugs included valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and others. Fialuridine (FIAU) was a nucleoside analogue in clinical development for the treatment of hepatitis B. The clinical trial was prematurely halted when patients developed evidence of liver failure and hepatic steatosis that was secondary to mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/15\">",
"     15",
"    </a>",
"    ]. Histological findings of liver tissue demonstrated severe accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/15\">",
"     15",
"    </a>",
"    ]. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes.",
"   </p>",
"   <p>",
"    FIAU is efficiently incorporated into internal positions of mtDNA in place of thymidine and led to ultrastructural changes in mitochondria and increased intracellular lipid droplets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/16\">",
"     16",
"    </a>",
"    ]. There is no known repair mechanism to remove the internal FIAU and the damage to mtDNA is permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/17\">",
"     17",
"    </a>",
"    ]. However, ZDV, ddC, ddI, and d4T are chain terminators and result in the reversible termination of the mtDNA chain. This point is important since discontinuation of medications may lead to reversibility of mitochondrial toxicity if recognized early.",
"   </p>",
"   <p>",
"    Seven NRTIs are available for clinical treatment including ZDV (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ), d4T (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ), ddI (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    ), 3TC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ), FTC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ), ABC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (TDF); zalcitabine (ddC) was withdrawn from the market. They all have different affinities for mtDNA polymerase gamma, explaining in part the different propensity of the drugs to induce toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/18\">",
"     18",
"    </a>",
"    ]. In vitro, the order of strength of inhibiting polymerase gamma for the different NRTIs is: ddC &gt;&gt; ddI &gt; d4T &ge; ZDV &gt;&gt;&gt; TDF = 3TC = FTC = ABC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies comparing the various NRTIs confirmed that dideoxynucleosides (ddC, ddI and d4T) were particularly associated with a decline in mtDNA content and ultrastructural changes, including swollen or enlarged mitochondria and loss and distortion of their cristae. Factors that may explain the varying effects of individual drugs on DNA polymerase gamma may be due to differences in cell entry, and transport to the mitochondrial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/9\">",
"     9",
"    </a>",
"    ]. Due to the significant risk of mitochondrial toxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    use, these drugs are generally avoided for the treatment of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain drugs have particular target organs. As an example, ZDV is the only drug associated with mitochondrial myopathy. The susceptibility of a given tissue to a particular drug may be related to the relative concentrations of various isoforms of thymidine kinase that phosphorylate NRTIs and their respective locations (cytoplasm versus mitochondria) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Myopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electron microscopy demonstrates markedly swollen mitochondria with loss of cristae, matrix dissolution, and scattered vesicular inclusions, consistent with the theory that the mitochondrion is the main target of injury. Other specific findings in various tissues are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of mitochondrial toxicity depends on the target organ that is involved (",
"    <a class=\"graphic graphic_table graphicRef54147 \" href=\"UTD.htm?13/2/13355\">",
"     table 1",
"    </a>",
"    ). There is little doubt that mitochondrial toxicity is the major cause of NRTI-induced myopathy, neuropathy, lipoatrophy, and lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/6,7,22\">",
"     6,7,22",
"    </a>",
"    ]. Whether mitochondrial toxicity is involved in other clinical manifestations, such as pancreatitis, myelosuppression, cardiomyopathy, tubular dysfunction, or osteopenia, is not as clear (",
"    <a class=\"graphic graphic_table graphicRef63753 \" href=\"UTD.htm?1/6/1133\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first reports of a toxic mitochondrial myopathy in HIV-infected patients were related to the use of ZDV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/24\">",
"     24",
"    </a>",
"    ]. Symptoms of myopathy included proximal muscle weakness, tenderness, and myalgia. The majority of patients have elevated serum creatinine phosphokinase levels and may occasionally have elevated lactate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Occasionally a patient may have electromyographic evidence of proximal muscle myopathy despite normal muscle enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link\">",
"     \"Muscle disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ZDV affects the muscle mitochondria by inhibiting DNA polymerase gamma, resulting in termination of the DNA chain and depletion of muscle mtDNA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. Histological features include an inflammatory, destructive mitochondrial myopathy with \"ragged-red\" fibers seen on trichrome stain, indicative of abnormal mitochondria with paracrystalline inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with ubiquitous \"ragged-red\" fibers also have significant lipid and glycogen accumulation in proximity to abnormal mitochondria, as seen in patients with inherited mitochondrial myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/29\">",
"     29",
"    </a>",
"    ]. When mitochondria are structurally and functionally abnormal, long-chain fatty acids cannot be effectively utilized, resulting in lipid accumulation within the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    , which is essential for the transport of long-chain fatty acids into the muscle mitochondria, is depleted in ZDV-treated patients who have significant numbers of \"ragged-red\" fibers on muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/29\">",
"     29",
"    </a>",
"    ]. Two patients who had repeat biopsies after discontinuation of ZDV showed marked histologic improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lipoatrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical alterations in adipose tissue and metabolic changes, such as insulin resistance and hyperlipidemia, are observed in patients taking highly active antiretroviral therapy. This constellation of findings is referred to as the \"lipodystrophy syndrome\". Lipoatrophy, or fat atrophy, is associated with nucleoside reverse transcriptase inhibitor use, particularly d4T [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several groups have demonstrated profound mtDNA depletion and morphologic alterations in subcutaneous fat biopsies of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Some have speculated that lipoatrophy is secondary to adipocyte apoptosis rather than necrosis, because the loss of fat is neither painful nor inflammatory. Furthermore, mitochondria are closely involved in apoptotic pathways, again implying a role for NRTI-induced toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/12,37\">",
"     12,37",
"    </a>",
"    ]. Others have suggested that HIV itself may cause mitochondrial dysfunction, either directly or indirectly through the induction of inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and treatment of lipoatrophy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatic steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic steatosis and hepatic failure together with lactic acidosis have been reported as rare but serious adverse effects of nucleoside analogue therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/27,38\">",
"     27,38",
"    </a>",
"    ]. In 1993, eight cases of severe hepatomegaly with diffuse steatosis were reported in HIV-infected patients without AIDS, six of which were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/39\">",
"     39",
"    </a>",
"    ]. All had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    for a minimum of six months prior to the onset of gastrointestinal symptoms and mild elevations of transaminases. Case reports of liver failure and hepatic steatosis have since been reported, especially in association with ddI and d4T [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microvesicular hepatic steatosis has been identified in most of these cases, which is related to mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/41\">",
"     41",
"    </a>",
"    ]. Decreased mitochondrial oxidation of fatty acids leads to increased esterification of triglycerides and a decreased egress of triglycerides from the liver, which accumulate as small lipid droplets. Prior to the era of potent ART, it was well recognized that other drugs that inhibit mitochondrial oxidation, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , ethanol, and salicylic acid, can lead to these histologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Without intervention, lactic acidosis appears to have a high rate of case fatality, most often due to liver failure and cardiac arrhythmias. NRTIs (and thus all other antiretroviral medications) should be stopped promptly and supportive medication should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=see_link\">",
"     \"Treatment and prevention of mitochondrial toxicity in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperlactatemia and lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlactatemia and lactic acidosis are associated with NRTI use and typically occur in the absence of systemic hypoperfusion (called type B lactic acidosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of lactic acidosis\", section on 'Type B lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lactic acidosis represents a serious metabolic manifestation of mitochondrial toxicity that can lead to death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/43\">",
"     43",
"    </a>",
"    ]. Hepatic dysfunction may be an essential prerequisite for the development of lactate accumulation, since the liver is the most important organ for clearance of lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of hyperlactatemia or lactic acidosis may be nonspecific and include nausea, vomiting, abdominal pain, weight loss, and severe fatigue (",
"    <a class=\"graphic graphic_table graphicRef73056 \" href=\"UTD.htm?2/10/2219\">",
"     table 3",
"    </a>",
"    ). Serum aminotransferases are only mildly abnormal in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lactic acidosis usually follows a minimum of six months of treatment, but may occur precipitously. Due to the nonspecificity of symptoms, hyperlactatemia may not be recognized for weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/45\">",
"     45",
"    </a>",
"    ]. Without intervention, lactic acidosis leads to a fatal outcome, most often due to liver failure and cardiac arrhythmias. NRTIs (and thus also other antiretroviral medication) should be stopped promptly and supportive medication should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=see_link\">",
"     \"Treatment and prevention of mitochondrial toxicity in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the pre-ART era, lactic acidosis was described in patients on monotherapy with high-dose ZDV (1200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and ddI with an estimated incidence of",
"    <span class=\"nowrap\">",
"     1.2/1000",
"    </span>",
"    treated patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/38\">",
"     38",
"    </a>",
"    ]. In the early era of combination therapy, d4T and ddI were most closely associated with this syndrome, sometimes in combination with each other [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/27,45-48\">",
"     27,45-48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    are no longer recommended for HIV treatment in resource-rich settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H40#H40\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Antiretroviral combinations to avoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lactic acidosis is still a clinical problem in resource-limited settings that are utilizing drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. In a prospective study in South Africa, 1771 HIV-infected participants were randomly assigned to a nucleoside backbone of",
"    <span class=\"nowrap\">",
"     d4T/3TC",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     ddI/AZT",
"    </span>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     .",
"    </span>",
"    Lactic acidosis was defined as a serum lactate concentration &gt;5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    with an arterial pH &lt;7.35 or a serum bicarbonate concentration &lt;20",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Symptomatic hyperlactatemia was defined as serum lactate &gt;2.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    with symptoms consistent with increased lactate (eg, nausea, anorexia, fatigue). A total of 13 cases with lactic acidosis (0.7 percent) and 28 cases with symptomatic hyperlactatemia (1.6 percent) were observed and two patients died. The risk of lactic acidosis or symptomatic hyperlactatemia was higher in female patients and among those taking",
"    <span class=\"nowrap\">",
"     d4T/3TC",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic hyperlactatemia (lactate &lt;5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    has been described in much higher prevalence (10 to 40 percent) and has also been observed in association with the use of d4T &plusmn; ddI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/43,53-56\">",
"     43,53-56",
"    </a>",
"    ]. Hyperlactatemia does not appear to be a constant phenomenon despite continuation of medication; some of these paradoxical observations may be related to incorrect blood sampling.",
"   </p>",
"   <p>",
"    The natural history of hyperlactatemia is unclear since cases of lactic acidosis have been described where normal lactate levels were documented just prior to onset. In order to interpret the importance of an elevated lactate, decision algorithms have been developed (",
"    <a class=\"graphic graphic_algorithm graphicRef64661 \" href=\"UTD.htm?40/10/41133\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dideoxynucleoside analogues are most closely associated with pancreatitis (ddI&gt;d4T). It has not been clearly established that pancreatitis is related to mitochondrial toxicity. However, concomitant chemical pancreatitis has been described in patients who had developed symptomatic lactic acidosis on NRTI therapy, suggesting a common mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/27,47\">",
"     27,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence that mitochondrial toxicity may be implicated in pancreatitis also comes from the clinical trial of FIAU for the treatment of hepatitis B. Seven of 15 patients who developed liver failure and hepatic steatosis secondary to mitochondrial toxicity also had biochemical evidence of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/15\">",
"     15",
"    </a>",
"    ]. All five patients who died had both gross and microscopic evidence of pancreatitis at autopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ZDV is associated with bone marrow suppression, which may be related to mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    have been linked to the development of peripheral neuropathy. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4920259\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequently used nucleotide analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    can induce proximal tubular dysfunction with subsequent renal failure, but a mitochondrial pathway for this adverse event has not yet been demonstrated. Accumulation of tenofovir in proximal tubular cells has been demonstrated in experimental models, with a pivotal role for membrane transporters as OAT1 and MRP4 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/58\">",
"     58",
"    </a>",
"    ]. Although in one animal study it was suggested that mtDNA content altered (increased) in isolated proximal tubular cells, mitochondrial dysfunction was not shown. Since tenofovir lacks affinity for DNA polymerase-gamma, it seems very unlikely that this drug can affect mtDNA levels via this pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4920285\">",
"    <span class=\"h2\">",
"     Osteopenia/osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the occurrence of decreased bone mineral density during chronic HIV infection has been associated with the use of antiretroviral treatment and in particular with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , it has not yet been demonstrated that mitochondrial dysfunction plays any role in this feature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all individuals will develop mitochondrial toxicity, even after exposure of several years to the most toxic drugs (like ddC or",
"    <span class=\"nowrap\">",
"     d4T/ddI",
"    </span>",
"    combinations). Systematic studies of risk factors have not been performed, but according to observations in inherited mitochondrial disease, other factors might be of importance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female gender [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/45,48,60\">",
"       45,48,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      with ddI for the treatment of hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased age [",
"      <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk in females may be even higher during pregnancy. After a report of three cases of lactic acidosis in pregnant females exposed to a combination of ddI and d4T, an official warning regarding this combination was sent to medical providers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An evaluation of the United States Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with HIV and chronic hepatitis C virus that were treated with a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and ddI, with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , were at increased risk for mitochondrial toxicity. Clinical events included hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia and lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/61,67-69\">",
"     61,67-69",
"    </a>",
"    ]. The simultaneous use of ribavirin and ddI is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of nucleoside-related mitochondrial toxic effects is a muscle or liver biopsy.",
"   </p>",
"   <p>",
"    When a patient presents with symptoms consistent with hyperlactatemia or lactic acidosis, a blood sample for lactate should be sent in a fluoride oxalate tube on ice and delivered within four hours to the laboratory for processing. Levels need to be assessed with the strictest of quality control measures since elevated lactate can be an artifact of collection techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/70\">",
"     70",
"    </a>",
"    ]. Therefore, it is critically important to avoid certain factors that can artificially elevate lactate levels. Ideally samples should be drawn without use, or prolonged use, of a tourniquet. Whenever possible, it is also best to monitor levels in patients who have not exercised shortly before sampling.",
"   </p>",
"   <p>",
"    Patients with pancreatitis (either chemical or clinical) should also have measurements of serum lactate, since these clinical entities have occurred concomitantly. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pancreatitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since hyperlactatemia may be a correlate of mitochondrial dysfunction, researchers have tried to determine if monitoring serial lactate levels could be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one longitudinal prospective study of 349 participants, venous blood lactate levels were serially obtained during routine patient care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/73\">",
"     73",
"    </a>",
"    ]. Over 516 patient-years of observation, two patients were identified with severe lactic acidosis and an additional five with symptomatic hyperlactatemia. All had been taking d4T-containing regimens. Asymptomatic hyperlactatemia was more common and associated with use of d4T.",
"   </p>",
"   <p>",
"    These data suggest that lactic acidosis is rare; chronic hyperlactatemia found by routine testing in asymptomatic patients had a poor predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In addition, hyperlactatemia does not appear to be a constant phenomenon; cases of lactic acidosis have been described, where normal lactate levels were documented just prior to onset.",
"   </p>",
"   <p>",
"    The possible role of monitoring mtDNA on venous blood has been explored [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. One group of researchers developed a PCR-based assay that can measure changes in mtDNA levels relative to nuclear DNA in peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/74\">",
"     74",
"    </a>",
"    ]. They suggested that HIV-infected patients on nucleoside analogues with symptomatic hyperlactatemia (n = 8) had markedly lower",
"    <span class=\"nowrap\">",
"     mtDNA/nDNA",
"    </span>",
"    ratios, which were on average 69 percent lower than HIV-uninfected controls (n = 24) and 45 percent lower than HIV-infected asymptomatic antiretroviral-naive controls (n = 47). The mtDNA levels increased significantly in those patients who discontinued ART. mtDNA declines preceded increases in venous lactate. Although promising, subsequent studies could not confirm the value of monitoring mtDNA measurements in PBMCs and other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/36,76-80\">",
"     36,76-80",
"    </a>",
"    ]. Furthermore, significant variance has been reported among laboratories assessing the same clinical sample [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS: IN UTERO EXPOSURE TO NRTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral drugs play an essential role in the prevention of mother-to-child-transmission (MTCT) of HIV. In utero exposure to NRTIs has been demonstrated to induce transient anemia, leucopenia, and hyperlactatemia in the newborns, without further sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30345/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. See (\"Interventions to prevent mother to child HIV transmission: PACTG 076 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prophylaxis &mdash; efficacy, mechanisms of action and safety-I\").",
"   </p>",
"   <p>",
"    The treatment and prevention of mitochondrial toxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=see_link\">",
"     \"Treatment and prevention of mitochondrial toxicity in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135123\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitochondrial toxicity is recognized as a major adverse effect of treatment with nucleoside reverse transcriptase inhibitors (NRTIs) and can lead to myopathy, peripheral neuropathy, and hepatic steatosis with lactic acidosis, which can be life-threatening. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondria play an important role in the generation of reactive oxygen species (ROS), which are produced physiologically during oxidative phosphorylation. Oxidative stress can occur if there is an imbalance between the production of these reactive metabolites and cellular antioxidant defenses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of mitochondria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NRTIs are effective in inhibiting HIV replication due to their high affinity for the viral enzyme reverse transcriptase. However, NRTIs can also bind to human DNA-polymerases, like mitochondrial DNA polymerase gamma, which is exclusively responsible for the replication of mitochondrial DNA. By inhibiting this enzyme, NRTIs can cause depletion of mitochondrial DNA, resulting in organelle dysfunction and mitochondrial toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The various NRTIs have different affinities for mitochondrial DNA polymerase gamma; those with the highest affinity (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ) are associated with the highest risk of mitochondrial toxicity. Due to the significant risk of mitochondrial toxicity associated with didanosine and stavudine use, these drugs are generally avoided for the treatment of HIV. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Implicated drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nucleoside analogues",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (3TC),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (FTC),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (ABC), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (TDF) lack affinity for mitochondrial DNA polymerase gamma; thus, it seems unlikely that these drugs can induce mitochondrial dysfunction of clinical significance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Implicated drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of mitochondrial toxicity depends on the target organ that is involved. Mitochondrial toxicity is the major cause of NRTI-induced myopathy, neuropathy, lipoatrophy, and lactic acidosis. Whether mitochondrial toxicity is involved in other clinical manifestations, such as pancreatitis, myelosuppression, cardiomyopathy, proximal tubular dysfunction, or osteopenia, is not as clear. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis of nucleoside-related mitochondrial toxic effects is a muscle biopsy in cases of myopathy, or a liver biopsy in cases of suspected lactic acidosis with steatosis. When a patient presents with symptoms consistent with hyperlactatemia or lactic acidosis, a blood sample for lactate should be sent in a fluoride oxalate tube on ice and delivered within four hours to the laboratory for proper processing. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring for lactic acidosis is not warranted since prospective monitoring is not predictive of risk. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/1\">",
"      Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/2\">",
"      Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/3\">",
"      Betteridge DJ. What is oxidative stress? Metabolism 2000; 49:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/4\">",
"      Graziewicz MA, Day BJ, Copeland WC. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res 2002; 30:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/5\">",
"      Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/6\">",
"      Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/7\">",
"      Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/8\">",
"      Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999; 354:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/9\">",
"      Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/10\">",
"      Apostolova N, Blas-Garc&iacute;a A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-&gamma; inhibition. Trends Pharmacol Sci 2011; 32:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/11\">",
"      Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol 2010; 6:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/12\">",
"      Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/13\">",
"      Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992; 256:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/14\">",
"      Brinkman K, ter Hofstede HJ. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Reviews 1999; 1:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/15\">",
"      McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/16\">",
"      Lewis W, Levine ES, Griniuviene B, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A 1996; 93:3592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/17\">",
"      Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994; 38:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/18\">",
"      Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/19\">",
"      Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/20\">",
"      Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/21\">",
"      Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001; 276:23616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/22\">",
"      Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/23\">",
"      Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med 2002; 347:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/24\">",
"      Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/25\">",
"      Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/26\">",
"      Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies. J Am Soc Nephrol 1992; 3:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/27\">",
"      Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/28\">",
"      Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/29\">",
"      Dalakas MC, Leon-Monzon ME, Bernardini I, et al. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994; 35:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/30\">",
"      Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/31\">",
"      Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/32\">",
"      van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/33\">",
"      Walker UA, Bickel M, L&uuml;tke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/34\">",
"      Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/35\">",
"      Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/36\">",
"      Morse CG, Voss JG, Rakocevic G, et al. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis 2012; 205:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/37\">",
"      Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/38\">",
"      Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/39\">",
"      Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/40\">",
"      Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med 1991; 115:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/41\">",
"      Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/42\">",
"      Deschamps D, DeBeco V, Fisch C, et al. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994; 19:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/43\">",
"      John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/44\">",
"      Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/45\">",
"      Falc&oacute; V, Rodr&iacute;guez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/46\">",
"      Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/47\">",
"      Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/48\">",
"      Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/49\">",
"      Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/50\">",
"      Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/51\">",
"      Geddes R, Knight S, Moosa MY, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/52\">",
"      Dlamini J, Ledwaba L, Mokwena N, et al. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. Antivir Ther 2011; 16:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/53\">",
"      G&eacute;rard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/54\">",
"      Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/55\">",
"      Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/56\">",
"      Mocroft A, Phillips AN, Friis-M&oslash;ller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/57\">",
"      Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/58\">",
"      Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/59\">",
"      Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs). 39th Interscience Conference on Antimicrobal Agents and Chemotherapy, San Fransisco, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/61\">",
"      Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/62\">",
"      Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/63\">",
"      McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/64\">",
"      Use of p24 antigen screening for HIV in primary care. AIDS Read 2001; 11:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/65\">",
"      Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/66\">",
"      Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/67\">",
"      Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/68\">",
"      Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 2003; 13:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/69\">",
"      Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004; 38:e79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/70\">",
"      Wohl DA, Pilcher CD, Evans S, et al. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr 2004; 35:274.",
"     </a>",
"    </li>",
"    <li>",
"     Brinkman K, Troost N, Schrijnders L, et al. Usefulness of routine lactate measurement to prevent lactic acidosis: evaluation of a protocol (abstract 709). 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/72\">",
"      Imhof A, Ledergerber B, G&uuml;nthard HF, et al. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infect Dis 2005; 41:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/73\">",
"      John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/74\">",
"      C&ocirc;t&eacute; HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/75\">",
"      Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/76\">",
"      Petit C, Mathez D, Barth&eacute;l&eacute;my C, et al. Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2003; 33:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/77\">",
"      Hoy JF, Gahan ME, Carr A, et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004; 190:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/78\">",
"      Brinkman K. Lipoatrophy and mitochondrial DNA assays: see all, know all? AIDS 2005; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/79\">",
"      Maagaard A, Holberg-Petersen M, Kollberg G, et al. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/80\">",
"      Casula M, Weverling GJ, Wit FW, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005; 192:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/81\">",
"      Hammond EL, Sayer D, Nolan D, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/82\">",
"      Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/83\">",
"      Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30345/abstract/84\">",
"      Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3765 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30345=[""].join("\n");
var outline_f29_40_30345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H135123\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF MITOCHONDRIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitochondrial DNA polymerase gamma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Production of lactate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMPLICATED DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lipoatrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatic steatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperlactatemia and lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4920259\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4920285\">",
"      Osteopenia/osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIAL SITUATIONS: IN UTERO EXPOSURE TO NRTIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135123\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3765|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/10/41133\" title=\"algorithm 1\">",
"      Management of plasma lactates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3765|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/41/4752\" title=\"figure 1\">",
"      Pathway of NRTI induced MT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/62/15343\" title=\"figure 2\">",
"      Metabolism of glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/2/13355\" title=\"table 1\">",
"      Mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/6/1133\" title=\"table 2\">",
"      Proof for mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/10/2219\" title=\"table 3\">",
"      Features of hyperlactatemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=related_link\">",
"      Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30346="Human herpesvirus 6 infection in hematopoietic cell transplant recipients";
var content_f29_40_30346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human herpesvirus 6 infection in hematopoietic cell transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Danielle Zerr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Michael Boeckh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/40/30346/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/40/30346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H709290626\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) is a member of the Roseolovirus genus of the beta-herpesvirus subfamily of human herpesviruses. There are two HHV-6 variants, HHV-6A and HHV-6B. Based on their distinctive biological properties and genome sequences, the Herpesvirales Study Group of the International Committee on Taxonomy of Viruses has classified HHV-6A and HHV-6B as two distinct herpesvirus species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of documented primary infections and reactivation events are due to HHV-6B. HHV-6B infects most children within the first three years of life and, like other herpesviruses, it establishes latency after primary infection. HHV-6B may reactivate in immunocompromised hosts, especially following allogeneic hematopoietic cell transplantation (HCT). Encephalitis is the most clearly established clinical manifestation of HHV-6 reactivation in allogeneic HCT recipients, and may result in substantial morbidity. Little is known about the epidemiology or clinical implications of HHV-6A.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6 infections in HCT recipients will be discussed here. HHV-6 infections in patients who are not HCT recipients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290633\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) reactivation occurs in 30 to 50 percent of patients undergoing allogeneic hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], with encephalitis occurring in only a small subset of these patients. HHV-6 reactivation often manifests as HHV-6 viremia, and typically occurs between two and four weeks after transplantation. HHV-6B accounts for most reactivations, with HHV-6A accounting for fewer than 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415572\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both demographic and clinical factors may influence the risk of HHV-6 reactivation. As an example, recipients of allogeneic HCT are at higher risk of HHV-6 reactivation than recipients of autologous HCT; among allogeneic HCT recipients, those who receive transplants from unrelated or HLA-mismatched donors are at particularly increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The source of stem cells also influences the risk of reactivation; recipients of umbilical cord blood stem cells experience reactivation rates of 70 to 90 percent, compared to rates of 30 to 50 percent in recipients of peripheral blood or bone marrow stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Younger age and underlying disease have variably been identified as pretransplantation risk factors for HHV-6 reactivation occurring after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], whereas receipt of glucocorticoids has been identified as a posttransplantation risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Receipt of an anti-CD3 monoclonal antibody, BC3 (which targets T lymphocytes and has been used for prophylaxis against graft-versus-host disease), has also been associated with an increased risk of HHV-6 reactivation following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415580\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 is associated with a number of important complications following HCT, including encephalitis and bone marrow suppression. Possible associations include graft-versus-host disease, cytomegalovirus reactivation, pneumonitis, and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415587\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small case series have described encephalitis in HCT recipients with HHV-6 detected in the cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14-17\">",
"     14-17",
"    </a>",
"    ], and observational studies have demonstrated an association between systemic HHV-6 reactivation and encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Taken together, these data support a causal association between HHV-6 infection and encephalitis in allogeneic HCT recipients.",
"   </p>",
"   <p>",
"    One group has termed the encephalitis associated with HHV-6 in HCT recipients, &lsquo;post-transplant acute limbic encephalitis,&rsquo; describing it as a distinct syndrome of anterograde amnesia, syndrome of inappropriate antidiuretic hormone, mild CSF pleocytosis, temporal electroencephalogram abnormalities often reflecting clinical or subclinical seizures, and magnetic resonance imaging hyperintensities in the limbic system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of reported HHV-6 encephalitis cases have occurred in recipients of unrelated HCT or HLA mismatched-related allogeneic HCT. Umbilical cord transplantation has also been identified as a risk factor for HHV-6 encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/18\">",
"     18",
"    </a>",
"    ]. In a study from the United States of 1344 allogeneic HCT recipients, the incidence of HHV-6 encephalitis was 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/18\">",
"     18",
"    </a>",
"    ]. In another study from Japan of 50 allogeneic HCT recipients, HHV-6 reactivation was detected in 24 patients (48 percent) and four patients (8 percent) developed HHV-6 encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/8\">",
"     8",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376325798\">",
"    <span class=\"h3\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the reports described above suggesting that HHV-6 can lead to encephalitis, several observational studies of HCT recipients have demonstrated associations between systemic HHV-6 reactivation and central nervous system dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/2,4,9,10,19\">",
"     2,4,9,10,19",
"    </a>",
"    ]. As an example, a study of 315 allogeneic HCT recipients demonstrated an independent association between HHV-6 reactivation and subsequent delirium, as indicated by neuropsychiatric screening [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/10\">",
"     10",
"    </a>",
"    ]. HHV-6 reactivation was also independently associated with subsequent neurocognitive decline at approximately three months after HCT, as measured by baseline and follow-up neurocognitive testing. An important limitation of this study is that a CSF sample was obtained from only 4 of 19 patients with delirium, two of whom had HHV-6 DNA detected by the polymerase chain reaction. In addition, brain magnetic resonance imaging (MRI) was obtained in only 9 of 19 patients with delirium; none had the typical abnormalities associated with HHV-6 encephalitis. Since MRI and CSF HHV-6 PCR were not obtained in all patients with delirium, it is not possible to determine how many of the patients with delirium had HHV-6 encephalitis. This study suggests that HHV-6 may lead to central nervous system dysfunction in the absence of encephalitis, but further studies are necessary to prove this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415594\">",
"    <span class=\"h3\">",
"     Bone marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have suggested an association between HHV-6 reactivation and bone marrow suppression in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/2,4,5,20-24\">",
"     2,4,5,20-24",
"    </a>",
"    ]. In one study, in vitro assays demonstrated that HHV-6 inhibits granulocyte-macrophage and erythrocyte progenitors in human bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, HHV-6 has been shown to latently infect early bone marrow progenitors in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/25\">",
"     25",
"    </a>",
"    ], and in vitro studies have demonstrated that HHV-6 infection of bone marrow progenitor cells suppresses the proliferation of granulocyte-macrophage, erythroid, and megakaryocyte cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415615\">",
"    <span class=\"h3\">",
"     Other possible associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other important clinical manifestations, such as acute graft-versus-host disease (aGVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4,28-30\">",
"     4,28-30",
"    </a>",
"    ] and cytomegalovirus (CMV) reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], have been associated with HHV-6 reactivation. However, these associations have not been consistently demonstrated and potential pathways of pathogenesis are not well defined.",
"   </p>",
"   <p>",
"    HHV-6 may cause pneumonitis in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/5,33-35\">",
"     5,33-35",
"    </a>",
"    ]. In a study of lung biopsy specimens from 15 HCT recipients with pneumonitis, high HHV-6 DNA levels in lung tissue were associated with idiopathic pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/33\">",
"     33",
"    </a>",
"    ]. Higher HHV-6 DNA levels were also correlated with severity of GVHD. In some patients with pneumonitis, immunohistochemical staining of lung tissue showed HHV-6 antigens without any other identifiable pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the association with HHV-6 has been less certain in other reports because of the isolation of additional potential pathogens such as cytomegalovirus, Pneumocystis jirovecii, and adenovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The role of HHV-6 as a pulmonary pathogen remains inconclusive and further study is needed to document causality.",
"   </p>",
"   <p>",
"    HHV-6 reactivation has been associated with an increased risk of mortality in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4,28,30\">",
"     4,28,30",
"    </a>",
"    ]. However, it is not clear that the HHV-6 itself is the cause. In one study in which plasma samples were collected prospectively from 315 allogeneic HCT recipients and tested serially for HHV-6 DNA, HHV-6 reactivation (&gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    was associated with non-relapse mortality (adjusted hazard ratio [aHR] 2.7, 95% CI 1.2-6.3) and subsequent aGVHD (aHR 2.4, 95% CI 1.6-3.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/30\">",
"     30",
"    </a>",
"    ]. Similarly, in another study of clinical outcomes in 100 allogeneic HCT recipients, HHV-6 reactivation was associated with an increased risk of aGVHD and all-cause mortality, as well as a lower probability of monocyte engraftment (aHR 0.42, 95% CI; 0.22-0.80) and platelet engraftment (aHR 0.47, 95% CI 0.21-1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290640\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of human herpesvirus 6 (HHV-6) transmission events are thought to occur via shared saliva early in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link&amp;anchor=H9#H9\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\", section on 'Incubation period and transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital infection occurs in approximately 1 percent of births [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/38\">",
"     38",
"    </a>",
"    ]. The majority of congenital infections have been attributed to germ-line inheritance of chromosomally integrated HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/39\">",
"     39",
"    </a>",
"    ]. Inherited chromosomal integration occurs when HHV-6 is integrated into a germ cell of an individual, and resulting offspring and subsequent generations have at least one copy of HHV-6 DNA in every cell of their body. Consequently, very high levels of HHV-6 DNA are detectable in blood and tissue samples of affected individuals.",
"   </p>",
"   <p>",
"    Population-based studies have estimated chromosomally integrated HHV-6 to be present in about 1 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In the HCT setting, high levels of HHV-6 DNA are detectable in the blood of HCT recipients with integrated HHV-6 as well as in HCT recipients whose donors have integrated HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H358775122\">",
"     'Detecting chromosomal integration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290647\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As most individuals are infected with human herpesvirus 6 (HHV-6) during early childhood, recipients of hematopoietic cell transplantation (HCT) have generally already been infected with HHV-6 prior to transplantation. Thus, following HCT, detectable virus in the plasma or serum is typically a result of reactivation of a latent infection.",
"   </p>",
"   <p>",
"    Multiple cell types can support HHV-6 infection, including",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and cells of the central nervous system, such as astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/17,47\">",
"     17,47",
"    </a>",
"    ]. It is unclear whether HHV-6 isolated or detected in the setting of encephalitis originated from latent virus associated with monocytes in the blood, cells of the central nervous system, or both. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link&amp;anchor=H3#H3\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\", section on 'Cell tropism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both clinical and experimental evidence suggests that HHV-6 may interfere with normal functioning of the immune system through a variety of mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/48\">",
"     48",
"    </a>",
"    ]. The virus can infect several types of immune cells and infection has been associated with a selective suppression of interleukin-12, an important cytokine in the T helper cell type 1 (Th1)-polarized antiviral immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Such suppression of antiviral immune responses could promote the HHV-6 infection itself as well as other viral infections, which may explain the documented associations between HHV-6 reactivation and subsequent cytomegalovirus reactivation in allogeneic HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H642415615\">",
"     'Other possible associations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Seemingly in contrast to the concept of an HHV-6-induced suppression of the Th1-polarized antiviral immune response, results from other studies suggest that HHV-6 appears to activate a Th1-polarized response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/19,51,52\">",
"     19,51,52",
"    </a>",
"    ]. In several studies, Th1-type cytokines have been associated with acute graft-versus-host disease (aGVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Few studies have explored potential associations between HHV-6 reactivation, the immune response, and aGVHD; however, a small study of six patients suggested a temporal association between HHV-6 reactivation, elevated cytokines, and rash or aGVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/51\">",
"     51",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The pathogenesis of HHV-6 infection is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358774586\">",
"    <span class=\"h1\">",
"     HHV-6 ENCEPHALITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, human herpesvirus 6 (HHV-6) encephalitis is the most clearly established clinical manifestation of HHV-6 reactivation in allogeneic hematopoietic cell transplant (HCT) recipients, and results in substantial morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14-16,19,57\">",
"     14-16,19,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290654\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 encephalitis has been described in several case reports and series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14-17,58,59\">",
"     14-17,58,59",
"    </a>",
"    ]. This syndrome is characterized by confusion and anterograde amnesia with or without seizures, along with the detection of HHV-6 DNA in the cerebrospinal fluid (CSF)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of active infection in brain tissue without other causes identified. The CSF cell count and protein concentration are usually normal or slightly elevated, and magnetic resonance imaging (MRI) typically demonstrates hyperintensities in the medial temporal lobes. Outcomes vary widely, with some patients recovering full neurologic function and others being left with residual neurologic deficits. (See",
"    <a class=\"local\" href=\"#H709290682\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76607197\">",
"    <span class=\"h3\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of HHV-6 encephalitis typically present between two and six weeks after transplantation. In a series of nine patients, engraftment preceded the onset of the neurologic syndrome in all patients, and the median time to onset of neurologic symptoms was 29 days following HCT (range 14 to 61 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. The syndrome began as confusion in most patients, and progressed to dense anterograde amnesia with patchy retrograde amnesia within several days in all patients. Fever was present in only two patients and could have been due to other processes that were present, such as graft-versus-host disease (GVHD) or concurrent infection.",
"   </p>",
"   <p>",
"    Overt seizures have been reported in 40 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/15,58\">",
"     15,58",
"    </a>",
"    ], and seizures have been detected by electroencephalogram in an even higher proportion of patients, indicating that subclinical seizures occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14,16,60\">",
"     14,16,60",
"    </a>",
"    ]. Among patients with clinically apparent seizures, some have generalized seizures, whereas others have partial seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76607205\">",
"    <span class=\"h3\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the nine patients with HHV-6 encephalitis described above, hyponatremia due to inappropriate production of antidiuretic hormone (SIADH) occurred just prior to or with symptom onset in eight [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. No other general laboratory abnormalities were observed.",
"   </p>",
"   <p>",
"    Although HHV-6 DNA is detected in the blood of patients with HHV-6 encephalitis, it is not specific for HHV-6 encephalitis, since HHV-6 reactivation is common following HCT and only a small proportion of patients with HHV-6 reactivation develop encephalitis. (See",
"    <a class=\"local\" href=\"#H1032076056\">",
"     'Peripheral blood'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337375\">",
"    <span class=\"h3\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF findings are typically normal or only mildly abnormal in patients with HHV-6 encephalitis. The most common abnormalities are elevations in CSF white blood cell count and protein concentration. In a series of nine allogeneic HCT recipients with HHV-6 encephalitis, the median CSF white blood cell count was 5",
"    <span class=\"nowrap\">",
"     leukocytes/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (range 1 to 41) with lymphocyte predominance; the median protein concentration was 48",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range 19 to 189) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. The glucose concentration was normal in all patients.",
"   </p>",
"   <p>",
"    Using the polymerase chain reaction (PCR), HHV-6 DNA levels from the CSF have varied widely in patients with HHV-6 encephalitis. In a series of eight patients with HHV-6 encephalitis, the peak median CSF viral level was 16,600",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and ranged from 600 to 288,975",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. In another series that included two patients with HHV-6 encephalitis who underwent quantitative PCR of the CSF at the time of onset, HHV-6 DNA levels were 203,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in one patient and &gt;999,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1032076240\">",
"     'CSF'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337382\">",
"    <span class=\"h3\">",
"     Imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings are noted on brain MRI in most patients with HHV-6 encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/15,58\">",
"     15,58",
"    </a>",
"    ]. Abnormalities typically involve the medial temporal lobes, particularly the amygdala and hippocampus; hyperintensities in these regions are visualized on T2, fluid-attenuated inversion recovery (FLAIR), and diffusion-weighted imaging (DWI) sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83215 \" href=\"UTD.htm?0/6/100\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83216 \" href=\"UTD.htm?11/62/12265\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77735 \" href=\"UTD.htm?28/17/28950\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16,58,61\">",
"     16,58,61",
"    </a>",
"    ]. Rarely, patients may have abnormalities in limbic structures outside the medial temporal lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the brain, especially when obtained early in the course of illness, is often normal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76606939\">",
"    <span class=\"h3\">",
"     EEG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, overt or subclinical seizures are common in patients with HHV-6 encephalitis (see",
"    <a class=\"local\" href=\"#H76607197\">",
"     'Signs and symptoms'",
"    </a>",
"    above). On electroencephalogram (EEG), focal abnormalities are often observed over the temporal or frontotemporal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. Abnormalities may include epileptiform activity, including electrographic seizures, periodic lateralized epileptiform discharges,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sporadic interictal discharges. Diffuse slowing can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290661\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies of patients who died with HHV-6 encephalitis demonstrate lesions involving the white",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grey matter and injuries characterized by necrosis, neuronal loss, demyelination, and astrogliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14,16,17,63,64\">",
"     14,16,17,63,64",
"    </a>",
"    ]. Earlier in the course of infection, edema and inflammation may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/65\">",
"     65",
"    </a>",
"    ]. Consistent with the clinical findings of memory impairment and focal findings on brain imaging, the hippocampus is the area most commonly involved on pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14,16,17,63,64\">",
"     14,16,17,63,64",
"    </a>",
"    ], but other areas of the brain may also be involved (",
"    <a class=\"graphic graphic_figure graphicRef85577 \" href=\"UTD.htm?23/3/23610\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/63,65\">",
"     63,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few published studies have attempted to correlate detection of HHV-6 with pathology. In the studies that have tried to do this, high levels of HHV-6 mRNA and HHV-6 antigen have been documented in diseased areas of the brain, with astrocytes being the predominant cell involved [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/17,63\">",
"     17,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290668\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HHV-6 is the most common cause of viral encephalitis in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/66\">",
"     66",
"    </a>",
"    ], a broad differential diagnosis, including other viral, bacterial, fungal, and parasitic pathogens, must be considered. Other herpesviruses, including Epstein-Barr virus, herpes simplex virus, varicella-zoster virus, and cytomegalovirus, may also cause viral encephalitis in the HCT setting, and CSF should be evaluated for these pathogens. JC virus, the cause of progressive multifocal leukoencephalopathy, is an uncommon cause of encephalitis in HCT recipients, but this diagnosis should be considered in patients with a consistent clinical picture. Other viral pathogens, such as arboviruses, enteroviruses, and certain respiratory viruses (influenza, adenovirus, metapneumovirus), should be pursued depending on the season and exposure history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link\">",
"     \"Viral encephalitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31590?source=see_link\">",
"     \"Acute viral encephalitis in children and adolescents: Pathogenesis and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Bacterial infections and fungal pathogens, such as Aspergillus, may disseminate to the brain and present with encephalopathy or seizures. Lung and brain imaging, along with microbiology studies of the CSF and blood, can assist in the identification of these infections. Although relatively rare, tuberculosis and parasitic infections, such as toxoplasmosis, should be considered, depending on whether the patient comes from an endemic region, whether there is a history of untreated latent tuberculosis, whether the pretransplant Toxoplasma serology was positive, and whether the patient has been receiving prophylactic drugs with activity against Toxoplasma (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H3038609#H3038609\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Central nervous system'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link&amp;anchor=H7#H7\">",
"     \"Toxoplasmosis in HIV-infected patients\", section on 'Toxoplasmic encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninfectious etiologies should also be considered in allogeneic HCT recipients with altered mental status since a wide range of causes can contribute to altered mental status in such patients. Examples include electrolyte abnormalities and adverse effects from narcotics or benzodiazepines. Reversible posterior leukoencephalopathy syndrome, which is characterized by headaches, altered consciousness, visual disturbances, and seizures, can occur as a toxicity of calcineurin inhibitors; this diagnosis should be considered in patients with suggestive findings since calcineurin inhibitors are used in allogeneic HCT recipients to prevent GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link&amp;anchor=H12#H12\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665911236\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337586\">",
"    <span class=\"h3\">",
"     Diagnostic tests for HHV-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to identifying HHV-6 include direct detection of the virus (by PCR, antigenemia assays, or culture) and detection of an immunologic response to the virus (by serology). Because serology is often negative in HCT recipients, direct detection of the virus is preferred. Detection of viral nucleic acids in blood is the most frequently used approach to detect HHV-6 in the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef83219 \" href=\"UTD.htm?33/18/34092\">",
"     table 1",
"    </a>",
"    ). Similarly, detection of HHV-6 by PCR from the CSF is the preferred method for detection in patients with HHV-6 encephalitis.",
"   </p>",
"   <p>",
"    Although isolation of HHV-6 from the blood by culture is considered the gold standard indicator of viremia, culturing the virus is labor-intensive and requires a relatively long turn-around time. Thus, it is not widely available and is rarely used outside of research settings.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337663\">",
"    <span class=\"h4\">",
"     PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of viral nucleic acids by PCR may reflect active or latent infection, depending on the clinical setting and the specimen tested. PCR can be performed on CSF, peripheral blood samples (plasma, serum, or whole blood), or tissue. Quantitative PCR methods are helpful for determining how high the HHV-6 DNA level is. However, PCR testing has not been standardized and it has, therefore, not been possible to develop cut-offs that are reliably predictive of disease. We prefer to use a quantitative PCR assay, so that the viral load can be determined. This can be helpful for determining trends over time. Real-time PCR can be used to distinguish between HHV-6 subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reverse transcription PCR detects messenger RNA, and thus, indicates actively replicating virus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/69\">",
"     69",
"    </a>",
"    ]. This can be helpful, especially when dealing with cellular specimens (eg, whole blood or peripheral blood mononuclear cells). Reverse transcription PCR is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1032076240\">",
"    <span class=\"h5\">",
"     CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of another identified etiology, detection of HHV-6 in the CSF is considered diagnostic of HHV-6 encephalitis. Most, but not all, patients diagnosed with HHV-6 encephalitis have a positive HHV-6 PCR of the CSF at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ]. As noted above, the HHV-6 viral load from the CSF varies widely in patients with HHV-6 encephalitis. As an example, in a series of eight patients with HHV-6 encephalitis, the peak median CSF viral load was 16,600",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and ranged from 600 to 288,975",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. In another series that included two patients with HHV-6 encephalitis who underwent quantitative PCR of the CSF at the time of onset, the HHV-6 DNA levels were 203,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in one patient and &gt;999,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    Many young children have detectable HHV-6 in their CSF around the age when primary HHV-6 infection occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/70\">",
"     70",
"    </a>",
"    ]. It is unknown what proportion of HCT recipients has detectable HHV-6 in the CSF at the time of HHV-6 reactivation, since reactivation occurs early after transplantation, a time when many HCT recipients have not yet engrafted and their physicians are reluctant to perform lumbar punctures. However, HHV-6 is rarely detected in the CSF of immunocompromised patients without encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/65\">",
"     65",
"    </a>",
"    ], and active HHV-6 infection is not routinely demonstrable in healthy brain tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/71\">",
"     71",
"    </a>",
"    ]. In one study, HHV-6 DNA was detected in CSF specimens from 5 of 22 HCT recipients with central nervous system (CNS) symptoms (23 percent) and in 1 of 107 immunocompromised controls without CNS symptoms (0.9 percent); most of the controls were not HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/65\">",
"     65",
"    </a>",
"    ]. In another study, HHV-6 was detected in 0 of 29 CSF samples from HCT recipients without encephalitis; CSF samples were obtained a median of 51 days after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 11 HCT recipients with HHV-6 detected by PCR in the CSF and serum (8 of whom had HHV-6 encephalitis) who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , the concentration of HHV-6 in the CSF declined more slowly than in the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, it has been demonstrated in three patients who died with or after HHV-6 encephalitis that active HHV-6 infection can still be detected in the brain tissue even after HHV-6 DNA has become undetectable in the serum and CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/17\">",
"     17",
"    </a>",
"    ]. This suggests that resolution of CSF HHV-6 DNA alone should not be used to shorten therapeutic courses for HHV-6 encephalitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1032076056\">",
"    <span class=\"h5\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of HHV-6 DNA in plasma or serum correlates well with viremia and seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. HHV-6 DNA detection in whole blood has also been used to identify HHV-6 reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/74\">",
"     74",
"    </a>",
"    ], with similar frequencies of detection after HCT as seen in studies using plasma or serum. In contrast, detection of viral DNA in peripheral blood mononuclear cells by PCR can be difficult to interpret since the mononuclear cell is a site of virus latency.",
"   </p>",
"   <p>",
"    Although peripheral blood HHV-6 PCR can be helpful for establishing that HHV-6 reactivation has occurred, it is not specific for HHV-6 encephalitis, since HHV-6 reactivation is common following HCT and only a small proportion of patients with HHV-6 reactivation develop encephalitis (see",
"    <a class=\"local\" href=\"#H709290633\">",
"     'Epidemiology'",
"    </a>",
"    above). A higher concentration of HHV-6 DNA in peripheral blood leukocytes or plasma after HCT has been observed in patients with encephalitis compared with patients without encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In addition, in a study in which HHV-6 PCR was performed on the plasma of 110 allogeneic HCT recipients, a higher level of HHV-6 DNA (greater than the median value of 138",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    was associated with subsequent CNS dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, patients with high levels of HHV-6 DNA from the peripheral blood appear to be at greater risk for CNS dysfunction and HHV-6 encephalitis.",
"   </p>",
"   <p>",
"    As noted above, in a study of 11 HCT recipients with HHV-6 detected by PCR in the CSF and serum (8 of whom had encephalitis) who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , the levels of HHV-6 DNA in the serum became undetectable more quickly than in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. Therefore, it is not adequate to rely on HHV-6 testing of the peripheral blood alone in an HCT recipient with signs and symptoms of encephalitis.",
"   </p>",
"   <p>",
"    Chromosomal integration of HHV-6 in the donor&rsquo;s cells or the recipient&rsquo;s cells can cause high concentrations of HHV-6 in the blood or CSF by PCR in the absence of active infection. This is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H358775122\">",
"     'Detecting chromosomal integration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13337525\">",
"    <span class=\"h4\">",
"     Antigenemia assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct detection methodologies using antigenemia have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/24,75\">",
"     24,75",
"    </a>",
"    ]. In contrast to PCR testing of plasma or serum specimens, approximately 60 percent of HCT patients will have positive tests for antigenemia prior to HCT. Following HCT, the proportion of patients with HHV-6 antigenemia increases to approximately 75 percent overall, and is as high as 90 percent in recipients of allogeneic transplants from unrelated donors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/24,75\">",
"     24,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94538367\">",
"    <span class=\"h4\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic methods have many limitations, including the low sensitivity of antibody assays in severely immunocompromised patients. There are serologic approaches that incorporate antibody avidity, exploiting the fact that during primary infection the first IgG antibodies have low avidity, but with time and maturation of the immune response, higher avidity antibodies are produced [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/76\">",
"     76",
"    </a>",
"    ]. This allows the immune response to primary infection to be distinguished from either maternal antibodies or antibodies of established infection. Although this may prove helpful in certain settings, primary HHV-6 infection is a concern for only a small fraction of HCT recipients, since most patients have been infected with HHV-6 prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58480509\">",
"    <span class=\"h3\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any allogeneic HCT recipient with clinical findings suggestive of HHV-6 encephalitis (confusion, anterograde amnesia, short-term memory loss, seizures) should undergo lumbar puncture and MRI of the brain. A peripheral blood sample (eg, plasma) and a CSF sample should be tested for HHV-6 PCR in addition to routine studies (eg, cell count and differential, protein, glucose, Gram stain, aerobic culture). Other potential etiologies should be pursued. The diagnosis of HHV-6 encephalitis is established in allogeneic HCT recipients with the characteristic clinical findings in whom HHV-6 DNA is detected in the CSF without other causes identified. Chromosomal integration of HHV-6 can cause a false positive HHV-6 PCR result in patients without evidence of encephalitis or other signs or symptoms attributable to HHV-6 disease. (See",
"    <a class=\"local\" href=\"#H358775122\">",
"     'Detecting chromosomal integration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If other causes of encephalitis are suspected, studies for other specific pathogens should be obtained (eg, herpes simplex virus PCR; varicella-zoster virus PCR; during the summer and fall, mosquito-borne viruses that cause encephalitis). (See",
"    <a class=\"local\" href=\"#H13337663\">",
"     'PCR'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13337382\">",
"     'Imaging findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H709290668\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link&amp;anchor=H11#H11\">",
"     \"Viral encephalitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HHV-6 reactivation and higher levels of HHV-6 reactivation have been associated with encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, HHV-6 PCR from the peripheral blood can be helpful for establishing that HHV-6 reactivation has occurred and should be obtained when considering a diagnosis of HHV-6 encephalitis. However, detection of HHV-6 DNA in the blood alone is not predictive of HHV-6 encephalitis, since only a small proportion of patients with HHV-6 reactivation develop encephalitis. In addition, HHV-6 viral load may become undetectable in the blood before it resolves from CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. Therefore, it is important to test not only the peripheral blood, but also the CSF in patients with signs of encephalitis. (See",
"    <a class=\"local\" href=\"#H709290633\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1032076056\">",
"     'Peripheral blood'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358775122\">",
"    <span class=\"h3\">",
"     Detecting chromosomal integration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal integration of HHV-6, also called inherited HHV-6, can cause a confusing clinical picture in the setting of HCT. Population-based studies have estimated germ-line inheritance of HHV-6 to occur in about 1 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Thus, a small proportion of HCT donors and recipients will have inherited chromosomal integration. Because patients with inherited HHV-6 have at least one copy of the viral genome in each cell of their body, they have unusually high levels of HHV-6 DNA detectable in blood, CSF, and other substances and tissues. Both HHV-6A and HHV-6B can be integrated and inherited. Since the vast majority of reactivation events following HCT are due to HHV-6B, detection of HHV-6A can be a clue to chromosomally integrated HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the donor has inherited HHV-6, HHV-6 levels will increase in the recipient with engraftment and very high levels are often detected, particularly when whole blood is tested (",
"    <a class=\"graphic graphic_figure graphicRef83220 \" href=\"UTD.htm?25/4/25679\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, in one HCT recipient who received a transplant from a donor with chromosomal integration, persistent HHV-6 concentrations of 2.5 x10",
"    <sup>",
"     6",
"    </sup>",
"    to 10 x10",
"    <sup>",
"     6",
"     <span class=\"nowrap\">",
"     </span>",
"    </sup>",
"    copies/mL",
"    were detected in whole blood following engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/42\">",
"     42",
"    </a>",
"    ]. In another report, two HCT recipients who received transplants from donors with chromosomal integration had 6.1 x10",
"    <sup>",
"     6",
"    </sup>",
"    and 9.7 x10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in the whole blood following engraftment, but only 3600 and 15,400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in the plasma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/43\">",
"     43",
"    </a>",
"    ]. Other features of chromosomal integration in donor cells are that HHV-6 DNA levels remain persistently and stably elevated, and do not decline with time or antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/77\">",
"     77",
"    </a>",
"    ]. Consequently, serial testing and quantification of HHV-6 DNA copies per cell assayed can provide evidence of inherited HHV-6 if more than one copy of HHV-6 per cell assayed is consistently detected over time.",
"   </p>",
"   <p>",
"    In contrast to the pattern observed when the HCT recipient receives a transplant from a donor with chromosomal integration with HHV-6, when the HCT recipient has inherited HHV-6, high levels of HHV-6 DNA can be detected in the blood immediately after transplantation, which then decrease with successful engraftment (",
"    <a class=\"graphic graphic_figure graphicRef83221 \" href=\"UTD.htm?29/12/29903\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, high levels of HHV-6 DNA can also be detected in the CSF in individuals with chromosomal integration. As an example, among 21 patients with presumed chromosomal integration, HHV-6 DNA was detected in the CSF with a mean level of 4.0 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (95% CI 3.5-4.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/78\">",
"     78",
"    </a>",
"    ]. This was higher than the mean level detected in immunocompetent children with primary HHV-6 infection (2.4 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    95% CI 1.0-3.7), but similar to levels detected in HCT recipients with HHV-6 encephalitis.",
"   </p>",
"   <p>",
"    Distinguishing inherited HHV-6 from HHV-6-associated disease can be challenging, especially when dealing with a single positive result. Fluorescent in situ hybridization (FISH) with a specific HHV-6 probe performed on metaphase chromosome preparations from peripheral blood will demonstrate integrated HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/42,79\">",
"     42,79",
"    </a>",
"    ]. In addition, in contrast to individuals with latent HHV-6 infection, individuals with integrated HHV-6 have detectable HHV-6 in their hair follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/80\">",
"     80",
"    </a>",
"    ]. Thus, if FISH is not available, PCR testing of hair follicles for HHV-6 DNA can be performed to identify an individual with integrated HHV-6. This would mean testing the donor&rsquo;s hair follicles in the case of an HCT recipient whose donor is suspected to have integrated HHV-6. When there is concern for integrated HHV-6 in the HCT donor cells, testing of donor serum or whole blood with HHV-6 PCR may provide supporting evidence for integrated HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/43,80\">",
"     43,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether HCT recipients with integrated HHV-6 can also reactivate HHV-6 and suffer complications such as encephalitis is unknown. A case of encephalitis occurring in an immunocompetent patient with integrated HHV-6 has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/81\">",
"     81",
"    </a>",
"    ]. Although a thorough evaluation was performed and an alternative etiology was not identified, causality remains uncertain.",
"   </p>",
"   <p>",
"    The possibility of chromosomally integrated or inherited HHV-6 should be considered in the setting of high and persistent levels of HHV-6 DNA in the peripheral blood, particularly if the patient has no clinical signs of encephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the level of viremia does not decline following initiation of antiviral therapy with activity against HHV-6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290675\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HHV-6 encephalitis caused by HHV-6 involves antiviral therapy and, when seizures are present, anticonvulsant therapy. We do not recommend treatment of HHV-6 viremia in the absence of HHV-6 encephalitis or another clinical entity that can be attributed to HHV-6. (See",
"    <a class=\"local\" href=\"#H642415712\">",
"     'Antiviral prophylaxis and preemptive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665911113\">",
"    <span class=\"h3\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No antiviral agent has been approved by the US Food and Drug Administration for the treatment of HHV-6 infection. However, in vitro studies demonstrate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    have antiviral activity against HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/82\">",
"     82",
"    </a>",
"    ]. There are also small case series suggesting potential anti-HHV-6 effect of foscarnet and ganciclovir. Studies of patients with HHV-6 encephalitis demonstrate an association between foscarnet or ganciclovir treatment and a reduction of viral DNA levels in serum and CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"     59",
"    </a>",
"    ]. However, these studies did not have a comparison group of patients with HHV-6 encephalitis who were not treated with these antivirals.",
"   </p>",
"   <p>",
"    Although the optimal therapy is unknown, based on the available data, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for the treatment of HHV-6 encephalitis in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/83-85\">",
"     83-85",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has been proposed as a second-line agent, but it is avoided as a first-line agent because it is highly nephrotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/85\">",
"     85",
"    </a>",
"    ]. The dosing of the first-line agents in patients with normal renal function is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      &ndash; 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours or 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      &ndash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have not improved or who have worsened on monotherapy, we sometimes switch from the agent that the patient has been receiving to the other agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or vice versa). It is important to note that cross-resistance has been reported for cytomegalovirus due to polymerase gene mutations, particularly when switching from foscarnet to ganciclovir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/86\">",
"     86",
"    </a>",
"    ]; it is possible that HHV-6 could harbor the same mutations. Unfortunately, resistance testing for HHV-6 is not available. We occasionally use combination therapy with full doses of foscarnet and ganciclovir in very severe cases or when there is lack of clinical improvement or worsening on single agent therapy.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    are associated with important toxicities. Foscarnet is associated with electrolyte depletion, which can lower the seizure threshold, as well as nephrotoxicity. It has occasionally been associated with genital ulcers. When foscarnet is used, electrolytes should be monitored frequently (eg, at least once daily) and repleted aggressively. We also recommend prehydration (eg, 500 cc normal saline) before each dose of foscarnet to protect the kidneys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H8#H8\">",
"     \"Foscarnet: An overview\", section on 'Electrolyte abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H10#H10\">",
"     \"Foscarnet: An overview\", section on 'Genital ulcerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    can cause bone marrow suppression, which is a particular concern in HCT recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link&amp;anchor=H6#H6\">",
"     \"Ganciclovir and valganciclovir: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415887\">",
"    <span class=\"h4\">",
"     Duration and monitoring during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No published studies have evaluated the optimal duration of therapy for HHV-6 encephalitis. Although not based on comparative clinical trial data, we recommend giving antiviral therapy for 21 days for most patients with HHV-6 encephalitis, particularly those who have had a good clinical response to therapy. We treat patients who have had a poor clinical response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in whom the CSF or peripheral blood HHV-6 remains detectable for a longer period (up to six weeks). In patients who require a longer duration of antiviral therapy but who are experiencing toxicity, the class of antiviral agent can be changed (from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or vice versa) with the caveat noted above. (See",
"    <a class=\"local\" href=\"#H665911113\">",
"     'Antiviral therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recheck the HHV-6 viral load from the peripheral blood weekly during therapy until it has become undetectable. We recheck the CSF HHV-6 viral load in patients who have not improved or who have worsened clinically despite appropriate antiviral therapy. Although the expected response of the CSF HHV-6 viral load to antiviral therapy has not been clearly established, we treat patients who continue to have substantial neurologic deficits and who have not had a significant reduction in CSF HHV-6 levels for a longer period than patients who have both improved clinically and who have had a substantial reduction in the CSF HHV-6 viral load.",
"   </p>",
"   <p>",
"    Optimally, we continue antiviral therapy until the peripheral blood HHV-6 PCR is undetectable (and for no fewer than 21 days). If there is an indication for rechecking the CSF HHV-6 viral load, then we continue antiviral therapy until it is undetectable as well. However, in&nbsp;the absence of clear improvement over an extended period (based on clinical response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PCR results), prolonged treatment is unlikely to&nbsp;provide further benefit, and may be toxic. One possible reason for a lack of virologic response is antiviral drug resistance (see",
"    <a class=\"local\" href=\"#H665911113\">",
"     'Antiviral therapy'",
"    </a>",
"    above). Thus, the potential risks and benefits of the antiviral regimen should be assessed when a prolonged course is considered.",
"   </p>",
"   <p>",
"    Active HHV-6 infection can sometimes still be detected in brain tissue even after HHV-6 DNA has become undetectable in the serum and CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/17\">",
"     17",
"    </a>",
"    ]. This suggests that a reduction in peripheral blood or CSF HHV-6 viral load to undetectable levels should not be used to shorten the therapeutic course for HHV-6 encephalitis to less than 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665911130\">",
"    <span class=\"h3\">",
"     Seizure prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the substantial incidence of overt or subclinical seizures in patients with HHV-6 encephalitis, we have a low threshold for checking an EEG in patients with subtle signs that may be consistent with seizure activity, including a reduced level of consciousness that does not have another explanation. In patients with overt seizures, it is not necessary to obtain an EEG.",
"   </p>",
"   <p>",
"    In patients with clinical or EEG evidence of seizure activity, we recommend an anticonvulsant that will not interact with other agents that the patient is taking (eg, for graft-versus-host disease or antifungal prophylaxis or treatment). We favor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    in such patients since it does not affect cytochrome P450.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial treatment of epilepsy in adults\", section on 'AED comparison trials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H24#H24\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Levetiracetam'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrolyte depletion associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    can increase the risk of seizures. In patients receiving foscarnet, electrolytes should be monitored closely and repleted aggressively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H8#H8\">",
"     \"Foscarnet: An overview\", section on 'Electrolyte abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642415712\">",
"    <span class=\"h2\">",
"     Antiviral prophylaxis and preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although small studies exploring the safety of preemptive or prophylactic antiviral therapy directed against HHV-6 in HCT patients have been conducted, large studies demonstrating the efficacy and safety of HHV-6 prophylaxis or preemptive therapy have not been performed. Therefore, there are insufficient data to recommend prophylactic antiviral strategies or preemptive monitoring and treatment aimed at reducing the risk of HHV-6-associated disease, such as HHV-6 encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of recipients of solid organ transplants who received cytomegalovirus (CMV)-directed prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    suggest a possible effect on HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Although ganciclovir prophylaxis was not associated with a decreased frequency of HHV-6 reactivation in a study of 134 renal transplant recipients, it was associated with delayed onset and shortened duration of HHV-6 detection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/88\">",
"     88",
"    </a>",
"    ]. Similarly, several small retrospective studies in HCT recipients suggest a potential benefit of prophylactic ganciclovir in reducing HHV-6 activity and its associated manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two very small (six to eight patients receiving drug) prospective studies have explored preemptive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    therapy in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. These studies highlight the challenge of initiating preemptive therapy after a viral threshold has been reached, but prior to the onset of manifestations of HHV-6 disease in high-risk patients. In a study of prophylactic foscarnet in 10 HCT patients, the drug was generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290682\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes of HHV-6 encephalitis have been difficult to evaluate since allogeneic HCT recipients often have complex comorbidities. It appears that outcomes vary widely, with some patients recovering full neurologic function and other patients being left with residual neurologic deficits. Similarly, some patients with HHV-6 encephalitis have appeared to die from encephalitis, but many have died of other identifiable causes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/14,16,17,63,64\">",
"     14,16,17,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of case reports and case series of patients with HHV-6 encephalitis, information was provided on the neurologic course and outcomes in 44 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/15\">",
"     15",
"    </a>",
"    ]. Although difficult to determine with certainty, 11 patients (25 percent) had a progressive course and died within one to four weeks of diagnosis. Eight patients (18 percent) improved but were left with residual neurologic compromise. Nineteen patients (43 percent) made a full recovery, although for some, the recovery process lasted several weeks and required rehabilitation services. Six patients (14 percent) initially showed improvement, but then succumbed to respiratory failure, multiorgan failure, or other documented infections. Whether these conditions were directly or indirectly a result of the HHV-6 infection remains unclear. Similar observations were made in a surveillance study of HHV-6 encephalitis in HCT recipients in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?29/40/30346/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term neurocognitive outcomes associated with HHV-6 reactivation have not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358775535\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF OTHER ENTITIES POTENTIALLY ASSOCIATED WITH HHV-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations do not exist for the treatment of clinical entities other than encephalitis that may be associated with human herpesvirus 6 (HHV-6) reactivation, such as bone marrow suppression or delayed engraftment. Some experts would consider giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    to hematopoietic cell transplantation (HCT) recipients with HHV-6 viremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a clinical entity potentially associated with HHV-6 if other etiologies with established causality have been ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709290689\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human herpesvirus 6 (HHV-6) reactivation occurs in 30 to 50 percent of allogeneic hematopoietic cell transplantation (HCT) recipients and viremia is typically detected two to four weeks after HCT. (See",
"      <a class=\"local\" href=\"#H709290633\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small subset of allogeneic HCT recipients with HHV-6 reactivation develop HHV-6 encephalitis, characterized by confusion and short-term memory loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anterograde amnesia with or without seizures. In such patients, HHV-6 DNA is usually detected in the cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) often shows hyperintensities in the medial temporal lobes. (See",
"      <a class=\"local\" href=\"#H709290633\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H709290654\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that HCT recipients who develop signs of encephalitis, especially during the first several weeks after transplantation, undergo lumbar puncture to have their CSF tested for HHV-6 using quantitative polymerase chain reaction (PCR) as well as for routine CSF studies and for other possible infectious agents. Such patients should also have peripheral blood (eg, plasma) tested using quantitative HHV-6 PCR and should undergo MRI to look for evidence of limbic encephalitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83215 \" href=\"UTD.htm?0/6/100\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83216 \" href=\"UTD.htm?11/62/12265\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77735 \" href=\"UTD.htm?28/17/28950\">",
"       image 3",
"      </a>",
"      ). The diagnosis of HHV-6 encephalitis is established in allogeneic HCT recipients with the characteristic clinical findings in whom HHV-6 DNA is detected in the CSF without other causes identified. (See",
"      <a class=\"local\" href=\"#H58480509\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of chromosomally integrated or inherited HHV-6 should be considered in the setting of extremely high and persistent levels of HHV-6 DNA in the peripheral blood, particularly if the patient has no clinical signs of HHV-6 encephalitis (",
"      <a class=\"graphic graphic_figure graphicRef83220 \" href=\"UTD.htm?25/4/25679\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H358775122\">",
"       'Detecting chromosomal integration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with HHV-6 encephalitis should receive an antiviral agent with activity against HHV-6. We recommend that such patients be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We give antiviral therapy for 21 days for most patients with HHV-6 encephalitis, particularly those who have had a good clinical response to therapy. Patients who have had a poor clinical response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in whom the CSF or peripheral blood HHV-6 remains detectable should be treated for a longer period. In patients who require a longer duration of antiviral therapy but who are experiencing toxicity, the class of antiviral agent can be changed. (See",
"      <a class=\"local\" href=\"#H709290675\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important toxicities of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      include nephrotoxicity and electrolyte depletion; prehydration and close monitoring of electrolytes are warranted when foscarnet is given. An important toxicity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      is bone marrow suppression. (See",
"      <a class=\"local\" href=\"#H709290675\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recheck the HHV-6 viral load from the peripheral blood weekly during therapy until it has become undetectable. We recheck the CSF HHV-6 viral load in patients who have not improved or who have worsened clinically despite appropriate antiviral therapy. (See",
"      <a class=\"local\" href=\"#H642415887\">",
"       'Duration and monitoring during therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HHV-6 encephalitis who have subtle signs that are suggestive of seizure activity should undergo an electroencephalogram (EEG). In patients with clinical or EEG evidence of seizure activity, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H665911130\">",
"       'Seizure prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to recommend prophylactic or preemptive therapy of HHV-6 viremia in HCT recipients in an attempt to prevent the development of encephalitis. (See",
"      <a class=\"local\" href=\"#H642415712\">",
"       'Antiviral prophylaxis and preemptive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     International Committee on Taxonomy of Viruses. ICTV Master Species List 2011. file://talk.ictvonline.org/files/ictv_documents/m/msl/4090.aspx (Accessed on June 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/2\">",
"      Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000; 111:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/3\">",
"      Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis 2002; 185:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/4\">",
"      Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/5\">",
"      Hentrich M, Oruzio D, J&auml;ger G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005; 128:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/6\">",
"      Reddy S, Manna P. Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay. Biol Blood Marrow Transplant 2005; 11:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/7\">",
"      Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/8\">",
"      Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006; 193:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/9\">",
"      Yamane A, Mori T, Suzuki S, et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007; 13:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/10\">",
"      Zerr DM, Fann JR, Breiger D, et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood 2011; 117:5243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/11\">",
"      Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood 2002; 100:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/12\">",
"      Chevallier P, Hebia-Fellah I, Planche L, et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010; 45:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/13\">",
"      Zerr DM, Gooley TA, Yeung L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 33:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/14\">",
"      Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 2001; 50:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/15\">",
"      Zerr DM. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol 2006; 37 Suppl 1:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/16\">",
"      Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/17\">",
"      Fotheringham J, Akhyani N, Vortmeyer A, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis 2007; 195:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/18\">",
"      Hill JA, Koo S, Guzman Suarez BB, et al. Cord-blood hematopoietic stem cell transplant&nbsp;confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a&nbsp;cohort analysis. Biol Blood Marrow Transplant 2012; 18:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/19\">",
"      Ogata M, Satou T, Kawano R, et al. Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2010; 45:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/20\">",
"      Drobyski WR, Dunne WM, Burd EM, et al. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. J Infect Dis 1993; 167:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/21\">",
"      Wang FZ, Dahl H, Linde A, et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996; 88:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/22\">",
"      Maeda Y, Teshima T, Yamada M, et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol 1999; 105:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/23\">",
"      Imbert-Marcille BM, Tang XW, Lepelletier D, et al. Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. Clin Infect Dis 2000; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/24\">",
"      Savolainen H, Lautenschlager I, Piiparinen H, et al. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer 2005; 45:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/25\">",
"      Luppi M, Barozzi P, Morris C, et al. Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. J Virol 1999; 73:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/26\">",
"      Isomura H, Yamada M, Yoshida M, et al. Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells. J Med Virol 1997; 52:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/27\">",
"      Isomura H, Yoshida M, Namba H, et al. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro. J Gen Virol 2000; 81:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/28\">",
"      de Pagter PJ, Schuurman R, Visscher H, et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008; 14:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/29\">",
"      Wang LR, Dong LJ, Zhang MJ, Lu DP. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/30\">",
"      Zerr DM, Boeckh M, Delaney C, et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/31\">",
"      Tormo N, Solano C, de la C&aacute;mara R, et al. An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/32\">",
"      Wang FZ, Larsson K, Linde A, Ljungman P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2002; 30:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/33\">",
"      Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/34\">",
"      Carrigan DR, Drobyski WR, Russler SK, et al. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991; 338:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/35\">",
"      Cone RW, Huang ML, Hackman RC. Human herpesvirus 6 and pneumonia. Leuk Lymphoma 1994; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     Carrigan DR. Human herpesvirus-6 and bone marrow transplantation. In: Human herpesvirus-6: Epidemiology, molecular biology, and clinical pathology, Ablashi DV, Krueger GRF, Salahuddin SZ (Eds), Elsevier Biomedical Press, Amsterdam, The Netherlands  Vol 4, p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/37\">",
"      Vuorinen T, Kotilainen P, Lautenschlager I, et al. Interstitial pneumonitis and coinfection of human herpesvirus 6 and Pneumocystis carinii in a patient with hypogammaglobulinemia. J Clin Microbiol 2004; 42:5415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/38\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr 2004; 145:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/39\">",
"      Hall CB, Caserta MT, Schnabel K, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 2008; 122:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/40\">",
"      Tanaka-Taya K, Sashihara J, Kurahashi H, et al. Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol 2004; 73:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/41\">",
"      Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007; 79:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/42\">",
"      Clark DA, Nacheva EP, Leong HN, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J Infect Dis 2006; 193:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/43\">",
"      Kamble RT, Clark DA, Leong HN, et al. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/44\">",
"      Jeulin H, Gu&eacute;ry M, Cl&eacute;ment L, et al. Chromosomally integrated HHV-6: slow decrease of HHV-6 viral load after hematopoietic stem-cell transplantation. Transplantation 2009; 88:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/45\">",
"      Kondo K, Kondo T, Shimada K, et al. Strong interaction between human herpesvirus 6 and peripheral blood monocytes/macrophages during acute infection. J Med Virol 2002; 67:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/46\">",
"      Kondo K, Kondo T, Okuno T, et al. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991; 72 ( Pt 6):1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/47\">",
"      He J, McCarthy M, Zhou Y, et al. Infection of primary human fetal astrocytes by human herpesvirus 6. J Virol 1996; 70:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/48\">",
"      Lusso P. HHV-6 and the immune system: mechanisms of immunomodulation and viral escape. J Clin Virol 2006; 37 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/49\">",
"      Smith A, Santoro F, Di Lullo G, et al. Selective suppression of IL-12 production by human herpesvirus 6. Blood 2003; 102:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/50\">",
"      Smith AP, Paolucci C, Di Lullo G, et al. Viral replication-independent blockade of dendritic cell maturation and interleukin-12 production by human herpesvirus 6. J Virol 2005; 79:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/51\">",
"      Fujita A, Ihira M, Suzuki R, et al. Elevated serum cytokine levels are associated with human herpesvirus 6 reactivation in hematopoietic stem cell transplantation recipients. J Infect 2008; 57:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/52\">",
"      Mayne M, Cheadle C, Soldan SS, et al. Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms. J Virol 2001; 75:11641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/53\">",
"      Fujii N, Hiraki A, Aoe K, et al. Serum cytokine concentrations and acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation: concurrent measurement of ten cytokines and their respective ratios using cytometric bead array. Int J Mol Med 2006; 17:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/54\">",
"      Ju XP, Xu B, Xiao ZP, et al. Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2005; 35:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/55\">",
"      Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005; 106:4407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/56\">",
"      Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol 2006; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/57\">",
"      Gewurz BE, Marty FM, Baden LR, Katz JT. Human herpesvirus 6 encephalitis. Curr Infect Dis Rep 2008; 10:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/58\">",
"      Muta T, Fukuda T, Harada M. Human herpesvirus-6 encephalitis in hematopoietic SCT recipients in Japan: a retrospective multicenter study. Bone Marrow Transplant 2009; 43:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/59\">",
"      Zerr DM, Gupta D, Huang ML, et al. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/60\">",
"      Tiacci E, Luppi M, Barozzi P, et al. Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor. Haematologica 2000; 85:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/61\">",
"      Noguchi T, Mihara F, Yoshiura T, et al. MR imaging of human herpesvirus-6 encephalopathy after hematopoietic stem cell transplantation in adults. AJNR Am J Neuroradiol 2006; 27:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/62\">",
"      Provenzale JM, vanLandingham KE, Lewis DV, et al. Extrahippocampal involvement in human herpesvirus 6 encephalitis depicted at MR imaging. Radiology 2008; 249:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/63\">",
"      Drobyski WR, Knox KK, Majewski D, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 1994; 330:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/64\">",
"      De Almeida Rodrigues G, Nagendra S, Lee CK, De Magalh&atilde;es-Silverman M. Human herpes virus 6 fatal encephalitis in a bone marrow recipient. Scand J Infect Dis 1999; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/65\">",
"      Wang FZ, Linde A, H&auml;gglund H, et al. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999; 28:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/66\">",
"      Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica 2011; 96:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/67\">",
"      Razonable RR, Fanning C, Brown RA, et al. Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts. J Infect Dis 2002; 185:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/68\">",
"      Boutolleau D, Duros C, Bonnafous P, et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol 2006; 35:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/69\">",
"      Norton RA, Caserta MT, Hall CB, et al. Detection of human herpesvirus 6 by reverse transcription-PCR. J Clin Microbiol 1999; 37:3672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/70\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/71\">",
"      Cuomo L, Trivedi P, Cardillo MR, et al. Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol 2001; 63:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/72\">",
"      Huang LM, Kuo PF, Lee CY, et al. Detection of human herpesvirus-6 DNA by polymerase chain reaction in serum or plasma. J Med Virol 1992; 38:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/73\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Human herpesvirus 6 infection after living related liver transplantation. J Med Virol 2000; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/74\">",
"      Betts BC, Young JA, Ustun C, et al. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/75\">",
"      Volin L, Lautenschlager I, Juvonen E, et al. Human herpesvirus 6 antigenaemia in allogeneic stem cell transplant recipients: impact on clinical course and association with other beta-herpesviruses. Br J Haematol 2004; 126:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/76\">",
"      Ward KN, Gray JJ, Fotheringham MW, Sheldon MJ. IgG antibodies to human herpesvirus-6 in young children: changes in avidity of antibody correlate with time after infection. J Med Virol 1993; 39:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/77\">",
"      Jeulin H, Salmon A, Gautheret-Dejean A, et al. Contribution of human herpesvirus 6 (HHV-6) viral load in whole blood and serum to investigate integrated HHV-6 transmission after haematopoietic stem cell transplantation. J Clin Virol 2009; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/78\">",
"      Ward KN, Leong HN, Thiruchelvam AD, et al. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. J Clin Microbiol 2007; 45:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/79\">",
"      Daibata M, Taguchi T, Nemoto Y, et al. Inheritance of chromosomally integrated human herpesvirus 6 DNA. Blood 1999; 94:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/80\">",
"      Ward KN, Leong HN, Nacheva EP, et al. Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol 2006; 44:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/81\">",
"      Troy SB, Blackburn BG, Yeom K, et al. Severe encephalomyelitis in an immunocompetent adult with chromosomally integrated human herpesvirus 6 and clinical response to treatment with foscarnet plus ganciclovir. Clin Infect Dis 2008; 47:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/82\">",
"      De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/83\">",
"      Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/84\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/85\">",
"      Dewhurst S. Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system. Herpes 2004; 11 Suppl 2:105A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/86\">",
"      Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/87\">",
"      Razonable RR, Brown RA, Humar A, et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/88\">",
"      Galarraga MC, Gomez E, de O&ntilde;a M, et al. Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Transplant Proc 2005; 37:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/89\">",
"      Rapaport D, Engelhard D, Tagger G, et al. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002; 4:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/90\">",
"      Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/91\">",
"      Cheng FW, Lee V, Leung WK, et al. HHV-6 encephalitis in pediatric unrelated umbilical cord transplantation: a role for ganciclovir prophylaxis? Pediatr Transplant 2010; 14:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/92\">",
"      Ishiyama K, Katagiri T, Hoshino T, et al. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant 2011; 46:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/93\">",
"      Ogata M, Satou T, Kawano R, et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008; 41:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/40/30346/abstract/94\">",
"      Ishiyama K, Katagiri T, Ohata K, et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis 2012; 14:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16146 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30346=[""].join("\n");
var outline_f29_40_30346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H709290689\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709290626\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709290633\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642415572\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642415580\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642415587\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1376325798\">",
"      - Delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642415594\">",
"      - Bone marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H642415615\">",
"      - Other possible associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709290640\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709290647\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H358774586\">",
"      HHV-6 ENCEPHALITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709290654\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76607197\">",
"      - Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76607205\">",
"      - Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13337375\">",
"      - Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13337382\">",
"      - Imaging findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76606939\">",
"      - EEG findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709290661\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709290668\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H665911236\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13337586\">",
"      - Diagnostic tests for HHV-6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13337663\">",
"      PCR",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1032076240\">",
"      - CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1032076056\">",
"      - Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13337525\">",
"      Antigenemia assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H94538367\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58480509\">",
"      - Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H358775122\">",
"      - Detecting chromosomal integration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709290675\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H665911113\">",
"      - Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H642415887\">",
"      Duration and monitoring during therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H665911130\">",
"      - Seizure prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642415712\">",
"      Antiviral prophylaxis and preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709290682\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H358775535\">",
"      MANAGEMENT OF OTHER ENTITIES POTENTIALLY ASSOCIATED WITH HHV-6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709290689\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16146|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/6/100\" title=\"diagnostic image 1\">",
"      HHV-6 encephalitis MRIs 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/62/12265\" title=\"diagnostic image 2\">",
"      HHV-6 encephalitis MRI 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/17/28950\" title=\"diagnostic image 3\">",
"      HHV-6 encephalitis MRI 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/3/23610\" title=\"figure 1\">",
"      HHV-6 detected in the brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/4/25679\" title=\"figure 2\">",
"      Inherited HHV-6 from an HCT donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/12/29903\" title=\"figure 3\">",
"      Inherited HHV-6 in an HCT recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/18/34092\" title=\"table 1\">",
"      Methods for diagnosing human herpesvirus 6 infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31590?source=related_link\">",
"      Acute viral encephalitis in children and adolescents: Pathogenesis and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=related_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_40_30347="Health risks from obesity";
var content_f29_40_30347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Health risks associated with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Coronary artery disease, hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperlipidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type II diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma, obesity hypoventilation syndrome, obstructive sleep apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroesophageal reflux, esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatty liver, cholelithiasis, non-alcoholic steatohepatitis (NASH), cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress urinary incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous stasis disease, deep vein thrombosis, pulmonary embolus, superficial thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hernias (inguinal, ventral, umbilical, incisional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular menstruation, hirsutism, gynecomastia, infertility, polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer (colon, prostate, uterine, breast)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (cellulitis, panniculitis, postoperative wound infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Degenerative joint disease, osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudotumor cerebri (idiopathic intracranial hypertension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical depression",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vivian Sanchez, MD and Edward Mun, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30347=[""].join("\n");
var outline_f29_40_30347=null;
var title_f29_40_30348="AHA NASPE driving after VT VF";
var content_f29_40_30348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AHA/NASPE guidelines for driving restriction following initiation of therapy for ventricular tachyarrhythmia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of treatment and arrhythmia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Noncommercial driving",
"       </td>",
"       <td class=\"subtitle1\">",
"        Commercial driving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        ICD or drugs for secondary prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sustained ventricular tachycardia (VT)",
"       </td>",
"       <td>",
"        Six months",
"       </td>",
"       <td>",
"        Indefinite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular fibrillation",
"       </td>",
"       <td>",
"        Six months",
"       </td>",
"       <td>",
"        Indefinite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        ICD for primary prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No symptomatic arrhythmia",
"       </td>",
"       <td>",
"        <p>",
"         At least one week post ICD implantation",
"        </p>",
"        <p>",
"         If appropriate ICD therapy received, especially with symptoms of cerebral hypoperfusion, should apply restrictions for treatment for secondary prevention",
"        </p>",
"       </td>",
"       <td>",
"        Indefinite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Candidates for primary prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsustained VT with impaired consciousness",
"       </td>",
"       <td>",
"        Three months",
"       </td>",
"       <td>",
"        Six months unless ICD placed (see above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsustained VT without impaired consciousness",
"       </td>",
"       <td>",
"        No restrictions (unless ICD placed; see above)",
"       </td>",
"       <td>",
"        No restrictions (unless ICD placed; see above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic VT without impaired consciousness*",
"       </td>",
"       <td>",
"        Three months",
"       </td>",
"       <td>",
"        Six months unless ICD placed (see above)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICD: implantable cardioverter-defibrillator.",
"     <br>",
"      * Idiopathic VT refers to VT occurring in patients with normal coronary arteries and normal ventricular function.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Epstein, AE, Miles, WM, Benditt, DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147 and Epstein, AE, Baessler, CA, Curtis, AB, et al. Addendum to \"Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology\": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and Heart Rhythm Society. Circulation 2007; 115:1170.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30348=[""].join("\n");
var outline_f29_40_30348=null;
var title_f29_40_30349="Percent nodal metastases";
var content_f29_40_30349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77954%7EONC%2F53008%7EONC%2F65834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77954%7EONC%2F53008%7EONC%2F65834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of nodal metastases as a function of location and tumor size",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        T1",
"       </td>",
"       <td class=\"subtitle1\">",
"        T2",
"       </td>",
"       <td class=\"subtitle1\">",
"        T3",
"       </td>",
"       <td class=\"subtitle1\">",
"        T4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyriform sinus",
"       </td>",
"       <td>",
"        38 to 91",
"       </td>",
"       <td>",
"        67 to 83",
"       </td>",
"       <td>",
"        69 to 80",
"       </td>",
"       <td>",
"        60 to 98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngeal wall",
"       </td>",
"       <td>",
"        33 to 70",
"       </td>",
"       <td>",
"        31 to 79",
"       </td>",
"       <td>",
"        47 to 85",
"       </td>",
"       <td>",
"        70 to 82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postcricoid space",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. McGavran MH, Bauer WC, Spjut HJ, Ogura JH. Carcinoma of the Pyriform Sinus: the Results of Radical Surgery. Arch Otolaryngol 1963; 78:826.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of nodal metastasis",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Subsites",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"12\">",
"        Pathological node assessment (percent cases with positive nodes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level I",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level II",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level III",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level IV",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level V",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        RP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyriform sinus",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngeal wall",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RP: retropharyngeal.",
"    </div>",
"    <div class=\"reference\">",
"     1. McLaughlin MP, Mendenhall WM, Mancuso AA, et al. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck 1995; 17:190.",
"     <br>",
"      2. Candela, FC, Kothari, K, Shah, JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990; 12:197.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of retropharyngeal (RP) lymph nodes metastasis based on stage",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        T stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive RP",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive RP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        2 of 55 (3.6 percent)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1 of 33 (3 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        14 of 156 (9 percent)",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        7 of 68 (7 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        16 of 76 (21 percent)",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        5 of 51 (9.8 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        22 of 79 (27.8 percent)",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        51 of 214 (19.2 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Yoshimoto S, Kawabata K. Retropharyngeal node dissection during total pharyngolaryngectomy for hypopharyngeal cancer. Auris Nasus Larynx 2005; 32:163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30349=[""].join("\n");
var outline_f29_40_30349=null;
var title_f29_40_30350="Pathogenesis of miliary TB";
var content_f29_40_30350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of tuberculosis and miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 432px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nesli Basgoz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30350=[""].join("\n");
var outline_f29_40_30350=null;
var title_f29_40_30351="Schatzki ring Endosc";
var content_f29_40_30351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schatzki ring seen on endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of a Schatzki ring which often cannot be well visualized unless the lower esophagus is widely distended. The ring appears as a thin membrane with a concentric smooth contour that projects into the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_40_30351=[""].join("\n");
var outline_f29_40_30351=null;
